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Abstract
IMPLEMENTATION AND ASSESSMENT OF HYPERGLYCEMIC CONDITIONS FOR
THE CREATION OF A DIABETIC BLOOD VESSEL MIMIC

By Vikramaditya Mediratta

Introduction: Diabetes Mellitus is a metabolic disorder that affects a person’s ability to
either produce insulin (Type I diabetes mellitus) or properly use insulin (Type II diabetes
mellitus) in order to maintain adequate blood glucose levels. The most severe diabetic
complications arise due to hyperglycemia – a state of extremely high blood glucose levels – such
as, coronary artery disease (CAD), in which coronary stent therapy is a popular method of
treatment. However, research has shown a high rate of in-stent restenosis in diabetic patients
with CAD, most likely due to activation of cellular adhesion molecules on endothelial cells
exposed to the hyperglycemic environment. Blood vessel mimics (BVMs) have been researched
as viable options for in vitro studies on vascular stents; thus, it would be beneficial to create an in
vitro diabetic BVM for stent manufactures to evaluate and determine the root cause of the high
failure rate of stents in the diabetic population. In addition, a diabetic BVM would help
manufactures optimize coatings or stent configurations for diabetic patients. Methods: The
purpose of this thesis was to take the initial steps towards the goal of a diabetic BVM. The first
aim was to establish a procedure of developing glycemic cell media solutions of various glucose
concentrations, and to establish a feasible method of monitoring the glucose concentration of the
solutions. Glycemic cell media solutions were developed and their glucose concentrations were
evaluated with a blood glucose meter (specifically, the Aviva Accu-Chek blood glucose meter)
iii

or visual blood glucose test strips (Glucoflex R visual blood glucose test strips). The second aim
was to ensure that the developed glycemic cell media solutions could be monitored in a cell
culture environment over time, and to determine if the hyperglycemic conditions induced any
change to endothelial cells. Bovine aortic endothelial cells (BAECs) and human umbilical vein
endothelial cells (HUVECs) were used to evaluate glucose consumption and cell morphology.
Glucose concentration of the cell media was recorded to evaluate glucose consumption, and the
cells were evaluated under a microscope in order to determine cell morphology and an increase
in cell death. Results & Conclusions: Data accumulated from the first set of experiments
confirmed that glycemic cell media solutions can be developed by adding Sigma G6512 D-(+)glucose to base cell media. Additionally, the Aviva Accu-Chek blood glucose meter recorded
the most accurate and precise glucose concentrations of the various glycemic cell media
solutions compared to the Glucoflex-R blood glucose visual test strips. Lastly, the series of
experiments with BAECs and HUVECs confirmed that the glycemic cell media solutions could
be effectively monitored over time, and that these conditions evoked higher glucose consumption
by the endothelial cells compared to the normal glycemic cell media solutions. Additionally,
neither glycemic environment evoked significant cell death. These results met the aims of this
thesis, and therefore provide the foundation for further development of a diabetic BVM.
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Chapter 1: An Introduction to Diabetes Mellitus
1.1

The History of Diabetes Mellitus
The name Diabetes Mellitus was coined in the 1600’s by scientists who were describing

their observations of patients with a particular set of symptoms; “diabetes” - intense thirst,
profuse urination, rapid waste production, intense vomiting, drowsiness eventually leading to a
coma and then death; “mellitus” – the apparent sweetness of the patient’s urine [1]. The
outcome of diabetes was a slow and painful death. There was no known reason behind the cause
of the disease and no thought of what a possible cure could be. This is why the discovery of
insulin in 1921 was one of the most dramatic discoveries in the history of diabetes and medicine,
contributing to a drastic change in lifestyle for patients with the disease.
Oxford physician Thomas Willis took the first step towards better understanding diabetes
in the 17th century [1]. He noted the sweet taste of urine from diabetic patients along with the
high volume they were producing. He was also the first to distinguish the sweet taste of urine
from patients with Diabetes Mellitus versus the non-sweet urine of patients with Diabetes
Insipidis [1]. While others were certain that diabetes was due to renal complications, Thomas
Willis believed that complications in blood were the main contributor to the disease. In 1776,
Willis’ theory was supported by scientist Matthew Dobson, of Liverpool, as Dobson discovered
that the sweet taste of urine was caused by a high concentration of glucose. He proved that there
was an excess of glucose in the blood of those who produced such sweet tasting urine [2].
Claude Bernard, of France, was one of the greatest figures of diabetes in the first half of
the 19th century. Some of his greatest findings included the discovery of the liver’s ability to
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store glycogen, as well as the liver’s ability to convert glycogen and secrete sugar into the blood.
This led him to believe that diabetes was due to an over-secretion of sugar from the liver [1].
Claude Bernard was such an influential figure that his view on the cause of diabetes was a staple
in the medical society. However, by extraordinary strokes of chance, an alternative proposition
regarding the cause and possible control of diabetes was discovered.

1.1.1 The Discovery of Insulin
In 1879, Joseph Von Mering of Germany discovered that removing the pancreas caused
diabetes. Interested mostly in digestion, Von Mering wanted to study the digestive effects of the
pancreas by removing it from a dog and analyzing what digestive limitations the dog exhibited.
Von Mering’s colleague, Oscar Minkowski (Figure 1) performed the procedure and later
discovered that the dog had urinated all over its cage even though it had been house trained.
Much more interested in what this discovery might mean, Minkowski tested the urine and found
high levels of glucose; thus, implying that the pancreas contained the anti-diabetic agent that
controlled glucose level and could possibly cure diabetes [1]. Unfortunately, the extraction of
this anti-diabetic substance was extremely difficult. It was widely held that the substance was in
the pancreatic islets, but it was believed that digestive enzymes produced by the pancreas were
interfering with the extraction. While some scientists were able to develop an unstable extract
that was lowering the blood glucose levels of dogs, none were successful in purifying the
substance for human testing [2]. Though discouraging, there was no lack of appreciation of how
much potential the purification of the anti-diabetic substance could have on the advancement of
diabetes treatment.
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Figure 1 - Oscar Minkowski surgically removed the pancreas of a dog which he later realized
induced diabetes mellitus. (Permission to reprint from Fischer I: Biographisches Lexikon der
hervorragenden Arzte der letzten funfzig Jahre. T. 1. Monachium-Berlin: Urban &
Schwarzenberg, 1933).
Finally in 1921, one of the greatest medical discoveries occurred at the University of
Toronto, Canada. Dr. Fredrick Banting (Figure 2), an unsuccessful orthopedic surgeon, was
reading on the association of pancreatic dysfunction with diabetes and became convinced that he
could produce the anti-diabetic substance [3]. Ironically, his greatest strength was his ignorance
towards how difficult the procedure was since he was unaware that so many other scientists had
attempted to find it in the forty years since Minkowski’s discovery. Nonetheless, Banting
approached Dr. John James Richard Macleod (Figure 3), Professor of Physiology at the
University of Toronto, and requested the funds and facilities to perform the experiment.
Knowing the difficulties behind the procedure, Macleod assigned medical student Charles Best
to aid Banting in the assembly of the experiment. Banting originally believed that the external
secretion of the pancreas was destroying the “insulin;” thus, he tied off the pancreatic duct and
allowed for pancreas atrophy [3]. Unfortunately, there was difficulty in stabilizing the pancreatic
secretion, so Macleod assigned James Bertram Collip (Figure 4), biochemist at the University of
Toronto, to perform standard chemical purification in order to stabilize the substance for human
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testing. Within six weeks, Collip felt comfortable enough with the insulin he had isolated to try
it on a human for the first time [3].

Figure 2 - Dr. Frederick Banting (shown), and medical student Charles Best, were able to extract
the first pure insulin substance (Permission to reprint from Nobel Lectures, Physiology or
Medicine 1922-1941, Elsevier Publishing Company, Amsterdam, 1965).

Figure 3 – Dr. John James Macleod, Professor of Physiology at the University of Toronto,
funded the experimentation for the first stable extraction of insulin (Permission to reprint from
Nobel Lectures, Physiology or Medicine 1922-1941, Elsevier Publishing Company, Amsterdam,
1965).
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Figure 4 – James Bertram Collip, biochemist from the University of Toronto, was able to purify
and stabilize the insulin extraction for human testing (Permission to reprint from the Library of
the University of Toronto, Canada).
The first human trial was performed on a young 14 year-old boy dying of diabetes. To
everyone’s astonishment, the insulin injection lowered the boy’s blood sugar, rid the glucose in
the urine, and eventually helped him regain his body weight and strength [3]. It was a
miraculous transformation; a universally fatal disease had been cured – or if not cured, at least
controlled. Banting and Best published their first paper in 1922, and in 1923 Banting and
Macleod were awarded the Nobel Prize in Medicine for their remarkable discovery [3].

1.1.2 Impact of the Discovery of Insulin
Before the discovery of insulin, diabetes was a slow and heartbreaking death. Mostly
diagnosed in young children, the only method of treatment was a strict diet that eventually
equaled starvation. It was an unfortunate situation for early “diabetologists,” especially Dr.
Frederick Allen, of New York, who had nothing else to offer other than starvation [1]. If the
patient got an infection and the diabetes got worse, the answer was even stricter starvation – a
miserable situation for the young patients, as well as the parents. However, the arrival of insulin
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brought a revival to the field that was best expressed by a nurse at Dr. Allen’s psychiatric
hospital in New York. She wrote [3]:
“…the mere illusion of new hope cajoled patient after patient into new life. Diabetics who had not been
out of bed for weeks began to trail weekly about, clinging to walls and furniture. Big stomachs, skin-and-bone
necks, skull-like faces, feeble movements, all ages, both sexes – they looked like an old Flemish painter’s depiction
of a resurrection after famine. It was a resurrection, a crawling stirring, as of some vague springtime.”

The patients heard that Dr. Allen had come back from Toronto:
“Bed immediately after dinner was the rule of our patients. But not that evening. My office opened on the
big center hallways. I could see them drifting in, silent as the bloated ghosts they looked like. Even to look at one
another would have painfully betrayed some of the intolerable hope that had brought them. So they just sat and
waited, eyes on the ground.
It was growing dark outside. Nobody had yet seen Doctor Allen. His first appearance would be at his
dinner, which followed the patients’ dinner hour. We all heard his step coming along the covered walk, past the
entrance to the main hallways. His wife was with him, her quick tapping pace making a queer rhythm with his. The
patients’ silence concentrated on that sound. When he appeared through the open doorway, he caught a full
beseeching of a hundred pair of eyes. It stopped him dead. Even now I am sure it was minutes before he spoke to
them, his voice curiously mingling concern for his patients with an excitement that he tried his best not to betray. ‘I
think,’ he said, ‘I think we have something for you’ ”.

The discovery of insulin changed the lives of doctors and patients. Those who were
headed to certain death in the coming years lived on for another fifty. The first insulin treatment
was quick acting insulin that required two injections a day – long lasting insulin was still to come
[4]. What was significant about this discovery was that it contradicted Claude Bernard’s work.
It was not an over-secretion of glucose from the liver that was causing diabetes, but rather an
autoimmune-induced deficiency of islet β-cells in the pancreas – cells that produced and secreted
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insulin [1]. This new understanding of diabetes brought about the distinction of two different
types of the disease – insulin dependent and non-insulin dependent diabetes mellitus. In 1936,
Harold Himsworth demonstrated the important biochemical differences in the two types by
identifying insulin sensitivity in type I and insulin resistance in type II diabetes [2]. This brought
about a new perspective in the search for the cure of diabetes – there was no longer one single
cure for the disease.

1.2

Overview of Diabetes Mellitus
Diabetes Mellitus is a disease that causes the body to insufficiently produce or

improperly use insulin. Insulin is a pancreatic hormone, secreted from β-cells in the pancreatic
islets, that breaks down sugars, starch, etc. into energy for the body. Diabetes Mellitus comes in
two common forms – insulin deficient, or type I diabetes, and insulin resistant, or type II
diabetes. Type I diabetes, also known as juvenile diabetes, is most common in children, while
type II diabetes is diagnosed mostly in adults. Diabetes Mellitus is also one of the most
prevalent diseases diagnosed in America today. According the American Diabetes Association,
about 23.6 million children and adults in the United States of America have diabetes mellitus
(about 7.8% of the population), of which only 17.9 million are diagnosed. This means that
nearly a quarter of the 23.6 million children and adults do not know that they have diabetes. Out
of the 23.6 million with diabetes, about 10% have type I, leaving the other 90% diagnosed with
type II diabetes. This section will discuss the key similarities and differences between the two
types of the disease.
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1.2.1 Type I (Insulin Deficient) Diabetes Mellitus
1.2.1.1

Causes/Pathology

Insulin deficient ( also known as insulin dependent) diabetes mellitus (IDDM), or type I
diabetes mellitus, is a T-cell mediated autoimmune disease resulting in the selective destruction
of insulin-secreting pancreatic β-cells through the detrimental immunoregulation of
inflammatory cytokines and auto-aggressive T lymphocytes [5,6]. While the etiology of β-cell
destruction is unknown, researchers are proposing that genetically susceptible persons, who are
exposed to certain environmental agents, trigger the inflammatory autoimmune response [7].
Various environmental agents have been proposed to contribute to the pre-clinical onset of the
disease, as outlined in Table 1, but no specific environmental factors have been identified with
certainty [8].

Table 1 - Most significant environmental factors that contribute to the increased incidence of
Type 1 diabetes [9, 10].
Environmental Factors

Hypothesis

Viral infections

Viral hypothesis

Exposure to certain food constituents

Dietary hypothesis

Increased hygiene; lack of childhood
infections

Hygiene hypothesis

Rapid growth in early childhood

Accelerator hypothesis

As discussed before, type I diabetes is most common in children and young adults.
Unfortunately, the incidence of type I diabetes seems to be increasing 3-5% per year [11].

There are five stages in the development of type I diabetes (Figure 5) [6, 7].
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1. Genetic susceptibility;
2. Pre-clinical β-cell autoimmunity with gradual dysfunction of insulin secretion;
3. Onset of clinical diabetes;
4. Transient clinical remission; and
5.

Established diabetes associated with acute and chronic complications and
premature death.

Figure 5 - Development of type I diabetes (Permission to reprint from [7]).
Environmental agents trigger the autoimmune attack against the pancreatic β-cells due to
the presence of certain antibodies. These antibodies include islet cell antibodies (ICA) against
islet-related antigens, anti-insulin auto-antibodes (IAA), anti-64 kDa protein antibodies, antiICA69, and anti-ICA512 [12, 13, 14, and 15]. These antibodies are now used for the detection of
patients high at risk for the development of type I diabetes. Studies have found that the presence
of two or more of the mentioned antibodies is highly predictive for the development of type I
diabetes [16].
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The first thing to happen during the pre-clinical onset of type I diabetes is the loss of
first-phase insulin secretion. This is due to the gradual degeneration of pancreatic β-cells;
however, the patient maintains a stable glycemic state [6]. The presence of these autoantibodies,
with β-cell antigens, also leads the onset of hyperglycemia due to the loss of first-phase insulin
secretion, and eventually results in the clinical onset of diabetes [7]. A significant effort is being
made to develop antigen- and antibody-based immunotherapies that effectively prevent and/or
treat type I diabetes [17]. While transient remission follows the clinical onset of the disease, the
disease continues to develop resulting in further complications that greatly degenerate the rest of
the body [18]. These complications will be discussed further in a subsequent section. Type I
diabetic patients manage their hyperglycemia with daily injections of insulin via insulin pens or
by subcutaneous insulin infusion therapy with an insulin pump. While effective, insulin therapy
is by no means a cure.

1.2.2 Type 2 (Insulin Resistant) Diabetes Mellitus
1.2.2.1

Causes/Pathology

Insulin resistant (also known as insulin independent) diabetes mellitus, or type II diabetes
mellitus, is the most common form of diabetes. Type II diabetes is characterized by the body’s
resistance to the metabolic effects of insulin – especially its suppressive effects on the body’s
blood glucose levels. Many clinical disorders, such as hypertension, dyslipidemia, and
atherosclerosis, are related to the development of insulin resistance and are linked to the high
glucose levels of type II diabetes. Several factors contribute to the impaired function of insulin
in type II diabetes – genes, environmental factors, and obesity (Figure 6).
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Figure 6 – The main contributors to the pathogenesis of type II diabetes insulin resistance are
genetics, environmental factors, and the adverse effects of obesity (Permission to reprint from
[19]).

1.2.2.2

Genetics

Type II diabetics may exhibit defects in insulin action, as well as insulin secretion; both
believed to be genetically predetermined [19]. Several rare mutations in genes associated with
insulin resistance have been linked to extreme insulin resistance, including mutations of insulin
receptors or polymorphisms of specific proteins (i.e. G972R polymorphism of insulin receptor
substrate-1). Genes associated with the development of type II diabetes include Transcription
factor 7-like 2 (TCFL2), KCNJ11, just to name a few [20]. TCFL2 is a protein that acts as a
transcription factor, and variance in this gene has been linked to the development of type II
diabetes. KCNJ11 is a gene that encodes the Kir6.2 major subunit of the ATP-sensitive K+
channel. Mutations to this gene are linked to development of congenital hyperinsulinism, which
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can lead to insulin resistance due to its over activity. There is an extremely strong inheritance
pattern for type II diabetes.

1.2.2.3

Environment

Environmental factors that lead to insulin resistance include different medical conditions,
homeostatic imbalance within the body, and life style choices (exercise and diet). For example,
different factors of renal failure, such as accumulation of uremic toxins, increased levels of
growth hormone (described below), abnormal filtration of glucose, metabolic acidosis, and
dyslipidemia are proposed mechanisms of increased insulin resistance [21]. Insulin resistance
has also been identified as a result to different types of cancers, particularly pancreatic cancer
[22]. Factors involving homeostatic imbalance, include abnormal hormone levels, especially
excess hormone levels such as hyperinsulinism – an abnormally high level of insulin secretion –
a classic indicator of insulin resistance [23].
Growth hormone also acts in many levels to block insulin activity, including inhibiting
the phosphorylation of the insulin receptor and its principal signaling molecule, IRS-1, in
response to insulin administration [20]. This results in a reduced sensitivity of insulin in both
glucose uptake and suppressing glucose production. In addition, insulin resistance induced by
abnormal nutrient intake, such as a high glucose diet causing hyperglycemica (glucose toxicity)
or increased levels of circulating free fatty acids, is a common feature of insulin resistance and
type II diabetes [24]. Poor diet paired with poor levels of exercise have linked the onset of type
II diabetes with obesity – a significant factor common among type II diabetics, especially when
the disease’s strong inheritance pattern was discussed.
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1.2.2.4

Obesity

Obesity is an important factor in the pathogenesis of insulin resistance and the increased
risk of type II diabetes [20]. In most patients, obesity is associated with inflammation of white
adipose tissue resulting from chronic activation of the innate immune system, which can lead to
insulin resistance, impaired glucose tolerance and type II diabetes [25]. Although BMI accounts
for only a part of the variance in insulin sensitivity, obesity and insulin resistance are related;
however, insulin resistance generally is directly proportional to body-mass [26].
Adipose tissue influences insulin action in the whole body through the release of free
fatty acids and adipose-derived proteins (proinflammatory peptides that cause inflammation of
adipose tissue, such as adiponectin, leptin, and resistin), and has dramatic effects on glucose
metabolism and insulin effectiveness [27, 28, 29]. These proinflammatory molecules induce
insulin resistance and can contribute to complications in obese diabetic patients, including
atherosclerosis [30]. It is still argued whether insulin resistance is the primary defect that
precedes β-cell failure in the development of hyperglycemia and type II diabetes, or vice versa.
However, in the end, there is a linear decrease in first-phase insulin release and insulin sensitivity
in patients who are excessively in a hyperglycemic state [31]. Along with obesity, abnormal fat
distribution and physical inactivity suffer the consequences of insulin resistance that include
hyperglycemia, high triglycerides, hypertension, atherosclerosis (just to name a few) – all having
shown to be predictors of type II diabetes [31].
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1.2.3 Phases of Insulin Secretion
In non-diabetics, about 50% of the total daily insulin is secreted during basal periods
(periods in between meals) to suppress lipids, proteins, and glucose. The remainder of insulin is
rapidly secreted postprandial in response to a meal. This rapid release, or bolus, of insulin from
the pancreatic β-cells is called the “first phase” of insulin secretion. The first phase promotes
utilization of the prandial nutrients, suppresses liver glycogen-to-glucose production, and limits
the elevation of blood glucose levels. First-phase insulin secretion occurs within two minutes of
food ingestion and continues for approximately ten minutes. The second phase of insulin
secretion follows and is sustained until normal blood glucose levels are restored. The effects of
hyperglycemia on insulin secretion will be discussed further in the following chapter.

1.2.4 β-cell Dysfunction of Diabetes Mellitus
Pancreatic β –cell dysfunction is an early and extremely significant step in the
progression of the pathophysiology of type II diabetes [32]; opposed to full degeneration of β cells in type I diabetes. Functioning pancreatic β –cells accomplish proper regulation and
storage of glucose through a negative feedback loop where elevated glycemic concentrations upregulate insulin secretion from the pancreatic β –cells, which in turn lowers glycemic
concentrations by inhibiting hepatic glucose production and increasing glucose uptake by cells
on target organs [33]. Assessments have shown that β-cell dysfunction affects both the firstphase and second-phase insulin response to elevated blood glucose. Thus, the decline in β-cell
function precedes the development of hyperglycemia and continues after the clinical diagnosis of
type II diabetes [34]. This characteristic of type II diabetes – the loss of first-phase insulin
response to a meal – is the main cause of postprandial hyperglycemia seen in diabetics [33]. The
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defects of insulin resulting from type II diabetes are likely due to both the cellular dysfunction
and reduction of the β-cell mass [34]. The mechanism and etiology of β-cell dysfunction is still
being studied, but proposed hypotheses include glucose toxicity: chronic hyperglycemia causing
hyperstimulation and overwork of the β-cells; and β-cell exhaustion: hyperstimulation of insulin
secretion due to chronic hyperglycemia. The dramatic involvement of β-cell function in the
development of type II diabetes will result in pancreatic β-cell-directed therapies for the
treatment of the disease.

1.2.5 Major Complications of Diabetes Mellitus
There are numerous major complications that result from diabetes mellitus. As discussed
earlier, type I diabetes is characterized by complete β-cell degeneration, and type II diabetes is
characterized by insulin resistance and β-cell dysfunction. This eventually leads to chronic
hyperglycemia, and a constant exposure to high blood glucose levels leads to significant
complications.

Of the extensive list of complications, the most significant resulting from

hyperglycemia includes hypertension, ketoacidosis, nephropathy, neuropathy, and most notably
heart disease.

1.2.5.1

Hypertension

Hypertension is a very common condition in diabetics, and especially common in patients
with type II diabetes. Normal blood pressure is commonly defined as 120/80 mmHg for people
without diabetes, and 130/80 mmHg for people with diabetes; however, stage one hypertension
begins with a consistent blood pressure reading of 140-160/90-100 mmHg.

Hypertension

increases the risk of macrovascular and microvascualr complications, specifically cardiovascular
15

diseases including stroke, coronary artery disease, peripheral vascular disease, retinopathy,
nephropathy, and even neuropathy [35]. In fact, when hypertension coexists with diabetes, the
risk of stroke or cardiovascular disease is doubled, and the risk of developing renal disease
increases five to six times compared to hypertensive patients without diabetes [36]. In type I
diabetics, hypertension is usually a mark of diabetic nephropathy, and these two disorders
aggravate each other. In type II diabetics, hypertension is associated with complications such as
microalbuminuria,

obesity,

insulin

resistance,

dyslipidemia,

hypercoagulation,

and

hyperuricemia [36]. Basic treatment of hypertension involves dietary and lifestyle modifications
such as weight loss, exercise, reduced sodium intake, and an improved balanced diet.
Pharmacologic therapy is another method with the use of drugs, such as ACE-inhibitors,
diuretics, and β-blockers [37].

1.2.5.2

Ketoacidosis

Diabetic ketoacidosis is the most common hyperglycemic complication in patients with
diabetes mellitus [38]. It occurs when there are dangerously high levels of ketone acids in the
blood. The combination of uncontrolled hyperglycemia, metabolic acidosis, and increased body
ketone concentration characterize diabetic ketoacidosis.

This is a serious condition more

commonly found in type I diabetics than type II, and can lead to a diabetic coma or even death if
not treated properly. Diabetic ketoacidosis occurs when glucose is not available as a fuel source
for the body; thus, fat is used instead. The byproducts of fat breakdown are ketones and acid,
dropping the blood pH and making it more acidic than usual. The basic mechanism behind
ketoacidosis is mostly insulin deficiency along with elevated levels of counter-regulatory
hormones, such as glucagon, cortisol, and growth hormone [39]. The treatment of diabetic
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ketoacidosis involves correcting the fluid and electrolyte imbalances with saline, water, and
potassium, normalizing the blood glucose levels with insulin, and correcting the acid-base
disturbances using insulin or bicarbonate [40].

1.2.5.3

Nephropathy

Renal dysfunction in diabetes, known as diabetic nephropathy, is a progressive disease
that occurs as a result of both direct and indirect effects of hyperglycemia and hypertension [41].
It is a multifactorial disorder that results from the interaction of both environmental and genetic
factors [42]. The risk of developing diabetic nephropathy is only partially determined by
glycemic control and is highly influenced by genetic susceptibility [43]. It is a progressive renal
disease caused by angiopathy of capillaries in the kidney glomeruli, resulting in the leakage of
albumin protein into the urine. It remains the leading cause of end-stage renal disease and
develops in 20-25% of type I diabetic patients [44]. Although the risk of diabetic nephropathy in
type I diabetes is similar to that of type II diabetes, it is most commonly associated with type II
diabetics [45] due to the low level of glycemic control and the high level of hypertension
associated with type II diabetes.

Diabetic nephropathy occurs first with glomerular

hyperflitration (due to the thickening of the glomerular basement membrane) followed by
increased urinary albumin excretion known as microalbuminuria - the leakage of albumin
proteins into the urine [46]. Once HA1C values pass the threshold value of 8.0%, there is a
significant increase in the chance of microalbuminuria [47]. Treatment of diabetic nephropathy
involves control of blood glucose levels to prevent chronic hyperglycemia, plus the management
of hypertension that is known to aggravate the disorder even further. Pharmacological therapy,

17

with the use of ACE-inhibitors, is another option to reduce the hypertension and also reduce
microalbuminuria to control proteinuria in both type I and type II diabetics.

1.2.5.4

Neuropathy

A common complication of diabetes, diabetic neuropathy occurs due to damaged nerves
as a result of hyperglycemia. Diabetic neuropathy affects both type I and type II diabetics, but
progresses more rapidly and has more severe consequences in type I diabetics [48]. There are
two common types of nerve damage; the first is peripheral diabetic neuropathy (PDN) that has
devastating complications to the cranial nerves and spinal nerves causing tingling, pain,
numbness, or weakness to the hands and feet and is the leading cause of foot amputations. PDN
occurs due to complex interactions among multiple hyperglycemia-initiated mechanisms,
impaired insulin signaling, inflammation, and disturbances of fatty acid and lipid metabolism
[49].

The second common type of nerve damage is called autonomic neuropathy that

significantly influences the nerves that regulate heart, gastrointestinal, and genitourinary system.
It also affects the regulatory function of microcirculation that may lead to different late diabetic
complications such as gastroparesis, bladder dysfunction, erectile dysfunction, and retinopathy
[48]. Parasympathetic nerve fibers are affected first, leading to a relative increase in sympathetic
tone resulting in the increase in resting tachycardia. This decrease in parasympathetic tone may
also be responsible for worsening ischemia in diabetics due to the exaggerated coronary
vasoconstriction [50]. Despite numerous drug trials and studies, other than strict glycemic
control, there are no other methods of treatment to slow the progression of diabetic neuropathy
[51].
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1.2.5.5

Cardiovascular Disease

Diabetes is the seventh leading cause of death in the United States, and much of that is a
result of cardiovascular disease. Type I and type II diabetes are independent risk factors for
atherosclerotic diseases, stroke, and peripheral arterial disease (PAD) [52]. These macrovascular
complications are coupled with microvascular complications such as retinopathy, neuropathy,
and nephropathy making diabetes mellitus, according to the American Heart Association, a
cardiovascular disease on its own. Chronic high blood pressure (hypertension) and abnormalities
in glucose metabolism are the mechanisms by which diabetes contributes to adverse heart
dysfunction and failure [53]. There is evidence that adequate glycemic control may improve
cardiac metabolism and myocardial function in diabetics with a high risk of heart disease;
therefore, there is a direct relationship between hyperglycemia and cardiovascular disease in type
I and type II diabetic patients [54].

1.2.5.6

Coronary Artery Disease

Out of all cardiovascular diseases, diabetes mellitus is a major contributor to the
development and the manifestations of coronary artery disease (CAD). Patients with CAD and
diabetes mellitus represent a particularly high-risk population because of the specific
characteristics associated with the atherosclerotic disease [55]. CAD occurs late in the third or
fourth decade of a diabetic’s life, regardless of whether diabetes developed early in childhood or
during late adolescence. While men are generally more susceptible to CAD than women, studies
have shown that women with diabetes are at especially high risk for CAD, relatively more so
than men with diabetes [56]. The disease results in the narrowing of coronary arteries due to
atherosclerosis – the build-up of atheromatous plaques (Figure 7).
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Figure 7 - Coronary artery disease results when a normal healthy coronary vessel, (a) narrows
due to atherosclerosis and plaque build-up, and (b) leads to inadequate blood flow through the
vessel (Permission granted from the National Heart, Lung, and Blood Institue as a part of the
National institute f Health and the US Department of Health and Human Services).
Risk factors that emerge as predictors for coronary artery disease in type I diabetics
include nephropathy and autonomic neuropathy [57]. Nephropathy has always emerged as a
major predictor [58], but coronary artery disease is still a risk even if the patient does not have
nephropathy. Diabetic nephropathy is associated with an atherogenic lipoprotein profile that
includes elevated levels of low-density lipoprotein (LDL) and very-low-density lipoprotein
(VLDL), and decreased levels of high-density lipoprotein (HDL) [59]. Several mechanisms
contribute to the atherosclerotic process, including hypertension, lipid abnormalities, fibrinolysis,
and coagulation alterations [60]. As discussed before, hypertension is frequently present in
patients with nephropathy and can intensify coronary artery disease in patients with type 1
diabetes. As for patients with type II diabetes, hypertension, hyperglycemia and increased
concentrations of LDL along with decreased concentrations of HDL are independent risk factors
that contribute to the development of coronary artery disease [61].
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Medical therapies for treating coronary artery disease in patients with diabetes include
insulin therapy, aspirins, β-blockers and ACE inhibitors. Lifestyle modifications should be taken
as well by reducing cholesterol levels, treating chronic hypertension, and controlling glycemic
concentrations. With the increase of endothelial dysfunction in the coronary blood vessels due to
hyperglycemic conditions, diabetics are more susceptible to CAD, which commonly manifests
itself into unstable angina or worse – myocardial infarction. CAD is a significant complication
related to diabetes and is the leading cause of death in the world. Due to the significant and
dominance of the heart disease, this thesis will focus on the involvement of CAD with diabetes
mellitus.

1.3

Treatments for Diabetics with Coronary Artery Disease
Regardless of whether a patient has diabetes or not, revascularization is a common

treatment for patients with coronary artery disease. Treatment procedures include coronary
angioplasty, coronary bypass surgery, and coronary stent placement. Numerous studies show that
patients with diabetes experience a greater need for repeat revascularization (angioplasty, bypass,
or stent replacement), a higher rate of cardiac events, and lower overall survival following the
coronary therapy procedures compared to their non-diabetic counterparts [62]. Diabetic patients
commonly have more pretentious coronary artery involvement than non-diabetics, which
probably contributes to their less favorable outcome following revascularization [62]. Each of
these treatments will be summarized below, along with a description of the additional impact of
diabetes on the treatment’s success.
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1.3.1 Angioplasty
Coronary angioplasty (Figure 8) is a medical procedure where a balloon catheter is
deployed to open a coronary artery that has been narrowed by plaque build-up from
atherosclerosis. Angioplasty provides effective relief of angina – chest pain that occurs when a
part of the heart is not receiving enough oxygenated blood – and is usually successful in patients
with or without diabetes mellitus. However, the great long-term effects of angioplasty are
greatly limited by the increased rates of restenosis in patients with diabetes (Figure 9) [63]. New
angioplasty devices have been used (laser angioplasty and directional coronary atherectomy), but
have failed to show any major improvement on the high rate of restenosis among patients with
diabetes.
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Figure 8 – With the build-up of plaque in a coronary artery, coronary angioplasty is a medical
procedure where, (a) a balloon catheter is inserted to the site of plaque buildup, (b) the balloon is
inflated and pushes the plaque against the blood vessel wall, and (c) proper blood flow is
restored to the artery (Permission granted from the National Heart, Lung, and Blood Institue as
a part of the National institute f Health and the US Department of Health and Human Services).
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Figure 9 – The graph above displays that angiographic restenosis (50% diameter stenosis) was
significantly greater in diabetic patients than non-diabetic patients (Permission to reprint by
[63]).
Diabetics may exhibit an accelerated form of intimal hyperplasia and atherosclerosis in
response to the vascular injury caused by balloon deployment. A study using intravascular
ultrasound found exaggerated intimal proliferation in patients with diabetes at the site of arterial
injury caused by angioplasty, and this response was striking in restenosis lesions [64].
Hyperinsulinemia, common in type II diabetics with insulin resistance, may contribute to the
atherogenic process since insulin may directly promote smooth muscle cell proliferation, and the
procoagulant state in diabetics may contribute directly to the progression of restenosis [65]. In
summary, while there are some similarities in the angiographic outcomes after successful
angioplasty in diabetics and non-diabetics, the vascular injury caused by treatment of balloon
angioplasty contributes to the increased risk of restenosis in the treated blood vessel.
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1.3.2 Coronary Artery Bypass Surgery
Coronary artery bypass surgery involves rerouting blood around a clogged artery to
reinstate proper blood flow to the heart. This is an extremely invasive procedure where surgeons
take a segment of a healthy blood vessel (preferably a portion of the great saphenous vein) and
make a new path around the blocked region on the coronary artery for blood to flow freely to the
heart muscle. Coronary artery bypass surgery is effective in relieving angina symptoms in
patients with and without diabetes, but with respect to vein grafts, several reports have noted
decreased survival of vein grafts in patients with diabetes [66]. Intimal proliferation, that causes
luminal loss in the first years following bypass surgery with venous vessels, may be accelerated
in patients with diabetes mellitus [67]. Studies have shown that restenosis after coronary artery
bypass grafting is more common among diabetics versus non-diabetics at 1-year angiography
mainly because of more graft failures in diabetics [68]. It is believed that the decreased success
of coronary artery bypass grafts in diabetics and the increased short-term mortality in diabetics is
due to metabolic abnormalities, such as hyperglycemia, and cardiac complications (especially in
type II diabetics), which include hypertension and a possible history of peripheral vascular
disease or stroke [74]. Thus, with reduced availability of healthy vein graft replacements within
diabetic patients, coronary artery bypass surgery is becoming a less common method of
treatment for CAD patients with diabetes mellitus.

1.3.3 Coronary Stent Placement
Coronary stent placement involves the placement of a man-made wire mesh tube during
angioplasty that expands and props open the coronary artery that is narrowed or blocked by
atherosclerotic plaque build-up. During the percutaneous coronary intervention, the same steps
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as other angioplasty procedures are performed as the stent expands and locks into place when the
balloon inflates.

Although bare metal stents have improved outcomes among patients

undergoing percutaneous coronary interventions, their efficacy has been limited by the
development of in-stent restenosis [69] (Figure 10).

Studies have shown that the rate of

restenosis increases in patients with both type I and especially type II diabetes, and specific
angiographic characteristics, such as vessel size and stent type (bare metal vs. drug-eluting), are
predictive of a higher rate of restenosis and a need for repeated revascularization procedures after
the initial stent implantation [70]. Although vessel recoil may also contribute to decrease of
lumen size, the increased restenosis rate in patients with diabetes, following stent placement, is
due primarily to the enhanced proliferation of smooth muscle cells, because coronary artery
“stenting” decreases the elastic recoil and vascular spasm at the treated site [63].
Restenosis is the healing response of the arterial wall to mechanical injury (stent
implantation in this case) and is composed of two main processes – neointimal hyperplasia (i.e.,
smooth muscle migration/proliferation, extra cellular deposition) and vessel remodeling [71].
From a few animal study observations, neointimal hyperplasia is a general wound-healing
response – platelet aggregation, inflammatory cell infiltration, release of growth factors, medial
smooth muscle cell modulation and proliferation, proteoglycan deposition, and extracellular
matrix remodeling as major milestones in the temporal sequence of the response [72]. Further
research added that thrombosis often occurred as a cause of smooth muscle cell proliferation
[73]. The adhesion of circulating leukocytes to endothelial cells plays an important role in the
initiation of CAD and certainly in the occurrences of restenosis in stent-implanted diabetic CAD
patients [74]. Levels of cellular adhesion molecules, particularly intracellular adhesion molecule
(ICAM)-1 and vascular cellular adhesion molecule (VCAM)-1, have been found at increased
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levels in diabetic patients [75, 76].

Notably, hyperglycemia was shown to condition the

concentration of these cellular adhesion molecules acutely [77, 78]. In support of this, recent
studies have shown that levels of VCAM-1 and ICAM-1 increase in high glucose environments;
thus, the hyperglycemic environment in diabetics is a significant contributing factor to the high
rate of in-stent restenosis [77, 79].

Figure 10 – The diagram shows the progression of in-stent restenosis as a vessel injury response
resulting in the proliferation of smooth muscle cells, the expression of vessel adhesion
molecules, and the adhesion of leukocytes (Permission to reprint from [71]).
The development and use of drug-eluting stents reduced the risk of restenosis, target
lesion revascularization, and myocardial infarction as compared to bare-metal stents; however,
the risk of very late thrombosis is higher with drug-eluting stents than with bare metal stents
[80]. There are two primary types of drug-eluting stents used in the market – sirolimus-eluting
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stents and paclitaxel-eluting stents. Recent studies have compared the use of sirolimus-eluting
stents and paclitaxel-eluting stents in diabetics and suggest that the sirolimus-eluting stent is
associated with a decrease in late lumen loss and a reduced risk of restenosis [81]. Implantation
of drug-eluting stents has emerged as the predominant revascularization strategy in diabetic
patients, especially with the improved reduction of in-stent restenosis [82].

1.4

Coronary Stent Treatment in the Diabetic Population

1.4.1 Restenosis in In Vivo Diabetic Studies
The increased atherothrombotic risk in patients with diabetes is related to their proinflammatory and pro-thrombotic status [162]. Coronary artery plaques of diabetic patients with
acute myocardial infarction had significantly higher necrotic core percentages and lower fibrofatty tissue percentages than non-diabetics [163, 164]. In addition, diabetic patients with stable
angina and significantly larger dense calcium in culprit lesions [164, 165]. The pathogenic
mechanism of restenosis after drug-eluting stent implantation under hyperglycemia is still not
completely understood, and most reports have been conducted in a clinical setting, with little
research done on animals. However, a recent rat study conducted showed increased thrombus,
inflammatory cell infiltration, and neointimal hyperplasia (NIH) without change of smooth
muscle cell number after drug-eluting stent implantation in diabetic rats (493.3 ± 85.8 mg/dL) vs.
non-diabetic rats (140.0 ± 8.5 mg/dL) (Figure 11) [162]. This discovery supported that the main
mechanism of restenosis after drug-eluting stent implantation under hyperglycemic conditions
was initial thrombus and inflammatory cell accumulation – causing a delay of
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reendothelialization – with changes of extracellular matrix rather than smooth muscle cell
proliferation [162].

Figure 11 - Increased thrombus was located in the surrounding region of the stent strut (green
arrows) of rats with diabetes vs. rats without diabetes (Permission to reprint from [162]).
In another recent diabetic rat model study showed the development of in-stent restenosis
enhanced by long-term type I diabetes in BBDP rats [166]. Quantitative analysis supported that
long-term diabetes resulted in a 32% increase in surface neointima compared to non-diabetic rats
BBDP rats (Figure 12) [166]. Though the underlying mechanism(s) were not studied, this study,
however, suggested that long-term diabetes increases the proliferative and migratory capacity of
medial and neointimal smooth muscle cells [166].
Future studies aimed at identification of cellular and molecular mechanisms involved
with increased restenosis in diabetic animal models are warranted to improve therapeutic
interventions.
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Figure 12 - Long-term type I diabetes in BBDP rats is associated with enhanced in-stent
restenosis four weeks after stenting the abdominal aorta (Permission to reprint by [166]).

1.4.2 Clinical Results of Diabetic Coronary Stent Implantation
1.4.2.1

Type I Diabetics vs. Type 2 Diabetics

In-stent restenosis is common occurrence in CAD patients, and is even greater in CAD
patients with diabetes. However, is there a difference in the rate of restenosis between type I and
type II diabetics? After reviewing the literature, no significant data has been reported showing
any difference between the rates of in-stent restenosis between type I and type II diabetics.
Studies do report that a chronic hyperglycemic state in the coronary vessels of diabetics
30

contributes to greater progression of CAD and an increased rate of restenosis, and since type I
diabetics have much more control over their levels of hyperglycemia compared to type II
diabetics, it would make sense that the occurrence of in-stent restenosis is greater in type II
diabetics than in type I diabetics. This also supports the fact that type II diabetics are much more
susceptible to cardiovascular complications – thus, needing more revascularization treatments –
which would produce higher cases of restenosis in that population compared to the other.

1.4.2.2

Bare Metal Stents vs. Drug-Eluting Stents in the Diabetic Population

The next studied comparison involved researching whether or not any significant
difference existed in the rate of restenosis between diabetics with implanted bare metal stents and
diabetics with implanted drug-eluting stents. Recent studies compared and reported the reduced
rate of in-stent restenosis for both types of drug-eluting stents (sirolimus and paclitaxel)
compared to bare metal stents. The results of a follow-up study concurred with the previous
results in that drug-eluting stents lowered the restenosis rate by 50% in diabetic patients with one
implanted drug-eluting stent, compared to diabetic patients with one implanted bare metal stent
[83]. Although, on average, sirolimus-eluting stents and paclitaxel-eluting stents are associated
with a significant reduction in target lesion revascularization compared to bare metal stents, the
overall mortality and cardiac mortality of all three stents are quite similar [84]. However, as
mentioned before in 1.3.3, when comparing paclitaxel-eluting against sirolimus-eluting stents in
patients with diabetes mellitus, the use of sirolimus-eluting stents is associated with a decrease in
late luminal loss and a reduced rate of restenosis compared to the use of paclitaxel-eluting stent
[85, 86].
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1.4.3 Summary of Clinical Results
To summarize, diabetic patients (mostly type II diabetics) with coronary artery disease
are highly susceptible to in-stent restenosis after stent implantation, due to the vascular
aggravation induced by the chronic hyperglycemic environment. There is an effort to improve
stent revascularization therapy for the diabetic population, but there is limited information from
clinical trials to guide manufacturers in the right direction for better treatment.

Thus, the

following section will reveal the purpose and goal of this thesis, and also touch upon the overall
perspective on how this study supports the development of improved in vitro testing of coronary
stent treatments.

1.5

Summary and Aims of the Thesis
Diabetes mellitus is an amazing disease to study – from its severe, deadly nature before

the dramatic discovery of insulin, to its variability as distinct types, it is a disease that seems to
produce new obstacles in treatment. However, its treatment coincides with the treatments of so
many other severe complications. The chronic hyperglycemic state exhibited by type II diabetics
is the root cause of the numerous complications associated with the disease – the most severe
complication being coronary artery disease; the leading cause of death in the world. The vessel
damage caused by hyperglycemia can lead to atherosclerotic plaque build-up in the coronary
vessels of the heart, and stent implantation is the most popular treatment to eliminate the
blockage. However, patients with diabetes experience a high rate of in-stent restenosis – the
reformation of the atherosclerotic blockage – due to the vascular injury caused by the
deployment of the stent.
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Stent designs are constantly modified and improved to meet the demands of
cardiovascular treatment, and it is important for stent producers to be able to evaluate the
practicality and mechanics of the designs in a time and cost efficient manner. While in vivo
animal models and clinical testing are vital for product evaluation, these are extremely expensive
and time consuming; thus, it would be beneficial to be able to test and evaluate stents beforehand
in a controlled in vitro setting that accurately replicates the environment of a coronary blood
vessel. A blood vessel model that accurately replicates the anatomy and physiology of a native
blood vessel – a blood vessel mimic (BVM) – could meet this need
The primary purpose of BVM research has been to evaluate the endothelialization of bare
metal and coated stents [87]. In the case of diabetes mellitus, an in vitro model of a diabetic
coronary blood vessel would be extremely useful to evaluate the failure behind the implantation
of bare metal and drug-eluting stents in the diabetic population with coronary artery disease, and
aid the improvement of the vascular treatment for the ailing population.
The goals of this thesis focused on the feasibility of creating and monitoring a
hyperglycemic environment that would help develop a diabetic/hyperglycemic BVM.
Hyperglycemia is the most significant root cause of the major complications in diabetics; thus, it
is no surprise that it was determined to be the basis of a diabetic BVM. However, before diving
into the creation of a diabetic BVM, it was necessary to test whether or not an induced
hyperglycemic environment could be created and monitored in vitro, and what the effects on
cells in culture would be.
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Therefore, this thesis was driven by the hypothesis that a high concentration of glucose
can be created and monitored in vitro to replicate the chronic state of hyperglycemia in a diabetic
environment. In order to test this hypothesis, the thesis was broken down into three major aims:
1. Establish a protocol to create high glucose solutions in standard cell culture media
2. Establish a protocol to accurately monitor the concentrations of the high glucose
solutions
3. Test this monitoring protocol in cell culture over time and determine how the high
glucose solutions affect endothelial cells
These aims served the purpose of determining whether or not a feasible hyperglycemic
environment can be induced into an in vitro BVM; thus, ultimately allowing the creation of a
diabetic blood vessel environment. The potential success of this study would progress towards
an improved evaluation of bare metal and drug-eluting stents that currently experience a high
rate of in-stent restenosis in diabetic patients with coronary artery disease.
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Chapter 2: Establishment & Evaluation of High
Glucose Solutions in Order to Create Hyperglycemic
Environments
2.1

Introduction
As discussed in Chapter 1, diabetes mellitus is one of the most common and deadliest

diseases among Americans. According to the American Diabetes Association, about 23.6
million adults and children in the United States are diagnosed with diabetes – which is 7.8% of
the population [88]. Diabetes is most commonly seen in two forms, type I and type II. Type I
diabetes, also known as insulin deficient (or dependent) diabetes, is an autoimmune disease that
degrades pancreatic ß-cells; thus, preventing the secretion of insulin. Patients suffering from this
type of diabetes are usually treated with subcutaneous insulin injections. Type II diabetes, also
known as insulin resistant (or independent) diabetes, occurs due to genetics, poor diet, and poor
health. The result is complete dysfunction of pancreatic ß-cells; thus, the body no longer
responds to the physiological effects of insulin and results in a chronic hyperglycemic state.
Patients suffering from type II diabetes may be treated with insulin along with oral medication;
however, significant lifestyle changes involving improved diet and increased exercise are
necessary. Out of the 7.8% of Americans diagnosed with diabetes, about 95% have type II
diabetes making it the more significant and deadly form of the disease [88].
The high death rate associated with diabetes mellitus is due primarily to the
complications caused by hyperglycemia - high blood glucose concentration – in the body. The
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body’s inability to adequately control its blood glucose levels induces this hyperglycemic
environment and can lead to the severe complications that were discussed in section 1.2.5. Due
to its severity and significance, replicating a hyperglycemic environment is the desired approach
to accurately replicating a diabetic environment for a blood vessel mimic (BVM). The focus of
this chapter will revolve around studying the glucose concentrations of a hyperglycemic
environment, and the most practical method of replicating this environment for incorporation
with a BVM.

2.1.1 Significance of Hyperglycemia & Common Complications in Diabetic
Patients
As described in detail in Chapter 1, hyperglycemia is a condition seen in type I and type
II diabetics. If not treated properly, the condition can result in a range of complications. The
condition usually occurs in type I diabetics if an insufficient amount of insulin has been
delivered, but is more prevalent in type II diabetics since the metabolic effect of insulin is
ineffective. Miscalculations in carbohydrate counting when adjusting insulin dosages, or daily
stresses from life can worsen the hyperglycemic condition. For patients, it is important to
constantly monitor their own glucose concentrations and avoid drastic hyperglycemic episodes.
It is also important for diabetic patients (especially type I diabetics) to avoid hypoglycemic
episodes – a state of extremely low blood sugar – as it can lead to a diabetic coma and even
death. Since this study focuses on the effects of hyperglycemia in CAD patients with diabetes,
the state of hypoglycemia will not be discussed.
It is extremely important for diabetic patients to treat a severe case of hyperglycemia as
soon as it is detected. Failing to do so can first lead to a complication called ketoacidosis, which
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can also lead to a diabetic coma. The human body usually relies on glucose as its natural fuel.
Without insulin working effectively, the body is unable to breakdown glucose properly and is
required to break down fats as an energy source instead. Once the body breaks down fats, waste
products called ketones are produced that the body cannot tolerate at high levels. This results in
the body’s attempt to rid of the ketones through urine but is usually unable to; thus, leaving an
excess that eventually ends up in the bloodstream causing ketoacidosis [89]. This condition is
life threatening and requires immediate attention (usual symptoms are shortness of breath,
nausea, vomiting, dry mouth, and even a fruity smelling breath) [89].
While lower states of hyperglycemia do not cause severe complications rapidly, a
prolonged hyperglycemic condition usually leads to more long-term complications including
hypertension, neuropathy, nephropathy, eye complications (retinopathy, cataracts, glaucoma),
and most significantly heart disease – notably, coronary artery disease (CAD) [88]. Table 2 lists
the most significant complications of hyperglycemia and provides brief descriptions.
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Table 2 - Common complications associated with diabetes mellitus resulting from hyperglycemia
Complication

Description

Ketoacidosis

Diabetic coma; increased blood ketone
concentration & metabolic acidosis

Hypertension

Increased blood pressure

Neuropathy

Impaired nervous system signaling

Nephropathy

Kidney disease leading to protein leakage
into urine

Retinopathy

Decreased vision or blindness due to
damages to retinal vasculature

Glaucoma

Disease affecting optic nerve and loss of
retinal ganglion cells

Heart Disease/Coronary Artery Disease

Disease of the coronary artery involving
accumulation of atherosclerotic plaques
within blood vessel walls

2.1.2 Vascular Damage Induced by Hyperglycemia
As noted before, microvascular diseases are extremely prevalent in diabetic patients [91],
and these alterations to the vasculature are the most common causes of mortality in diabetics
[90]. Hyperglycemia is associated with endothelial cell dysfunction and reduced
neovascularization – essential steps for wound healing and prevention of cardiovascular ischemia
[92]. Studies have demonstrated that in patients with cardiovascular risk factors, such as the
complications associated with diabetes, the number of endothelial progenitor cells is reduced and
their functions are impaired [93]. For example, several animal models of diabetes showed
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increased vascular permeability [94], alterations in erythrocyte velocity [95], entrapment of
leukocytes in microcirculation [96, 97], and morphological alterations, such as changes in
vascular density [95]. All these alterations are mainly described as a result of hyperglycemia
[98, 99]. One study has illustrated that in type I diabetes, endothelial progenitor cell numbers are
inversely correlated with HbA1C levels, demonstrating that a high degree of blood glucose
concentration directly affects endothelial cell proliferation and differentiation [100].
Further studies with diabetic mice showed a decrease in vascular density; however, there
was also an increase in vessel diameter (Figure 13) [90]. The increase in vessel diameter
resulted in the combination of an unchanged blood flow rate and a lower vascular density,
therefore, leading to decreased tissue perfusion in subcutaneous tissue and an impaired supply of
oxygen and nutrients [90]. This explains the impaired wound healing seen in diabetics as
mentioned previously. The increase in vessel diameter and the reduction in vessel density
correlated with the levels of hyperglycemia represented by the blood glucose levels and body
weight of the diabetic mice. Additionally, these correlations support the hypothesis that
impaired glycemic control progressively leads to functional and morphologic alteration in the
vasculature of early-stage diabetes [90].
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Figure 13 - A study by Algenstaedt et al. showed that diabetic mice experienced a decrease in
vascular density, but an increase is vascular diameter with an increase in glycemic concentration
(Permission to reprint from [90]).
Despite the drastic impact of hyperglycemia on endothelial dysfunction and
microcirculatory properties, more needs to be understood about the alterations of endothelial
cells during the development of diabetes. Recall, diabetics with CAD have a high rate of in-stent
restenosis after implantation. With all of the supporting information, it is reasonable to propose
that the high rate of restenosis in diabetics is the result of the chronic hyperglycemic
environment of their blood vessels.

2.1.2.1

Molecular Mechanisms of Glucose-Mediated Vascular Damage

Four main mechanisms have been hypothesized on how hyperglycemia causes diabetic
complications. These four mechanisms are: increased polyol pathway flux; increased advanced
glycation end-product (AGE) formation; activation of protein kinase C (PKC); and increased
hexosamine pathway flux (Figure 14) [167].
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Figure 14 - Potential mechanisms by which hyperglycemia-induced mitochondrial superoxide
overproduction activates four pathways of hyperglycemic damage (Permission to reprint by
[167]).
For the polyol pathway, aldose reductase is the first enzyme that is responsible for
catalyzing glucose. In normal glucose concentrations, a very small percentage of glucose is
metabolized via this pathway; however, in a hyperglycemic environment, the increased
intracellular glucose concentration results in the conversion of glucose to the polyalcohol sorbitol
and a coinciding decrease in NADPH [167]. Mechanisms have been proposed as the root cause
of the negative effects induced by a hyperglycemic environment. These mechanisms include
osmotic stress induced by elevated sorbitol concentrations; decreased (Na+ + K+) ATPase
activity; and an increase in cytosolic NADH/NAD+ and a decrease in cytosolic NADPH [167].
The reduction of glucose to sorbitol by NADPH consumes NADPH, which is required for
regenerating reduced glutathione (GSH). Decreased levels of GSH have been found in
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transgenic mice that overexpress aldose reductase; thus, is most likely the mechanisms that
results in detrimental consequences via the increased flux through the polyol pathway [168].
However, in vivo studies of inhibition of the polyol pathway have yielded inconsistent results – a
five-year study in dogs showed a prevention of diabetic neuropathy but failure to prevent
retinopathy or thickening of capillary basement membrane in the retina and kidney, with the
inhibition of aldose reductase [169].
Advanced glycation end-products (AGEs) have been found at excessive concentrations in
diabetic retinal vessels [170] and renal glomeruli [171]. Additionally, it now seems likely that
intracellular hyperglycemia initiates the formation of intracellular and extracellular AGEs [172].
Intracellular auto-oxidation of glucose to glyoxal [173], decomposition of glucose-derived 1amino-1-deoxyfructose lysine adducts to 3-deoxyglucosone, and fragmentation of
glyceraldehyde -3-phosphate and dihydroxyacetone phosphate to methylglyoxal [174] can cause
an acrease in AGEs. The production of intracellular AGE precursors damage target cells by
three general mechanisms. First, intracellular proteins modified by AGEs have altered function;
second, extracellular matrix components modified by AGE precursors interact abnormally with
other matrix components and receptors for matrix proteins on cells; and third, plasma proteins
modified by AGE precursors bind to AGE receptors on endothelial cells, mesangial cells and
macrophages, inducing receptor-mediated production of reactive oxygen species [167]. For
endothelial cells specifically, fibroblast growth factor is one of the main AGE-modified proteins
[175]. Additionally, AGE formation alters the functional properties of several matrix molecules
– intermolecular AGE crosslinking induces an expansion of the molecular packing on type I
collagen [176], which has been shown to decrease elasticity in large vessels from diabetic rats
[177]. Lastly, AGE formation on extracellular matrix also interferes with matrix-cell interaction
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[167]. For example, type IV collagen’s cell-binding domains are modified by AGE causing a
decrease in endothelial cell adhesion [178].
Increased protein kinase C (PKC) activity is induced by hyperglycemia since
hyperglycemia increased diacylglyceral (DAG) concentration; DAG is responsible for the
activation of protein kinase C. Activation of PKC has numerous detrimental consequences.
Early studies have shown that the activation of the β PKC isoform mediated blood flow
abnormalities by depressing nitric oxide production and/or increasing endothelin-1 activity
[167]. Activation of PKC also causes an increased expression of VEGF, which enhances
vascular permeability of smooth muscle cells and also induces angiogenesis [167]. Additionally,
PKC activity contributes to increased microvascular matrix protein accumulation by inducing the
expression of TGF- β1, fibronectin, the fibrinolytic inhibitor PAI-1, and type IV collagen, which
contributes to capillary and overall vascular occlusion [179, 180].
Lastly, excessive intracellular glucose into the hexosamine pathway may also induce
several diabetic complications [181]. In this pathway, when glucose is converted to glucose-6phosphate and then converted to fructose-6-phosphate, instead of entering glycolysis, fructose-6phosphate is used to provide substrates for reactions that require UDP-N- acetylglucosamine,
such as proteoglycan synthesis and the formation of O-linked glycoproteins [167]. Conversion
of fructose-6-phosphate to glucosamine with the rate-limiting enzyme GFAT increases
hyperglycemia-induced increased in the transcription of TGF- β1 and PAI-1; thus, this pathway
is also plays an important role in hyperglycemia-induced and fat-induced insulin resistance [182,
183]. Though it is not entirely known how the mechanisms by which increased activity through
the hexosamine pathway initiates hyperglycemic-induced increases in gene transcription, there
has been an observation that binding sites for the transcription factor Sp1 regulate the
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hyperglycemia-induced activation of PAI-1 promoter in vascular smooth muscle cells [184].
This suggested that modification of Sp1 by N-acetylglucosamine (G1cNAc) might explain the
link between the activation of the hexosamine pathway and the hyperglycemic-induced changes
in the transcription of the gene for PAI-1 [167]. Additionally, recent studies have shown
hyperglycemia increasing activity of the hexosamine pathway 2.4-fold in aortic endothelial cells
[185]. In addition to transcription factors, many other nuclear and cytoplasmic proteins are
modified by O-linked G1cNAc, such as the inhibition of eNOS activity by hyperglycemicinduced O-acetylglucosaminylation at the Akt site of the eNOS protein [186]. Thus, activation
of the hexosamine pathway by hyperglycemia can result in changes to gene expression and
protein function, contributing to the pathogenesis of diabetic complications.
Since hyperglycemia is one of the most significant factors in diabetes, high glucose
solutions were proposed as the most feasible method of replicating a diabetic environment in a
BVM. However, before exploring the creation and evaluation of the hyperglycemic
environments, it is essential to first understand the fundamental physiology of blood glucose in
the human body, and the basics behind the metabolic dysfunction that results in hyperglycemia.

2.1.3 Blood Glucose
2.1.3.1

Properties of Glucose

Glucose is an extremely important monosaccharide – a simple sugar – used as a source of
energy and metabolic intermediate for living cells. The name “Glucose” comes from the Greek
word glukus, meaning “sweet.” The suffix “-ose” denotes sugar [101].
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The chemical formula for glucose is C6H12O6, and its structure makes it an aldohexose,
that is, a hexose with an aldehyde at the end (Figure 15) [102]. A hexose is a monosaccharide
with six carbon atoms and usually has the chemical formula C6H12O6 [102]. An aldehyde is an
organic compound containing a terminal carbonyl group (Figure 16) [103]. This is a functional
group that contains a carbon atom bonded to a hydrogen atom and double-bonded to an oxygen
atom (chemical formula O=CH). In solution, the glucose molecule can exist in an acyclic (openchain) and a cyclic (ring) form. The cyclic form, also referred to as glucopyranose, is a result of
the aldehyde carbon atom double-bonded to the hydroxyl group (oxygen bonded to a hydrogen)
on the fifth carbon of the open chain – making a six-member ring (Figure 17) [102]. At a neutral
pH of 7 and in solid form, glucose takes its cyclic form.

Figure 15 - Glucose is an aldohexose; a hexose with an aldehyde attached at the end (Permission
to reprint from [102]).
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Figure 16 - An aldehyde is an organic compound containing a terminal carbonyl group
(Permission to reprint by [103]).

Figure 17 - The cyclic form of glucose, glucopyranose, results from the aldehyde carbon atom
double-bonded to the hydroxyl group on the fifth carbon of the open chain (Permission to reprint
by [102]).
There are two stereoisomers of the aldohexose sugars referred to as glucose: L-glucose
and D- glucose, but only D-glucose is biologically active (Figure 18) [102]. Stereoisomers are
isomeric molecules with the same molecular formula and sequence of bonded atoms, but differ
only in 3-D orientation. The orientation of L-glucose (pretty much a mirror-image of D-glucose)
disables it from being metabolized by cells via glycolysis; however, L-glucose is not entirely
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unnecessary [102]. While it is less sweet than D-glucose and it cannot be used as a source of
energy, L-glucose can be converted into a low-calorie sweetener. In addition, L-glucose has
been found to be a laxative and has been proposed as a colon-cleansing agent [104].

Figure 18 - D-glucose and L-glucose are two stereoisomers of the aldohexose sugars. However,
D-glucose is the biologically active form (Permission to reprint by [102]).

2.1.3.2

Normal Blood Glucose Levels

Most mammals normally maintain a blood glucose level within the range of 3.6 mmol/L
and 5.8 mmol/L (about 80 mg/dL to 120 mg/dL). The average normal blood glucose level in a
human is 5 mmol/L (approximately 90 mg/dL). Thus, the total amount of glucose circulating in
blood, assuming the blood volume in an adult human is 5 L, is about 3.3 to 7.0 grams [105].
According to the American Diabetes Association, after a person consumes an average size meal,
the post-meal glucose levels for a non-diabetic person usually reach 140 mg/dL (7-8 mmol/L)
[88]. Diabetics, however, have a pre-meal glucose level of 90 mg/dL-130 mg/dL and can reach a
post-meal glucose level of 180 mg/dL [106].
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While this may seem like a substantial difference to some, it is actually quite surprising
that such a small amount of glucose is circulating in the blood. Assuming that the average adult
male is 165 lbs. (75 kg) and contains a blood volume of 5 L (1.3 gal), a normal blood glucose
level of 100 mg/dL (5.5 mmol/L) is equivalent to only 5 g of glucose in the entire volume of
blood, and about 45 g in the total volume of body water [105]! To visualize this, 5 grams of
sugar is about the mass of a small packet of Splenda sugar. It is astonishing that such an
insignificant amount of glucose can differentiate a healthy patient from a diabetic patient.
Knowing the various blood sugar ranges is useful when diagnosing diabetes mellitus. A
type I diabetic will usually have very low plasma insulin levels during fasting and after a meal.
This is contrary to type II diabetics who have abnormally high levels of plasma insulin during
fasting and after a meal. This level increases even more after ingesting a “load” of glucose
during a glucose tolerance test [107]. A glucose tolerance test helps establish the diagnosis of
diabetes and also the type. As seen in the “glucose tolerance curve” (Figure 19), when a normal
fasting person ingests 1 gram of glucose per kilogram of body weight, the blood glucose level
increases from about 90-100 mg/dL to about 120-140 mg/dL, and falls back to its normal values
after 2 hours [107]. Recall that in a person with diabetes, the starting fasting blood glucose level
is usually around 120-130 mg/dL (it can even be above 140 mg/dL depending on the severity).
After ingesting 1 gram of glucose, these patients exhibit a much greater rise in blood glucose
concentration and take about 4-6 hours to return to normal levels, sometimes not even reaching
normal levels and never dipping below it [107]. The slow fall of the curve and the failure to fall
below healthy glucose levels demonstrates that either normal insulin secretion after glucose
ingestion does not occur, or there is a decreased sensitivity to insulin. Distinguishing between
type I and type II diabetes in these patients comes down to analyzing the plasma insulin levels –
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again, with plasma insulin being low or undetectable in type I diabetics, and high in type II
diabetics.

Figure 19 – A glucose tolerance test illustrates that a normal patient who has consumed glucose
will return to homeostasis after about 2 hours. A diabetic patient, however, will take 4-6 hours
and sometimes not even reach normal glycemic levels. Distinguishing between type I and type II
diabetes comes down to analyzing the plasma insulin levels – low levels in type I diabetics, and
high levels in type II diabetics (Permission to reprint by [107]).

2.1.3.3

Metabolism & Regulation of Glucose

Most of the mechanics and characteristics of the human body’s physiologic functions are
based on one common goal – achieving and maintaining homeostasis. Homeostasis is a property
of an open or closed system, in this case the human body, which regulates its internal
environment and tries to maintain a stable, constant condition. Vitals such as blood pressure,
heart rate, calcium-release, hormonal secretions, and especially blood glucose levels try to
achieve and maintain a homeostatic state. When it comes to maintaining a stable blood glucose
level, carbohydrate metabolism with the help of insulin plays a key role. The final products of
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carbohydrate digestion are usually glucose, fructose, and galactose – glucose usually
representing about 80% of the end products [108]. After absorption through the intestinal tract,
most of the fructose and almost all of the galactose is converted to glucose in the liver; thus,
leaving little fructose and galactose circulating in the blood [108]. Therefore, more than 95% of
all monosaccharides circulating in the blood is glucose, and when carbohydrates transport
through cell membranes, it is common for carbohydrates to convert into glucose first [109].
The maximum molecular weight for a particle to diffuse readily through a cell membrane
is usually 100 atomic mass units (amu). Although glucose has a molecular weight of 180 amu, it
still passes into the interior of cells with a reasonable degree of freedom via facilitated diffusion
[109, 110]. Facilitated diffusion is the transport of a particle, in this case glucose, with the help
of a carrier enzyme. Penetrating through the lipid matrix of the cell membrane are large numbers
of protein carrier molecules that bind with glucose, cause glucose to undergo a conformational
change, and easily transport the newly structured glucose to the other side of the cell membrane.
This process is usually initiated by an existing concentration gradient that promotes more
glucose to follow into the cell [110].
Insulin drastically increases the rate of glucose transport – nearly ten times more than the
rate of transport when insulin is not present. To initiate the process of glucose consumption on a
target cell, insulin first binds to the α-subunits of its cell membrane receptor protein outside of
the cell, which causes the autophosphorylization of the receptor’s β-subunits inside the cell; thus,
making the insulin receptor protein an enzyme-linked receptor[107] (Figure 20). Enzyme-linked
receptors are proteins that pass through the cell membrane only once and have a hormone
binding site on the outside of cell and the enzyme-binding site inside the cell [110]. Once
activated by the hormone binding to the receptor, the enzyme inside the cell is immediately
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activated. The autophosphorylization of the β-subunits activates tyrosine kinase, which causes
the phosphorylation of insulin-receptor substrates (IRS) [107]. IRS control glucose metabolism
cause glucose transporters to be moved to the cell membrane in order to facilitate glucose entry
into the cell [107].

Figure 20 - The binding of insulin to its cell membrane receptor induces a series of subsequent
events, which cause the facilitated diffusion of glucose into the cell (Permission to reprint from
[107]).
Insulin secretion is associated with energy abundance, that is, when there is a great
abundance of energy-giving foods in a person’s diet (high carbohydrate diet), large quantities of
insulin are secreted due to the high concentration of blood glucose [111]. Therefore,
carbohydrate metabolism is a significant factor for diabetes. Insulin also plays a key role in
storing excess energy in liver cells in the form of glycogen – a large polymer of glucose –
through the process of glycogenesis. Between meals, when food is not available and blood
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glucose concentration begins to fall, insulin secretion decreases rapidly and the glycogen in the
liver is converted back into glucose and secreted back into the blood to maintain homeostasis.
As blood glucose concentrations rise above 100mg/dL, the rate of insulin secretion increases
rapidly [107] (Figure 21).

Figure 21 - As blood glucose concentration rises, the rate of insulin secretion rises at a rapid rate.
This increase in insulin secretion is non-existent in type I diabetics, and ineffective in type II
diabetics – thus, resulting in hyperglycemia (Permission to reprint by [107]).
The rate of insulin secretion can reach nearly 20-25 times the basal level at extremely
high blood glucose concentrations. The cessation of insulin secretion is almost equally as rapid,
occurring within 3-5 minutes after blood glucose levels return back to the normal fasting level
[107]. This association is an important feedback mechanism for regulating blood glucose
concentration; however, in type I diabetics, this feedback mechanism is non-existent [112].
While this mechanism is present in type II diabetics, a dysfunction in the insulin-signaling
cascade results in insulin resistance.
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2.1.3.4

Dysfunction of Glucose Metabolism & Insulin Signaling

The dysfunction in the mechanism of insulin secretion in diabetic patients starts with the
destruction of pancreatic ß-cells. The ß-cells have a large number of glucose transporters,
GLUT-2 and GLUT-4 for example, that permit a rate of glucose influx that is correlated to the
blood glucose concentration [113]. Glucose is then phosphorylated inside the ß-cells into
glucose-6-phosphate by an enzyme called glucokinase. This step senses and adjusts the amount
of insulin that will be secreted. Glucose-6-phosphate is oxidized to form adenosine triphosphate
(ATP), which inhibits ATP-sensitive potassium channels. This inhibition of potassium entering
the cell causes drastic depolarization, which in turn, activates voltage-gated calcium channels.
The entrance of calcium stimulates vesicles, containing insulin, to fuse with the cell membrane,
and secrete insulin into the blood via exocytosis [114] (Figure 22).

Figure 22 - The influx of glucose into the pancreatic ß-cells is controlled by glucose transporters
(GLUT-2 and GLUT-4) depending on the blood glucose concentration (Permission to reprint
from [107].
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With the destruction of ß-cells in type I diabetics, there is a lack of glucose transporters
and glucokinase to phosphorylate the glucose into glucose-6-phosphate; thus, resulting in a lack
of insulin secretion to compensate for the increase in blood glucose concentration.
Insulin resistance in type II diabetes is caused by abnormalities of the signaling pathway
that link the activation of the cell membrane insulin receptor with the multiple subsequent
cellular mechanisms that result in glucose uptake [115]. Although many of the proximal steps in
insulin signaling have been identified [116], the downstream pathways that are important for
insulin to maintain glucose homeostasis are less well defined [117]. Different IRSs are
expressed in different tissues, but produce the desired effects on insulin signaling [107, 115].
Some animal studies associated insulin resistance with the defects and inactivity of
phosphoinositide 3-kinase – an enzyme responsible for intracellular trafficking – resulting in
decreased activation of glucose transport proteins [117, 118]. Other animal studies claim that the
defect in signaling occurs between the insulin receptors and the phosphorylation of IRS and other
enzymes within the cell [119]. The exact dysfunction in the signaling cascade is still under
investigation, but proposed mechanisms, if correct, offer new therapeutic targets for insulinsensitizing agents, especially for type II diabetics.

2.1.3.5

Summary

Hyperglycemia is the major consequence of diabetes since it is the root cause of so many
complications in diabetic patients. Hyperglycemia is characterized as high concentration of
blood glucose. The aim of this thesis is to create a diabetic BVM, and from the research that was
conducted, the most practical method of inducing a diabetic environment was to induce a state of
hyperglycemia. Therefore, the first set of experiments conducted and explained in this chapter
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involved the creation of a hyperglycemic environment, which was hypothesized as a high
glucose cell media solution. In addition, an established method of monitoring the glycemic cell
media solutions was necessary. Thus, the goals of the studies in this chapter were:
1. To explore and identify practical methods of measuring levels of glucose in different
glycemic cell media solutions;
2. To develop and establish a procedure to create hyperglycemic cell media solutions
with the addition of glucose into base cell media; and
3. To use the hyperglycemic cell media solutions in order to evaluate the different
methods of monitoring glucose concentrations and determine the most feasible method.
The following section begins by describing various methods available for measuring
blood glucose concentrations, followed by methods of creating different hyperglycemic solutions
to test the reliability of various glucose monitoring methods.

2.2

Methods
There are a variety of methods to measure blood glucose concentrations, ranging from

bio-implants and continuous monitoring systems, to blood glucose meters and visual blood
glucose test strips. Since the glycemic solutions in these experiments would be produced using
cell culture media instead of blood, it was essential to assess not only the feasibility of each
method, but also the method that would provide the most accurate and precise results in cell
culture solutions. A range of methods was first reviewed, as will be summarized below, and then
the top two methods were selected for experimental testing.
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2.2.1 Methods of Measuring and Monitoring Blood Glucose
In this section, three methods for measuring blood glucose are described: blood glucose
meters, continuous glucose monitoring systems, and visual blood glucose strips. In addition to
these methods, a look into future methods of monitoring, such as glucose sensing bio-implants,
and other non-invasive technologies, are briefly discussed.

2.2.1.1

Blood Glucose Meter

A blood glucose meter is a medical device used to measure blood glucose concentrations.
The meter requires only a small drop of blood (3 µL – 10 µL) that is obtained by pricking the tip
of a finger with a small lancet, and a disposable test strip consumes the drop of blood, via
capillary action and measures the blood glucose level in units of mg/dL or mmol/L. This device
is a key addition to “home blood glucose monitoring” and helps patients avoid
hyperglycemic/hypoglycemic episodes by testing several times a day.
The blood glucose meter functions via the oxidation of glucose to gluconolactone that is
catalyzed by glucose oxidase (GOD), or some meters use a similar reaction catalyzed by glucose
dehydrogenase (GDH) instead [120]. Most meters use an electrochemical method with the
mentioned reagents. The disposable test strips contain a capillary that sucks up the drop of blood
and the glucose within the blood reacts with an enzyme electrode containing either GOD or
GDH [121]. The enzyme is reoxidized with an excess of ferricyanide ion, a mediator reagent,
and this mediator in turn is reoxidized by the reaction at the electrode that generates an electric
current. The total charge that passes through the electrode is proportional to glucose
concentration in the drop of blood that reacted with the electrode [122]. This method is an
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example of the coulometric method – very much equivalent to determining how hard a ball was
thrown by measuring the distance it traveled in a certain amount of time.
The first two models of the blood glucose meters to dominate North America were the
Glucometer (owned by Bayer) and the Accu-Chek (by Roche, previously known as Boehirnger
Mannheim) (Figure 23) [123]. Compared to visual glucose test strips, which were more popular
before the arrival of the blood glucose meter, blood glucose meters are preferred by patients
mostly for the ease of use. However, the accuracy of glucose meters is a common clinical
concern [123, 124].

Figure 23 - The Aviva Accu-Chek blood glucose meter is the most popular meter used among
diabetics to test blood sugar levels (Permission to reprint by Accu-Chek Blood Glucose
Monitoring Systems).
Most blood glucose meters have the same level of accuracy (+/- 10%-15%); however,
factors such as calibration of the meter, ambient temperature, size and quality of the blood
sample, contamination of the meter, humidity, and aging of the associated test strips can affect
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the accuracy of each test [125]. To limit the inaccuracy of test results, the Clarke Error Grid
Analysis (EGA) (Figure 24) was a common way of analyzing and displaying accuracy of
readings [126]. The EGA was developed in 1987 to quantify the clinical accuracy of a patient’s
estimate of their blood glucose levels compared to the value obtained on the meter [127]. The
EGA became accepted as the key reference for determining the accuracy of blood glucose
meters. The grid was broken down as a scatter plot comparing a reference glucose meter and an
evaluated glucose meter into five regions:
Region A – values within 20% of the reference glucose meter
Region B – values outside of 20% but do not lead to inappropriate treatment
Region C – values leading to unnecessary treatment
Region D – values indicating potentially dangerous failure to detect glycemic imbalance
Region E – values that confuse treatment of hypoglycemia or hyperglycemia
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Figure 24 - The Clarke Error Grid Analysis (EGA) was developed to quantify the clinical
accuracy of a patient’s estimate of their blood glucose compared to the value obtained on the
meter. Patients could estimate their blood glucose levels by another blood glucose meter or
visual test strips (Permission to reprint by [127]).
The analysis takes into account the value of the evaluated blood glucose meter, the value
of the reference blood glucose meter, the relative difference between the two values, and the
clinical significance of the difference [127]. Although there is a level of inaccuracy in blood
glucose meters, animal and clinical studies monitoring diabetic patients use multiple blood
glucose meters to ensure that an accurate blood glucose level is being measured [128].

2.2.1.2

Continuous Glucose Monitoring

A continuous glucose monitoring system (CGMS) is a device that monitors and records
blood glucose concentrations twenty-four hours a day (Figure 25). The idea behind this device is
to measure blood sugars continuously for 3-5 days while the diabetic patient conducts daily
routines and activities. The “sensor” of the CGMS is inserted subcutaneously just under the skin
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of the abdomen where it measures glucose levels in the tissue every 10 seconds. Information is
transmitted from the sensor to the associated insulin pump that reads and plots the changes in
glucose concentration. The entire system usually records an average glucose value every 5
minutes and plots it on a curve for the patient to see. While standard blood glucose meter
measurements are still taken and entered into the insulin pump for calibration, the CGMS
continuously measures the glucose concentrations during those critical times, such as before and
after a meal, during and after exercise, and during the night when the patient is asleep. After the
3-5 day period, the sensor is removed and stored information in the insulin pump is downloaded
to a computer where the plots of recorded glucose concentrations are printed in order to evaluate
fluctuations and patterns.

Figure 25 - The MiniMed Paradigm REAL-Time System uses a glucose sensor attached to a
wireless transmitter that records blood glucose levels and graphs it on the incorporated insulin
pump (Permission to reprint by Medtronic Diabetes).
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This system is not intended for long-term self-care or as a replacement for the blood
glucose meter; the CGMS is mostly used to study patterns of a patient’s glucose levels,
especially at those critical times mentioned above. For example, a pattern or trend can indicate
that a patient’s blood glucose level is dangerously low during the night and is at risk of a
hypoglycemic episode while fast asleep. Or, a pattern revealing an elevated blood glucose level
during the afternoon can expose a patient’s tendency to eat a high carbohydrate lunch at work.
Though studies have shown that with the information given from the CGMS, patient HA1c
levels have decreased with adjustments to their therapies, the CGMS still cannot replace frequent
testing with blood glucose meters [129]. Animal tests are continuously conducted to ensure
CGMS are accurately monitoring glucose concentration. Testing on diabetic cats showed that
there was a good correlation between the CGMS values and blood glucose concentration
measured using a blood glucose meter [130]. Numerous clinical studies have shown that using
CGMS provides adequate information, and treatment changes would not have been made on the
basis of glucose meter data alone. The improvement of a patient’s health, however, is only
achieved if the information supplied by the system is used properly and effectively towards
improved insulin therapy [131, 132].
There are three main CGMS manufacturers – Medtronic, DexCom (Animus/J&J), and
Abbott. Medtronic currently has two FDA-approved CGM systems in the market – the Guardian
REAL-Time CGMS, and the MiniMed Paradigm REAL-Time System. DexCom has the
DexCom Seven, and Abbott has the FreeStyle Navigator. Though these systems are produced by
different manufactures, the overall concepts among the products are very similar with no
significant advantage of one over another.
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2.2.1.3

Visual Blood Glucose Test Strips

Visual blood glucose test strips are a convenient and simple alternative for diabetic
patients who occasionally monitor blood glucose levels (usually type II diabetic patients) and
patients who cannot afford the disposable test strips used for blood glucose meters. Visual blood
glucose test strips that change color (not to be confused with disposable test strips that are
associated with the blood glucose meter) were widely used in the 1980s and had a slight
advantage over the blood glucose meter since they could be cut longitudinally to save money.
However, once the accuracy and insurance coverage improved for the blood glucose meter,
visual blood glucose test strips lost popularity [124].
There are various types of visual blood glucose strips, usually taking measurements using
blood or urine. Blood glucose dipsticks react with blood glucose and display a color that
correlates with a specific glucose concentration. Unfortunately, urine glucose dipsticks cannot
reflect simultaneous blood glucose concentrations but do have incredible reproducibility and can
answer the question of whether or not a stable glucose concentration is being tested.
The type of visual blood glucose strip this chapter will focus on is the Betacheck
Glucoflex-R that uses a color comparison for accurate and clear readings with only a drop of
blood (10-20 µL) from the fingertip placed on the droplet zone of the test strip. The test zone of
the Glucoflex-R consists of two test pads that undergo a reaction with glucose via the glucose
oxidase/peroxidase reaction. This reaction causes a color change in direct proportion to the
amount of glucose in the blood. Typically, visual blood glucose test strips (including the
Glucoflex-R) will have approximately ten color assortments that correlate with glucose levels
from 20 mg/dL all the way to 800 mg/dL.
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One advantage of visual blood glucose strips over blood glucose meters is accuracy.
Glucose meters have to go through constant maintenance and calibration to ensure accurate
readings. The accuracy of chemical visual test strips (+/-5%) outdoes the accuracy of blood
glucose meters (+/- 10%-15%). The quality check for Glucoflex-R visual strips, however, only
involves comparing a new test strip against the “0” color reference on the container.
The most obvious limitation of these test strips, however, is the limited quantitative result
that is given along with the potential variance of the results. While blood glucose meters are able
to give an exact measurement, visual glucose strips can either give a range of values or an
estimation of a close value. In a comparative study, for blood glucose values less than or equal
to 180 mg/dL, blood glucose meters had the best correlation. For glucose values of 181-400
mg/dL, visual strips were just as accurate as meters, but not as precise [133].

2.2.1.4

Glucose sensing bio-implants

To ease the burden of continuous blood glucose monitoring on patients, the development
of long-lasting glucose sensing bio-implants is under development.
One particular product under development is the SMSI Glucose Sensor. The sensor is
implanted under the skin in a short outpatient procedure and is designed to automatically
measure interstitial glucose every few minutes. With a small external reader, the sensor will
communicate wirelessly allowing the user to monitor levels on demand [134]. The implanted
sensor’s targeted operational life is 6-12 months, after which it would be replaced [135].
Currently, this product is in the process of completing animal studies; however, results and
conclusions are not yet available for public viewing.
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2.2.1.5

Non-Invasive Technologies

One major burden diabetics continuously complain about is the constant finger pricking
that is necessary for blood glucose testing. Manufacturers of diabetic devices are researching
and developing new technologies that will not require direct contact with blood to measure
glucose levels. These new non-invasive technologies range from near IR detection, to
ultrasound, to dielectric spectroscopy [136, 137].
Although a thorough review of these emerging technologies is beyond the scope of this
thesis, one intriguing product under development is the Sensy Glucose Tracking System. Sensy
Medical is developing the new method of glucose monitoring using near-infrared (NIR) diffuse
reflectance spectroscopy (DRS) to measure glucose levels in a non-invasive manner [138]. NIR
light ranges from 750-2500nm and interacts differently with various molecules (fat, glucose,
protein, water, etc.) by absorbing different amounts of NIR light. The amount of light absorbed
is proportional to the concentration of the particular molecule [138]. Thus, the blood glucose
concentration will be measured in light absorbance units that can be converted to the usual blood
glucose units of mg/dL.

2.2.1.6

Summary

After researching and discussing the different practical methods available to measure
blood glucose concentrations, the next step was to determine the most feasible method(s) for the
laboratory and apply that method of measurement to the measurements of various glycemic
solutions. Based on the information from the above section, the most feasible methods to
monitor the glycemic solutions were the blood glucose meter and visual blood glucose test strips,
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mostly due to their quick return of results, availability, and affordability. Thus, the next step in
the study was to develop the procedure to create cell media solutions of various glucose
concentrations, in hopes that a solution with elevated glucose concentrations properly replicates
a hyperglycemic environment, and can be accurately measured by either the blood glucose meter
or the visual blood glucose test strips.
The following section discusses the experimentation conducted to develop and establish
various cell media solutions of specific glucose concentrations, and whether the tested methods
of measuring these glycemic solutions – the blood glucose meter and visual blood glucose test
strips – accurately and precisely measured the expected glucose concentrations.

2.2.2 Methods of Producing and Monitoring Different Glycemic Solutions
2.2.2.1

Levels of Glycemia

The first step taken when developing the proper procedure for creating glycemic cell
media solutions was to determine what glucose concentrations to achieve. Based on the
discussion regarding the different levels of hyperglycemia seen in diabetics, three different
glucose concentrations were specified, created, and monitored over time. The different glucose
concentrations were organized as follows:
Normal glycemic level: 100 mg/dL
Hyperglycemic level: 250 mg/dL
Extreme Hyperglycemic level: 400 mg/dL
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Four levels of hyperglycemia were initially attempted, but after preliminary testing, it
was difficult to maintain a degree of separation among the three glycemic levels without crossing
over into another level of hyperglycemia (see Appendix A for summary of preliminary testing).
Recall that only 5 grams of glucose are within the entire volume of blood in an average human
male (5 L); thus, there is an extremely small margin of error when adding glucose to small
volumes of cell culture media.

2.2.2.2

Cell Media with D-(+)-Glucose

To create the different glycemic cell media solutions, Sigma G6152 D-(+)-glucose
(Figure 26) was added to Gibco Medium 199 (+: Earle’s salts, L-Glutamine, 2.2 g/L Sodium
bicarbonate) (Figure 27) by Invitrogen. An important note to consider is that cell media does not
contain the same properties as blood. Blood contains many constituents (plasma, albumin,
hemoglobin, uric acid, etc.); thus, the viscosity of blood is much greater than the viscosity of just
cell media with added glucose. In addition, blood contains functioning and circulating cells that
are not present in cell media; however, for the purposes of creating an in vitro environment, the
use of cell culture media was appropriate.
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Figure 26 - Sigma G6512 D-(+)-Glucose was added to Gibco Medium 199 in the attempt to
create glycemic cell media solutions.

Figure 27 - Gibco Medium 199 by Invitrogen was used as the base cell media for the
experimentation of different glycemic cell media solutions. This media was also used for later
experimentation when developing glycemic cell media solutions for use with human umbilical
vein endothelial cells (HUVECs).
Three separate solutions were created for each level of glycemia. In order to produce the
different solutions, the following recipes were used:
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•

For the 100 mg/dL normal glycemic solution:
0.100 g of Sigma G6152 D-(+)-Glucose was weighed and added to 100
mL of Gibco Medium 199 in a 150 mL beaker

•

For a 250 mg/dL hyperglycemic solution:
0.250 g of Sigma G6152 D-(+)-Glucose was weighed and added to 100
mL of Gibco Medium 199 in a 150 mL beaker

•

For a 400 mg/dL extremely hyperglycemic solution:
0.400 g of G6152 D-(+)-Glucose was weighed and added to 100 mL of
Gibco Medium 199 in a 150 mL beaker

After the glucose was weighed and added to the cell media, each solution was placed on a
stir plate with a magnetic stir bar, and stirred for 30 minutes at 25ºC to promote uniform mixing.

2.2.2.3

Monitoring Hyperglycemic Levels

The blood glucose meter and the visual blood glucose test strips were the selected
methods of measurement to be tested. For this experiment, the glucose concentration of the
developed glycemic cell media solutions were then taken at t = 1, 2, 3, 4, 5, 6, 12, 24, 36, and 48
hours after mixing began.
Two blood glucose meters were used to monitor glucose concentration – the Aviva AccuChek blood glucose meter, and the Bayer Contour blood glucose meter. These meters were
chosen because the meters and the associated test strips were easily obtainable. Also, from
personal experience as a Medical Assistant in an Endocrinology office, these meters were the
favorite among doctors and patients due to their accuracy and reliability.
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The type of visual blood glucose strips used was the Glucoflex-R Blood Glucose Strips
(Figure 28). These strips were purchased from Ambe Medical Group in England and were at
$16.11 (9.99 GBP) for a set of 50 strips.

Figure 28 - Glucoflex-R Blood Glucose Strips by Ambe Medical Group in England (Permission
to reprint by Ambe Medical Group).
Before taking measurements for each solution at the specific time point, both meters and
the visual test strips were “calibrated” using Hyclone Dulbecco’s Modified Eagle Medium
(DMEM) / High Glucose (+: 4.00 mM L-Glutamine, 4500 mg/L Glucose, Sodium pyruvate)
4500 mg/L high glucose cell media. This was manufactured high-glucose cell media that was
already calibrated to accurately resemble a glucose concentration of 450 mg/dL; thus, it was used
to ensure each monitoring device was functioning properly.
The intention of using multiple blood glucose meters was to accumulate more data in
hopes of obtaining normalized data, while also assessing which method was most consistent and
appropriate for this application. The intention of the visual blood glucose strips was to ensure
that the tested cell media was at least within the correct glucose range, and also confirm an
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accurate and stable glucose environment. Considering the levels of inaccuracy for both glucose
meters and visual blood glucose strips, it was necessary to use both methods in order to identify
any variance in the results. Plus, it would also expose whether or not one of the methods was
significantly different from another.
After the glucose concentrations were recorded for the three solutions of each glycemic
level, an average was taken along with the standard deviation, and a percent error was calculated
based off of the targeted glucose level. Lastly, a series of two-tailed T-tests were conducted
between each solution based on method of measurement, and an ANOVA test was conducted on
all three solutions to ensure there was no statistical significant difference among the solutions
within the same method of measurement. The following section discusses the accumulated
results and analysis.

2.3

Results

2.3.1 Results of Preliminary Testing
Preliminary testing was conducted in order to establish the proper procedure of creating
the different glycemic solutions. Once established, the glycemic cell media solutions were tested
over a period of 48 hours in order to see which method of measurement was best for the
glycemic solution study. The Bayer Contour meter and its test strips were unable to give
consistent readings as an “error message” would continuously appear on the meter at random
time intervals. Therefore, only the results from the Accu-Chek blood glucose meter and the
Glucoflex-R visual blood glucose strips were used to draw conclusions. The following sections
analyze and discuss the results accumulated for each method of measurement for each developed
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glycemic cell media solutions. However, one note must be mentioned before discussing the
results, as it plays a significant role in the analysis of the results.

2.3.1.1

Glycemic Level of Gibco Medium 199

After testing, a significant attribution was discovered regarding the composition of the
Gibco Medium 199. The recorded glucose concentrations were higher than the expected; thus,
the chemical composition of the cell media was researched on the Invitrogen website. What was
discovered was that the Gibco Medium 199 was a “low glucose” cell media that already
contained of 1000 mg/L (100 mg/dL) of D-glucose (Figure 29).

Figure 29 - The Invitrogen website confirmed that the composition of the Gibco Medium 199
contained 1000 mg/L (100 mg/dL) of D-glucose.
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To confirm, measurements were taken via the Accu-Chek blood glucose meter as well as
the Glucoflex-R visual blood glucose strips, and both confirmed a glucose concentration of 100
mg/dL. Therefore, to compensate for the additional 100 mg/dL already within the cell media, the
expected glucose concentrations for each solution were adjusted to the following levels:
Adjusted Normal glycemic level: 200 mg/dL
Adjusted Hyperglycemic level: 350 mg/dL
Adjusted Extreme Hyperglycemic level: 500 mg/dL
Using the adjusted glucose concentrations, the accumulated data was analyzed.

2.3.1.1

Normal Glycemic Solutions (200 mg/dL)

A glycemic cell media solution of 200 mg/dL was developed to replicate a normal
glycemic environment. Recall, three solutions composed of 0.100 g of Sigma G6152 D-(+)Glucose and 100 mL of Gibco Medium 199 were created. Three solutions gave an adequate data
sample size for practical and repeatable data analysis. Table 3 displays the exact amounts of
glucose added to each volume of cell media.

Table 3 - Amount of Sigma G6152 D-(+)-Glucose added to 100 mL of Gibco Medium 199 for
200 mg/dL Normal Glycemic Solutions

1

Amount of Glucose Added
(g)
0.1009

2

0.1003

100

3

0.1004

100

Solution Sample
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Volume of Cell Media (mL)
100

The purpose of the additional glucose was to compensate for any glucose lost during the
transfer from the weigh boat to the beaker containing the cell media. After taking glucose
concentrations at the specific time intervals for 48 hours, the accumulated results matched the
expected glucose concentration of 200 mg/dL.
Figure 30 is a plot showing the recorded glucose concentrations using the Aviva AccuChek blood glucose meter. This plot shows that the blood glucose meter recorded values very
close to the expected concentration, and took approximately until t = 2 hours to reach the
expected glucose concentration of 200 mg/dL.

Figure 30 – The plot shows that the accumulated glucose concentrations by the Aviva AccuChek blood glucose meter matched the expected glucose concentration of 200 mg/dL for each
solution. The glucose concentration rose rapidly, but plateaued at the expected value after
roughly 2 hours of mixing.
As for the accumulated results by the Glucoflex-R visual blood glucose test strips, Figure
31 shows that, it too, was able to consistently measure a glucose concentration throughout the
entire test, and the results were approximately equivalent to the expected 200 mg/dL. However,
the recorded measurements were not nearly as precise as those of the Aviva Accu-Chek blood
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glucose meter, as outliers within the Glucoflex-R measurements are obviously apparent. The
Glucoflex-R visual strips also took until approximately t = 2 hours to record a consistent
measurement of roughly 200 mg/dL.

Figure 31 - The recorded glucose levels, using the Glucoflex-R visual test strips, were within the
expected range of 200 mg/dL. However, the variance of the recorded results was quite high, and
is not an ideal characteristic for a sensitive hyperglycemic environment.
Error! Reference source not found.Table 4 shows the average glucose concentrations
of each solution using the Aviva Accu-Chek blood glucose meter and the Glucoflex-R visual test
strips, as well as the percent error in relation to the expected 200 mg/dL glucose concentration.
Both methods of measurement had average glucose concentration close to the expected value
(except for solution 3, which consisted of the outlier), considering they had low percent errors.
However, the key factor to take into consideration is the low variance for the Aviva Accu-Chek
blood glucose meter compared to the high variance for the Glucoflex-R visual test strips. It can
be seen on Figure 30 and Figure 31 that the variance is much greater for the Glucoflex-R visual
test strips compared to the Aviva Accu-Chek meter. This level of variance is not ideal for
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obtaining an accurate and precise glucose concentration, especially given the sensitivity of any
hyperglycemic environment.

Table 4 - Average Glucose Concentrations Recorded with Accu-Chek Blood Glucose Meter &
Glucoflex-R Visual Blood Glucose Strips for 200 mg/dL Glycemic Solutions
Aviva Accu-Chek Blood Glucose Meter

Average
Glucose
Concentration
(mg/dL)
Standard
Deviation
% Error

Solution 1

Solution 2

Solution 3

Hyclone High Glucose
450 mg/dL Calibration

204.70

198.50

195.30

446.56

6.55

7.54

12.89

11.383

2.35 %

-0.75 %

-2.35 %

-0.765 %

Glucoflex-R Visual Blood Glucose Strips

Average
Glucose
Concentration
(mg/dL)
Standard
Deviation
% Error

Solution 1

Solution 2

Solution 3

Hyclone High Glucose
450 mg/dL Calibration

205.00

194.00

312.00

N/A

53.59

109.16

199.38

N/A

2.50%

-3.00 %

56.00 %

N/A

Lastly, a two-tailed T-test was conducted to compare the mean glucose concentrations of
each solution based on the method of measurement. The null hypothesis was that the mean
glucose concentration accumulated by the Aviva Accu-Chek blood glucose meter was equal to
the mean glucose concentration accumulated by the Glucoflex-R visual test strips (Ho: χAccu-chek =
χGlucoflex-R). Thus, the alternative hypothesis was that these two means were not equal (Ha: χAccuChek ≠

χGlucoflex-R). With a 95% confidence interval (α = 0.05), all p-values were greater than 0.05;
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thus, not rejecting the null hypothesis, and confirming that there was no statistical significant
difference.

In addition, an ANOVA test was conducted to compare the mean glucose concentrations
of all three solutions within each method of measurement. The null hypotheses were that the
mean glucose concentration of each solution measured by the Aviva Accu-Chek blood glucose
meter were equal (Ho: χSolution1 = χSolution2 = χSolution3), and that the mean glucose concentration of
each solution measured by the Glucoflex-R visual test strips were equal as well (Ho: χSolution1 =
χSolution2 = χSolution3). Once again, a 95% confidence interval was used (α = 0.05), and the
resulting p-values were greater than 0.05; thus, confirming no statistical significant difference
among the average glucose concentrations of each solution within the specific method of
measurement. Both the two-tailed T-tests and ANOVA tests indicated that the accumulated
glucose concentrations were statistically similar, and recording a concentration consistently close
to the expected concentration of 200 mg/dl. However, the high variance of the Glucoflex-R
visual strips was not an ideal attribute for the purposes of further experimentation.

2.3.1.2

Hyperglycemic Solution (350 mg/dL)

A hyperglycemic solution of 350 mg/dL was created to replicate a hyperglycemic
environment. The established protocol called for 0.250 g of glucose to be weighed and added to
100 mL of media for each solution. Table 5 displays the exact amount of glucose added to each
volume of cell media.
Table 5 - Amount of Sigma G6152 D-(+)-Glucose added to 100 mL of Gibco Medium 199 for
the 350 mg/dL hyperglycemic solutions
Solution Sample

Amount of Glucose Added
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Volume of Cell Media (mL)

1

(g)
0.2506

100

2

0.2501

100

3

0.2508

100

As with the 200 mg/dL solutions, after recording glucose concentrations for t = 48 hours,
the accumulated results matched closely with the expected concentration of 350 mg/dL.
Figure 32 shows that the recorded glucose concentrations for each solution, using the
Aviva Accu-Chek blood glucose meter, were very close to expected concentration of 350 mg/dL.
While it took approximately two hours for the 200 mg/dL solutions to settle at a consistent
concentration, the concentrations of the 350 mg/dL solutions gradually increased for the first few
hours and finally settled after approximately four hours of mixing.

Figure 32 – The plot shows that the glucose concentrations recorded by the Aviva Accu-Chek
blood glucose meter were similar to the expected glucose concentration of 350 mg/dL for each
solution. The glucose concentration rose rapidly, but settled after approximately four hours of
mixing.
As for the Glucoflex-R visual test strips, Figure 33 shows results similar to that of the
200 mg/dL solutions. The visual test strips were able to consistently record a glucose
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concentration, throughout the 72 hour experimentation time, that was within range of the
expected 350 mg/dL concentration. However, the reoccurrence of high variance of the recorded
glucose measurements continued to question the precision of the visual test strips. Recall, a high
variance is not an ideal characteristic for a method of measurement glucose concentrations
considering the sensitivity of any glucose environments.

Figure 33 – The recorded glucose concentrations, using the Glucoflex-R visual test strips, for the
350 mg/dL solutions, were within range of the expected glucose concentration. However, the
extremely high variance further proved the lack of precision of the visual test strips.
Table 6 shows the average glucose concentrations for each solution recorded by the
Aviva Accu-Chek blood glucose meter and the Glucoflex-R visual test strips, along with the
standard deviation and percent error from the expected glucose concentration of 350 mg/dL.
Since it took approximately four hours for the solutions to mix uniformly, the average glucose
concentration for each solution was calculated from t = 4 hours to t = 48 hours. This limited the
amount of variance in the data since the glucose concentrations recorded from t = 1 to t = 3 hours
did not properly represent the actual glucose concentration of each solution. Looking at Error!
Reference source not found.Table 6, the Aviva Accu-Chek blood glucose meter recorded
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concentrations close to the expected concentration of 350 mg/dL with limited variance. The
glucose concentrations recorded by the Glucoflex-R visual test strips, however, once again had
extremely high variance and were not as precise as the Aviva Accu-Chek blood glucose meter.

Table 6 - Average Glucose Concentrations Recorded with Accu-Chek Blood Glucose Meter &
Glucoflex-R Visual Blood Glucose Strips for 350 mg/dL Hyperglycemic Solutions
Aviva Accu-Chek Blood Glucose Meter

Average
Glucose
Concentration
(mg/dL)
(t = 4)
Standard
Deviation
(from t = 4)
% Error

Solution 1

Solution 2

Solution 3

Hyclone High Glucose
450 mg/dL Calibration

356.71

354.00

357.57

449.00

23.91

11.54

9.91

13.06

1.92 %

1.14 %

2.16 %

-0.222%

Glucoflex-R Visual Blood Glucose Strips

Average
Glucose
Concentration
(mg/dL)
(t = 4)
Standard
Deviation
(t = 4)
% Error

Solution 1

Solution 2

Solution 3

Hyclone High Glucose
450 mg/dL Calibration

364.29

321.43

292.86

N/A

201.48

128.64

18.90

N/A

4.08 %

-8.16%

-16.33 %

N/A

Again, to finalize the analysis, a two-tailed T-test was conducted to compare the
mean glucose concentrations of each solution based on the method of measurement. The null
hypothesis was that the mean glucose concentration accumulated by the Aviva Accu-Chek blood
79

glucose meter was equal to the mean glucose concentration accumulated by the Glucoflex-R
visual test strips (Ho = χAccu-Chek = χGlucoflex-R). Thus, the alternative hypothesis was that these two
means were not equal (Ha = χAccu-Chek ≠ χGlucoflex-R). With a 95% confidence interval (α = 0.05),
all p-values were greater than 0.05, therefore, not rejecting the null hypothesis and confirming
that there was no statistical significant difference between the means of the Aviva Accu-Chek
blood glucose meter and the Glucoflex-R visual test strips.

Lastly, an ANOVA test was conducted to compare the mean glucose concentrations of
each solution within each method of measurement. The null hypotheses were that the mean
glucose concentration of each solution measured by the Aviva Accu-Chek meter were equal (Ho
= χSolution1 = χSolution2 = χSolution3), and that the mean glucose concentration of each solution
measured by the Glucoflex-R visual test strips were equal as well (Ho = χSolution1 = χSolution2 =
χSolution3). Once again, a 95% confidence interval was used (α = 0.05), and both resulting pvalues were greater than 0.05, therefore, not rejecting the null hypothesis and confirming that
there was no statistical significant difference between the means of each solution within the
method of measurement.

Although statistical analysis confirmed that the glucose concentrations recorded by the
Glucoflex-R visual test strips were not statistically different from the glucose concentrations
recorded by the Aviva Accu-Chek blood glucose meter, the variance of the data accumulated
with the Glucoflex-R visual test strips was even higher than the variance from the 200 mg/dL
solutions. It was possible that the accuracy of the Glucoflex-R visual test strips decreased as the
glucose concentrations of the tested solutions increased.
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2.3.1.3

Extreme Hyperglycemic Solution (500 mg/dL)

A hyperglycemic solution of 500 mg/dL was created to replicate an extremely
hyperglycemic environment. The established protocol called for 0.400 g of glucose to be
weighed and added to 100 mL of media for each solution. Table 7 displays the exact amounts of
glucose added to each volume of cell media.

Table 7 - Amount of Sigma G6152 D-(+)-Glucose added to 100 mL of Gibco Medium 199 for
500 mg/dL extreme hyperglycemic solutions
Solution Sample

Volume of Cell Media (mL)

1

Amount of Glucose Added
(g)
0.4006

2

0.4002

100

3

0.4003

100

100

After accumulating the data, the results were very similar to those of the 200 mg/dL and
350 mg/dL solutions.
Figure 34 shows the plot of measured glucose concentrations for each 500 mg/dL
solution using the Aviva Accu-Chek blood glucose meter. The plot shows that the measured
glucose concentrations were very close to the expected concentration of 500 mg/dL. In addition,
the plot shows that it took approximately five hours for the solutions to mix uniformly. This was
not a surprise since it took approximately four hours for the 350 mg/dL solutions to mix
completely.
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Figure 34 - Even though the Accu-Chek glucose meter continued to measure glucose
concentrations higher than the expected value of 400 mg/dL, the average measurements were
much more accurate compared to the average measurements for the other glycemic
environments.
Figure 35 shows a plot of measured glucose concentrations for each 500 mg/dL solution
using the Glucoflex-R visual test strips. As with the results from the 200 mg/dL and 350 mg/dL
solutions, the visual test strips were able to consistently measure a glucose concentration for each
solution throughout the test, but the variation of the measurements was again very high relative
to the variation of the Aviva Accu-Chek blood glucose meter.
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Figure 35 - The Glucoflex-R strips were able to monitor the glucose concentrations of the
extremely hyperglycemic 400 mg/dL solutions much more accurately than the other glycemic
environments.
Error! Reference source not found.Table 8 shows that the calculated average glucose
concentrations obtained from the Aviva Accu-Chek blood glucose meter and the Glucoflex-R
visual test strips. Recall, it took approximately five hours for the solution to mix uniformly;
thus, the averages were taken from t = 5 hours to t = 48 hours. The calculated averages from the
Aviva Accu-Chek blood glucose meter were extremely close to the targeted value of 500 mg/dL,
resulting in a very low percent error for each solution. In addition, the Aviva Accu-Chek blood
glucose meter was able to measure glucose concentrations with limited variance (higher variance
than 200 mg/dL and 350 mg/dL solutions, but expected with the increased amount of glucose
added to the solutions). While the calculated average glucose concentrations obtained from the
Glucoflex-R visual test strips were close to the expected glucose concentration as well (solution
1 even hit 500 mg/dL exactly), the significant factor once again was the relatively high variance
of the Glucoflex-R data, especially in relation to the low variance seen with the data accumulated
by the Aviva Accu-Chek blood glucose meter. This confirms that, while the visual test strips are
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able to consistently measure the glucose concentrations throughout the test, the precision of the
blood glucose meter is much higher than that of the visual test strips in all three tested levels of
glucose concentration.

Table 8 - Average Glucose Concentrations Recorded with Accu-Chek Blood Glucose Meter &
Glucoflex-R Visual Blood Glucose Strips for 500 mg/dL extreme hyperglycemic solutions
Aviva Accu-Chek Blood Glucose Meter
Solution 1

Solution 2

Solution 3

Hyclone High Glucose
450 mg/dL Calibration

493.33

472.67

466.50

447.33

Standard
Deviation
(from t = 5)

27.990

10.482

11.221

6.250

% Error

-1.33

-5.48

-6.70

N/A

Average
Glucose
Concentration
(mg/dL)
(t = 5)

Glucoflex-R Visual Blood Glucose Strips

Average
Glucose
Concentration
(mg/dL)

Hyclone High Glucose

Solution 1

Solution 2

Solution 3

500.00

383.33

400.00

N/A

189.737

75.277

89.443

N/A

0.00

-23.33

-20.00

N/A

450 mg/dL Calibration

(t = 5)
Standard
Deviation
(t = 5)
% Error
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Lastly, a two-tailed t-Test was conducted to compare the mean glucose concentrations of
each solution based on the method of measurement. The null hypothesis was that the mean
glucose concentration accumulated by the Aviva Accu-Chek blood glucose meter was equal to
the mean glucose concentration accumulated by the Glucoflex-R visual test strips (Ho = χAccu-Chek
= χGlucoflex-R). Thus, the alternative hypothesis was that these two means were not equal (Ha =
χAccu-Chek ≠ χGlucoflex-R). With a 95% confidence interval (α = 0.05), all p-values were greater than
0.05, therefore, not rejecting the null hypothesis and confirming that there was no statistical
significant difference between the means of the Aviva Accu-Chek blood glucose meter and the
Glucoflex-R visual test strips.

Lastly, an ANOVA test was conducted to compare the mean glucose concentrations of
each solution within each method of measurement. The null hypotheses were that the mean
glucose concentration of each solution measured by the Aviva Accu-Chek meter were equal (Ho
= χSolution1 = χSolution2 = χSolution3), and that the mean glucose concentration of each solution
measured by the Glucoflex-R visual test strips were equal as well (Ho = χSolution1 = χSolution2 =
χSolution3). Once again, a 95% confidence interval was used (α = 0.05), and both resulting pvalues were greater than 0.05 (though, the p-value for the ANOVA test conducted on the
Glucoflex-R solutions was very close to 0.05, further confirming the troubles of high variance),
therefore, not rejecting the null hypothesis and confirming that there was no statistical significant
difference between the means of each solution within the method of measurement.

2.4

Discussion and Conclusions
Recall, the goals of this chapter were the following:
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1. To explore and identify practical methods of measuring levels of glucose in different
glycemic cell media solutions;
2. To develop and establish a procedure to create hyperglycemic cell media solutions
with the addition of glucose into base cell media; and
3. To use the hyperglycemic cell media solutions in order to evaluate the different
methods of monitoring glucose concentrations and determine the most feasible method.
Reviewing the literature confirmed that the most practical methods of monitoring glucose
concentrations of cell media solutions were the blood glucose meter and the visual blood
glucose test strip. Additionally, preliminary tests showed that the Aviva Accu-Chek glucose
meter and Glucoflex-R visual blood glucose strips gave accurate and reliable measurements.
Therefore, the Aviva Accu-Chek blood glucose meter and the Glucoflex-R visual blood glucose
test strips were used to measure glucose concentrations of three glycemic cell media solutions –
200 mg/dL, 350 mg/dL, and 500 mg/dL.
The results from the experiments in this chapter indicated that a high glucose
concentrated solution, with Sigma G6152 D-(+)-Glucose and Gibco Medium 199, can properly
represent a hyperglycemic environment. In addition, the Aviva Accu-Chek blood glucose meter,
over a 48 hour time period, was able to accurately and precisely monitor and record glucose
concentrations very close to the expected concentration of each glycemic cell media solution.
Though the Glucoflex-R visual test strips were able to consistently record an average glucose
concentration close to the expected concentration, the variability of the visual test strips was very
high – a characteristic that would be extremely detrimental to the data acquisition of further
experiments. In addition, although t-tests confirmed that there was not a statistical significant
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difference between the averages accumulated by the Aviva Accu-Chek blood glucose meter and
averages accumulated with the Glucoflex-R visual test strips, the combination of a low percent
error with a low standard deviation made the Aviva Accu-Chek blood glucose meter the better
option for evaluation of glucose concentration for glycemic cell media solutions.
One key observation was the amount of time necessary to ensure that all the added
glucose completely mixed into the cell media. While the 200 mg/dL media took relatively little
time to uniformly mix, the 350 mg/dL and 500 mg/dL solutions needed approximately four to
five hours of mixing before the solution mixed to its expected concentration. This time was
taken into consideration when establishing the protocol for developing glycemic cell media
solutions (Appendix D).
The greatest challenge of the experiments in this chapter was adding an accurate amount
of Sigma G6152 D-(+)-Glucose to the 100 mL of cell media. Even in a large volume of media,
an extremely small amount of glucose can cause a great fluctuation in the glucose concentration.
This error was limited by ensuring that a very small amount of additional glucose was weighed
to compensate for any lost glucose during transfer from the weigh boat to the solution. The
calculated percent errors of the results confirmed that this test procedure was executed correctly.
A possible way to avoid this complication, however, would be to use an even greater volume of
cell media. Adding glucose to 100 mL of cell media to achieve 200 mg/dL leaves an extremely
small margin of error; thus, it would be beneficial to increase the cell media volume to 500 mL
or even 1000 mL if necessary.
In addition, the concentrations that were used were slightly higher than the initial target
values, due to the existing glucose in M199. If cell media with 1000 mg/L (100 mg/dL) of D87

glucose is used in the future, here are the recipes that should be used for achieving 100mg/dl,
250mg/dl, and 400mg/dl as initially intended:
•

100 mg/dL
o 100 mL of M199 only
*Gibco Medium 199 already contains 1000 mg/L (100 mg/dL) of Dglucose; thus, no additional modifications are necessary

•

250 mg/dL
o Add 0.15 g of Sigma G6152 D-(+)-Glucose to 100 mL of M199

•

400 mg/dL
o Add 0.30 g of Sigma G6152 D-(+)-Glucose to 100 mL of M199

One last note was that the test initially called for two blood glucose meters to be used to
measure the glucose concentrations of the glycemic cell media solutions (the Bayer Contour
blood glucose meter along with the Aviva Accu-Chek blood glucose meter). Unfortunately, the
Bayer blood glucose meter was unable to give any recording at all as it consistently gave an
“error” message. One reason for this was probably due to the meter’s inability to analyze
glucose when it is in its cyclic structure. Recall, that at a neutral pH of 7.0, D-glucose is in its
cyclic form. The human body is not always at a pH of 7.0; thus, it is possible that glucose
circulating in blood is not in cyclic form and glucose meters accurately measure glucose
concentrations of blood only when it is in its straight chain form. The Gibco Medium 199 has a
pH of about 7.4 meaning that the tested glycemic solutions probably contained glucose in its
cyclic form.
The series of experiments in this chapter both established a procedure of creating
glycemic cell media solutions with the addition of Sigma G6152 D-(+)-Glucose to Gibco
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Medium 199, as well as a method of monitoring the glucose concentration of these solutions with
the Aviva Accu-Chek blood glucose meter. The next step of this thesis study involved the
incorporation of the developed glycemic solutions with endothelial cells, in an attempt to
determine whether or not the glycemic cell media solutions evoked a negative response by
endothelial cells. This work will be described in the next chapter.
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Chapter 3: Evaluation of Endothelial Cells in High
Glucose Solutions
3.1

Introduction
In Chapter 2, hyperglycemia – the major dysfunction of diabetes mellitus – was

discussed. It was determined that hyperglycemia was the most practical attribute to take into
consideration when trying to replicate a diabetic environment. Thus, in order to create and
monitor a hyperglycemic environment, a protocol was established to develop high glucose
concentrated solutions using Sigma G6152 D-(+)-Glucose and Gibco Medium 199, and different
methods of measuring glucose concentrations were discussed. After reviewing the literature, the
Aviva Accu-Chek blood glucose meter and the Glucoflex-R visual blood glucose test strips were
the most feasible methods of measuring the glucose concentration of various glycemic cell media
solutions. Three different glycemic cell media solutions were developed to resemble three
glycemic environments:
1. Normal glycemic level: 100 mg/dL
2. Hyperglycemic level: 250 mg/dL
3. Extreme Hyperglycemic level: 400 mg/dL
It was determined that the Aviva Accu-Chek blood glucose meter was the best method to
measure the glucose concentrations of glycemic cell media solutions because of its ability to
record very accurate and precise result,. In addition, it was uncovered that the Gibco Medium
199 was a “low glucose” solution and already contained 1000 mg/L (100 mg/dL) of glucose.
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Therefore, it was necessary to compensate and adjust the amount of glucose added to the cell
media when creating the glycemic cell media solutions for further experiments.
The next step then was the incorporation of the developed glycemic cell media solutions
with endothelial cells in the attempt to determine whether or not the hyperglycemic cell media
solutions evoked a noticeable negative response in endothelial cells. Specifically, bovine aortic
endothelial cells (BAECs) and human umbilical vein endothelial cells (HUVECs) were used to
evaluate the effect of hyperglycemic cell media recipes. The BAECs and HUVECs in this study
were exposed to two different glycemic environments – a normal glycemic environment of 100
mg/dL, and a hyperglycemic environment of 400 mg/dL. The development of these recipes will
be discussed in the proceeding “Methods” section.
Remember, a very small amount of glucose is circulating in the body (roughly 5 grams of
glucose in the average human body). Thus, the chance of error due to a minor miscalculation in
the amount of glucose added to the cell media is relatively high. Therefore, the hyperglycemic
environment of 350 mg/dL, which was tested in the previous chapter, was removed from
experiments in this chapter to avoid any overlapping. Therefore, experimentation with BAECs
and HUVECs focused entirely on a 100 mg/dL normal glycemic environment, and a 400 mg/dL
hyperglycemic environment.

3.1.1 Bovine Aortic Endothelial Cells (BAECs)
Bovine aortic endothelial cells are vascular cells from the aortic valve of USDA-cattle.
These cells are usually preserved at second passage and can be cultured and passed for at least
sixteen population doublings [139]. These cells play a critical role in cardiac homeostasis; thus,
studies have linked changes in structure and function of these endothelial cells to vascular
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diseases such as thrombosis, atherosclerosis, and hypertension – all significant complications of
diabetes mellitus [139]. Therefore, these endothelial cells are a suitable and economical option
to study endothelial function and metabolism.
Researchers have used BAECs to study the effects of elevated glucose levels on cultured
endothelial cells [140]. One study showed that hyperglycemia inhibits endothelial nitric oxide
activity in BAECs; nitric oxide synthase 3 (eNOS) plays an important role in preventing vascular
diseases [141]. Figure 36 shows how increased glucose concentration hindered eNOS activity.
BAECs exposed to a 5 mM glucose environment (90 mg/dL) had much higher eNOS activity
than BAECs exposed to a 30 mM environment (540 mg/dL).

Figure 36 - This study showed how exposure of BAECs to a hyperglycemic environment
hindered nitric oxide (eNOS) activity. BAECs exposed to a 5 mM (90 mg/dL) normal glycemic
environment had higher eNOS activity than BAECs exposed to the 30 mM (540 mg/dL)
hyperglycemic environment. eNOS plays an important role in preventing many vascular
diseases (permission to reprint from [141]).
Another study showed that hyperglycemia increased intracellular reactive oxygen species
(ROS) production in cultured BAECs [142]. The study showed that ROS activates mechanisms
that link hyperglycemia to several functional pathways that are responsible for the microvascular
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damage induced by diabetes [142]. These mechanisms include an altered cellular redox state, an
increase in diacylglycerol (DAG), which in turn adds the subsequent activation of protein kinase
C (PKC) isoforms [143]. Recall from the beginning of Chapter 2 that the activation of the DAGPKC pathway has been associated with many vascular abnormalities in the retinal, renal, neural
and cardiovascular tissues in diabetes mellitus. The DAG-PKC pathway affects the regulation of
endothelial cell permeability, vasoconstriction, extracellular matrix (ECM) synthesis, endothelial
cell growth, and angiogenesis [143]. These studies are a few of the examples that support the
use of BAECs in a hyperglycemic environment as a suitable method to study the function and
metabolism of endothelial cells in vitro.

3.1.2 Human Umbilical Vein Endothelial Cells (HUVECs)
Human umbilical vein endothelial cells (HUVECs) are isolated from human umbilical
veins. These cells are responsive to cytokine stimulation in the expression of cell adhesion
molecules; thus, these cells are primarily used to study physiological and pharmacological
functions, such as macromolecule transport, blood coagulation, and fibrinolysis [144].
A previous study had shown that incubation of HUVECs in high glucose environments
(roughly 30 mmol/L or 540 mg/dL) for 72 hours caused a significant increase in apoptosis,
possibly related to increased oxidative stress [145, 146]. The study showed that the
hyperglycemic environment altered fatty-acid metabolism, which in turn hindered Akt activation
by insulin (Akt phosphorylation usually occurs in the presence of insulin that induces optimum
metabolism of glucose). In addition, there was an increase in caspase-3 activity preceding
HUVEC apoptosis in the hyperglycemic environment (Figure 37).
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Figure 37 – TUNEL staining will typically show apoptotic configuration among the HUVECs
with shrinkage and fragmentation of the nuclei. This figure shows how exposure of HUVECs in
a 30 mM hyperglycemic environment caused a significant amount of cell death after 72 hours
compared to after only 24 hours. Supporting pictures are also shown, which support greater
apoptosis in the 30 mM hyperglycemic environment (permission to reprint from [145]).
Figure 37 also shows the apoptotic effect of 5-aminoimidazole-4-carboxamide-riboside
(AICAR) on the HUVECs exposed to the 30 mM hyperglycemic environment. Earlier studies
showed that HUVEC incubation with AICAR, which activates AMPK (an enzyme that promotes
cellular uptake of glucose), enhanced fatty-acid oxidation in many of the endothelial cells and
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inhibited apoptosis [147, 148, 149]. This indicates that exposure of HUVECs to a
hyperglycemic environment induces a negative response by the endothelial cells, which is
expected in the experiments of this chapter.
In addition, an earlier study showed that a high oxidative stress level may play a
significant role in the pathogenesis of diabetic complications via a hyperglycemic environment
causing an increase in oxygen-derived free radicals [150]. Evidence has supported that these
reactive molecules play a prominent role as mediators of endothelial cell dysfunction in diabetes
[150]. Specifically, the expression of the antioxidant enzymes CuZn-superoxide dismutase, Mnsuperoxide-dismutase, catalase, and glutathione peroxidase were all evaluated after 14 days of
culture in a high glucose environment (superoxide dismutase is a class of enzymes that catalyze
the separation of superoxide, O2-, into oxygen and hydrogen peroxide [151]). The study
demonstrated that a hyperglycemic environment induced an overexpression of these antioxidant
enzymes, suggesting that high levels of glucose produce an oxidative stress level in endothelial
cells – specifically, HUVECs.
The studies mentioned above are just a small sample of the number of studies researchers
have conducted involving the culturing of HUVECs in a high glucose environment. Thus, along
with BAECs, researchers have shown the use of HUVECs as a suitable method to study the
physiological effects of a hyperglycemic environment on endothelial cells.

3.1.3 Purpose of This Study
The purpose of this study was to evaluate BAECs and HUVECs in a normal glycemic
(100 mg/dL) and hyperglycemic (400 mg/dL) environment. The hypothesis of this study was
that the 400 mg/dL hyperglycemic cell media solution would evoke a cellular response similar to
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cells exposed to an actual hyperglycemic environment. Therefore, the BAECs and HUVECs
exposed to the 400 mg/dL glycemic cell media solution should exhibit greater glucose
consumption over a 72 hour time period than the BAECs and HUVECs exposed to the 100
mg/dL normal glycemic cell media solution. In order to measure glucose consumption, the
glucose concentration of the glycemic cell media solutions was taken, with an expectation of a
decreased concentration over time.
Recall, cells try to maintain a homeostatic balance, and a 100 mg/dL glycemic
environment is considered state of homeostasis. Thus, it was expected that relatively minimal
glucose consumption would occur in the normal glycemic environment. Additionally, a 400
mg/dL hyperglycemic environment is a state of homeostatic imbalance. Thus, cells should
consume higher amounts of glucose to the state of glucose toxicity. The following sections
discuss the methods of creating the experiments and the analysis of the accumulated results.

3.2

Methods
Three experiments were conducted per cell type – three experiments using BAECs and

three experiments using HUVECs. Thus, a total of six experiments were conducted. For each
experiment, the endothelial cells were thawed and cultured into 6 wells of a six-well plate using
standard cell culture technique, and incubated at 37˚C. During the culture time for the
endothelial cells, the two glycemic cell media solutions were prepared and stored at 4˚C inside
the lab refrigerator. Thus, before adding the glycemic media to the cells, it was necessary to
warm the solutions in a 37˚C water bath. Also, since the 400 mg/dL cell media solutions were
made with the unsterile Sigma G6152 D-(+)-Glucose, it was necessary to sterilize it via syringefilter sterilization. The following sections describe the development of each glycemic cell media
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solution, the sterilization of the 400 mg/dL hyperglycemic cell media solutions, and the
incorporation of the glycemic cell media solutions with the endothelial cells.

3.2.1 Preparation of Glycemic Media Solutions
The initial preparation for the study involved developing the 400 mg/dL hyperglycemic
cell media solution. For the experiments with BAECs, Sigma G6152 D-(+)-Glucose was added
to Lonza Endothelial Cell Basal Media (EBM) (Figure 38). For the HUVEC experiments, Sigma
G6152 D-(+)-Glucose was added to Gibco Medium 199.

Figure 38 - For experiments with BAECs, the glycemic cell media solutions were made using
Lonza Endothelial Cell Basal Medium (EBM).
Recall from Chapter 2, the Gibco Medium 199 was a “low glucose” solution; thus, it
already contained 1000 mg/L of D-glucose (100 mg/dL). This was also the case for the Lonza
EBM. Therefore, neither further modification nor sterilization was necessary for the 100 mg/dL
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normal glycemic cell media solutions. The following section describes the method used to
develop the 400 mg/dL hyperglycemia cell media solutions for the BAEC and HUVEC
experiments.

3.2.1.1

Preparation of the 400 mg/dL Hyperglycemic Cell Media Solution

The procedure established in Chapter 2 was used to create the 400 mg/dL hyperglycemic
cell media solution for the BAEC and HUVEC experiments. Recall, the method involved adding
x g of Sigma G6152 D-(+)-Glucose to be added to y mL of cell media. Additionally, it took
approximately five hours for the 500 mg/dL glycemic cell media solution to uniformly mix.
Thus, the 400 mg/dL hyperglycemic cell media solutions for these experiments were mixed for
at least six hours on a magnetic hot plate with a magnetic stir bar at 25˚C and then stored at
approximately 4˚C inside the laboratory refrigerator (Figure 39).

Figure 39 - After adding the Sigma G6152 D-(+)-Glucose to the cell media, the solution was
stirred with a magnetic stir plate and bar for at least six hours at 25 ºC to ensure uniform mixing.
Error! Reference source not found.Table 9 below summarizes the recipes used to
create the glycemic solutions for the initial four experiments. Since a substantial volume of the
400 mg/dL hyperglycemic cell media solution was created for the first HUVEC experiment,
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much of it was left over and available for the second experiment with HUVECs. The last two
experiments will be discussed later.

Table 9 - Recipes to Create the 400 mg/dL Hyperglycemic Cell Media Solutions for Initial
BAEC & HUVEC Experiments

Experiment

Volume of Cell
Media (mL)

Amt Glucose
Added (g)

BAECs 1

30

0.0906

BAECs 2

20

0.0613

HUVECs 1

40

0.1214

HUVECs 2

40

0.1214

Mixing
Parameters
12 hours
25˚C
12 hours
25˚C
12 hours
25˚C
12 hours
25˚C

Recorded
Glucose
Concentration
(mg/dL)
432
435
465
465

3.2.2 Sterilization of the 400 mg/dL Hyperglycemic Cell Media Solutions
Before adding the 400 mg/dL hyperglycemic cell media solution to the endothelial cells,
it was necessary to sterilize it first to prevent any contamination to the sterile environment of the
cells. The method of sterilization used was syringe-filter sterilization with 10 mL syringes and
0.22 µm syringe filters.
Sterilization was conducted in an aseptic environment under a laminar flow hood.
During sterilization, the 10 mL syringe took up 10 mL of the hyperglycemic cell media solution
(Figure 40a). The 0.22 µm syringe filter was placed on the end of the syringe and the 10 mL of
cell media solution was slowly transferred through the filter and into a brand new sterile 50 mL
conical (Figure 40b). A brand new filter was used for every 10 mL of glycemic media solution
being sterilized. The solution in the new 50 mL conicals was now sterile 400 mg/dL
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hyperglycemic cell media solution that was ready to be warmed and added to the endothelial
cells.

(b)

(a)

Figure 40 – Syringe-filter sterilization was conducted to sterilize the 400 mg/dL hyperglycemic
cell media solutions. (a) 10 mL of the solution was taken up by a 10 mL syringe and the 0.22
µm syringe filter was added onto the end of the syringe. (b) The 10 mL of solution was slowly
transferred into a sterile 50 mL conical. This entire sterilization was conducted in a laminar flow
hood.

3.2.3 Applying the Glycemic Media Solutions to the Endothelial Cells
Once sterilization of the 400 mg/dL hyperglycemic cell media solution was complete,
both glycemic solutions were ready to be added to the endothelial cells. The most important
factor taken into consideration when working with the endothelial cells was sterility. It was
crucial to ensure that, along with the glycemic cell media solutions, the surrounding work
environment, the tools, and the hands managing all the equipment were properly sterilized or
made aseptic with 70% isopropyl alcohol (IPA). Therefore, the first step of every experiment
was to wash hands with soap and warm water, wear properly fitted latex gloves, and spray the
gloves with the 70% IPA. Next, it was critical to spray the entire inside of the sterile hood with
70% IPA both before and after the experiment.
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To introduce the glycemic cell media solutions to the cultured cells, an electronic pipette
was used with 10 mL sterile tubes. For each experiment, the 100 mg/dL normal glycemic cell
media solutions were introduced to the cells in the bottom three wells, and the 400 mg/dL
hyperglycemic cell media solutions were introduced to the cells in the top three wells (Figure
41).

Figure 41 - To introduce the glycemic cell media solutions to the endothelial cells, an electronic
pipette was used. The 100 mg/dL solution was added to the bottom three wells, and the 400
mg/dL solution was added to the top three wells.
For the first BAEC experiment, 10 mL of the 100 mg/dL and 400 mg/dL cell media
solutions was introduced to each well (Figure 42a). For the second BAEC experiment, and the
two HUVEC experiments, the volume of media solution introduced to each well was reduced
from 10mL to 3 mL (Figure 42b). The reason for this reduction was to prevent exaggerated
glucose toxicity for the endothelial cells and to ensure the media did not overflow from the well.
As mentioned before, the method for the third BAEC and HUVEC experiments will be discussed
later.
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(a)
First BAEC experiment

(b)
Second BAEC experiment & first two HUVEC experiments
Figure 42 - (a) For the first BAEC experiment, 10 mL of the glycemic cell media solutions was
added to each well. The 400 mg/dL cell media was introduced to the cells in the top three wells,
and the 100 mg/dL cell media was introduced to the cells in the bottom three wells. (b) For the
second BAEC experiment and the first two HUVEC experiments, the volume of media
introduced to each well was reduced to 3 mL. Again, the 400 mg/dL cell media was introduced
to the cells in top three wells, and 100 mg/dL cell media was introduced to the cells in the bottom
three wells.
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3.2.4 Evaluation of BAECs and HUVECs
The purpose of this study was to compare and evaluate the glucose consumption and
cellular death of BAECs and HUVECs in the hyperglycemic environment. In order to evaluate
the glucose consumption, the glucose concentration of the introduced glycemic cell media
solution was monitored over the seventy-two hour experimentation time. The glucose
concentration of each well was recorded at t = 0, 24, 48, and 72 hours.
In addition to glucose consumption, it was ideal to evaluate cellular morphology,
especially of the cells in the 400 mg/dL hyperglycemic cell media solution to determine if cell
death was occurring. Cells in 100mg/dL could serve as a control. However, the cells of only the
third and final BAEC and HUVEC experiments were evaluated and recorded under a microscope
with pictures. It was expected that the wells with the 400 mg/dL hyperglycemic cell media
solutions would have much greater cell death than the wells with the 100 mg/dL normal
glycemic cell media solution, as indicated by a rounded, ball-like morphology.
Once the glycemic cell media solutions were properly introduced to the BAECs and
HUVECs, the glucose concentration of each well was recorded with the Aviva Accu-Chek blood
glucose meter (the blood glucose meter was sprayed with 70% IPA before being appended to the
aseptic environment under the laminar flow hood). Once the initial t = 0 evaluation was
complete, the cells were stored in the incubator. Again at t = 24, 48, and 72 hours, the cells of
each well were re-evaluated. The following section explains the recorded results for each of the
first two BAEC and HUVEC experiments. In addition, the following section will lead into the
reason and results of the third and final BAEC and HUVEC experiments.
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3.3

Results
This section displays the accumulated data of the first two BAEC and HUVEC

experiments and is formatted to assess the results between the cells exposed to the 100 mg/dL
normal glycemic cell media solutions and the cells exposed to the 400 mg/dL hyperglycemic cell
media solutions.

3.3.1 100 mg/dL Normal Glycemic Environment
3.3.1.1

Glucose Consumption

Recall from Chapter 1, the average blood glucose level of a healthy individual falls
within the 80-120 mg/dL range. The initial expectation for the endothelial cells exposed to the
100 mg/dL solution was for there to be minimal glucose consumption since the cells are in a
state of homeostasis. Therefore, the results should show minimal decrease in glucose
concentration throughout the entire 72 hour test period.
Figure 43 shows the average glucose concentrations of all wells exposed to the 100
mg/dL normal glycemic cell media solution at each time of evaluation. Additionally, Table 10
lists the average glucose concentrations for each experiment, as well as the calculated difference
in glucose concentration between t = 0 and t = 72 hours.
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Figure 43 – There was minimal decrease in glucose concentration throughout the 72 hour test
period; therefore, the glucose consumption for the BAEC and HUVEC studies was minimal.
Table 10 - Average Glucose Concentrations of 100 mg/dL Normal Glycemic Cell Media
Solutions Exposed to BAECs & HUVECs
Average Glucose Concentrations of the 100 mg/dL Normal Glycemic Cell Media
Solutions Exposed to BAECs & HUVECs
Time
(Hours)

Average Glucose Concentration of Three 100 mg/dL Wells
BAECs 1

BAECs 2

HUVECs 1

HUVECs 2

0

98.67

88.00

103.00

91.67

95.33

6.76

24

100.33

89.00

94.00

81.67

91.25

6.83

48

93

82.33

89

81

86.33

4.90

72

95.33

71.67

90.33

77.67

83.75

9.49

∆ (t0–t72)

3.33

16.33

12.67

14.00

11.58

5.70
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Average St. Dev.

Looking at Figure 43, the glucose consumption for the BAEC and HUVEC trials looked
minimal; thus, showing that there was little glucose consumption by the endothelial cells
exposed to the normal glycemic solution. The values recorded in Table 10 were calculated by
taking the average of the recorded glucose concentrations for all three wells containing the 100
mg/dL normal glycemic cell media solution at each evaluation period (these values can be seen
in Appendix B). In addition, Table 10 gives the average of these averages, as well as the
standard deviation, in order to illustrate the low degree of variance in the accumulated data.
In order to analyze whether an average ∆ (t0–t72) of 11.58 mg/dL was a significant
reduction in glucose concentration, a series of two-tailed T-tests were conducted on the recorded
glucose concentrations of each well for each experiment between each time of evaluation. The ttests were conducted assuming that the recorded data was normally distributed. Table 11 shows
the calculated p-values for each T-test with the null hypothesis Ho: µ 1=µ 2, the alternative
hypothesis Ha: µ 1≠µ 2, and α=0.05.

Table 11 - Two-Tailed T-Tests Results for BAECs & HUVECs Exposed to 100 mg/dL Normal
Glycemic Cell Media Solutions
Two-Tailed T-Tests Results for the BAECs & HUVECs Exposed to the 100 mg/dL
Normal Glycemic Cell Media Solutions
Ho: µ1=µ2; Ha: µ1≠µ2; α=0.05
Array 1 (hours)

Array 2 (hours)

p-Value

0

24

0.165750622

0

48

0.00129592

0

72

0.002858474

24

48

0.080847457

24

72

0.050738757

48

72

0.444784919
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Table 11 shows a statistically significant difference between the average glucose
concentrations for t = 0 and t = 72 hours. The question turned to how this difference compared
with the difference seen in the 400 mg/dL hyperglycemic environment. Therefore, it was
essential to review the data recorded from the endothelial cells exposed to the 400 mg/dL
hyperglycemic cell media solutions, and compare the amount of glucose consumption between
the two environments.

3.3.2 400 mg/dL Hyperglycemic Environment
3.3.2.1

Glucose Consumption

Figure 44 shows the average glucose concentrations of all wells exposed to the 400
mg/dL hyperglycemic cell media solution at each time of evaluation. (Note: the reason that t=0
does not closely correspond to 400mg/dL will be discussed later.) Additionally, Table 12 lists the
average glucose concentrations for each experiment, as well as the calculated difference in
glucose concentration between t = 0 and t = 72 hours.
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Figure 44 – There was a greater decrease in glucose concentration throughout the 72 hour test
period. The data also shows that there was a substantial decrease in glucose concentration for
the second BAEC experiment, as well as the two HUVEC experiments starting at t = 0.
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Table 12 - Average Glucose Concentrations of 400 mg/dL Hyperglycemic Cell Media Solutions
Exposed to BAECs & HUVECs
Average Glucose Concentrations of the 400 mg/dL Hyperglycemic Cell Media
Solutions Exposed to BAECs & HUVECs
Time
(Hours)

Average Glucose Concentration of Three 400 mg/dL Wells
BAECs 1

BAECs 2

HUVECs 1

HUVECs 2

Average St. Dev.

0

409.33

287.67

246.67

282.33

306.50

70.93

24

347.00

277.33

224.33

270.33

279.75

50.62

48

346.67

257.33

222.00

269.00

273.75

52.56

72

336.67

248.33

227.00

259.00

267.75

47.83

∆ (t0–t72)

72.67

39.33

19.67

23.33

38.75

24.17

The initial expectation for the BAECs and HUVECs exposed to the 400 mg/dL
hyperglycemic cell media solutions was for a high level of glucose consumption over a 72 hour
period. Looking at Figure 44, there was a greater decrease in glucose concentration over the 72
hour time period. The values in Table 12 were calculated by taking the average of the recorded
glucose concentrations for all three wells containing the 400 mg/dL hyperglycemic cell media
solution at each evaluation period (these values can also be seen in Appendix B).
The average ∆ (t0–t72) of the glucose concentration in the cells was 38.75 mg/dL – a
substantial amount of glucose consumption. In order to analyze whether the average ∆ (t0–t72) of
38.75 mg/dL was a significant reduction in glucose concentration, a series of two-tailed t-tests
was conducted on the recorded glucose concentrations of each well for each experiment between
each time of evaluation. These tests were conducted assuming that the recorded data was
normally distributed. Table 13 shows the calculated p-values for each t-test with a null
hypothesis Ho: µ 1=µ 2, an alternative hypothesis Ha: µ 1≠µ 2, and α=0.05.
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Table 13 - Two-Tailed T-Tests Results for BAECs & HUVECs Exposed to 400 mg/dL
Hyperglycemic Cell Media Solutions
Two-Tailed T-Tests Results for the BAECs & HUVECs Exposed to the 400 mg/dL
Hyperglycemic Cell Media Solutions
Ho: µ1=µ2; Ha: µ1≠µ2; α=0.05
Array 1 (hours)

Array 2 (hours)

p-Value

0

24

0.264684404

0

48

0.176583635

0

72

0.102422521

24

48

0.761585943

24

72

0.526862047

48

72

0.752230261

Although the average ∆ (t0–t72) was approximately 38.75 mg/dL, the calculated p-values
showed no statistical significant difference between any average glucose concentrations at any
evaluation points – especially between t = 0 and t = 72 hours.
Additionally, there was cause for concern in the results. The expected t = 0 glucose
concentration of approximately 400 mg/dL was recorded for the first BAEC experiment.
However, the data shows a substantial decrease in glucose concentration at t = 0 for the second
BAEC experiment, and the two HUVEC experiments. This observation will be discussed and
explored in the following sub-sections.
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3.4

Investigating the Decreased Glucose Concentration at t = 0 for
the 400 mg/dL hyperglycemic cell media solutions

3.4.1 Testing the Loss of Glucose during Syringe-Filter Sterilization
Recall from Section 3.2.3, sterilization of the 400 mg/dL hyperglycemic cell media
solutions was necessary before introducing the solutions to the endothelial cells. The method of
sterilization used was syringe-filter sterilization with 10 mL syringes and 0.22 µm syringe filters.
A significant step missed in the procedure was that the glucose concentration of the solutions
was not taken right after sterilization. This would have been useful, since the glucose
concentration of the solution was going to be recorded after it was added to the cells.
A potential cause for the initial loss of glucose was thought to be the syringe-filter
sterilization. Remember, an extremely small amount of glucose can differentiate a
hyperglycemic glucose concentration from a normal glycemic concentration; therefore, even a
minuscule amount of glucose lost in the 0.22 µm filters could cause the glucose concentration of
the 400 mg/dL hyperglycemic solutions to drop to roughly 250 mg/dL – as seen in the second
BAEC experiment and the two HUVEC experiments.
In order to test this hypothesis, four sets of 400 mg/dL hyperglycemic cell media
solutions were created and sterilized into three separate 10 mL samples per solution (a total of
twelve test samples).

From previously derived calculations, approximately 0.12 g of Sigma

G6152 D-(+)-Glucose was added to 40 mL of Gibco Cell Medium 199. Table 14 displays the
exact amounts of glucose added to the volume of cell media.
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Table 14 – Recipes to Create 400 mg/dL Hyperglycemic Solutions to Test Glucose Loss during
Syringe-Filter Sterilization
Solution Sample

Glucose Added (g)

Volume of Cell Media (mL)

1

0.1213

40

2

0.1208

40

3

0.1209

40

4

0.1211

40

Each solution was mixed on a magnetic hot plate with a magnetic stir bar at 25º C for at
least six hours. Once the solutions were uniformly mixed, the glucose concentration was taken
with the Aviva Accu-Chek blood glucose meter. Next, the solutions were sterilized and
transferred into twelve different sterile 50 mL conicals. The glucose concentration was
measured again for each sample and the amount of glucose loss was calculated and recorded in
Table 15. The calculations were conducted by converting the post sterilization glucose
concentration into grams per volume of cell media. Additionally, the calculated glucose loss was
based off the initial amount of glucose added to the solutions, not the initial glucose
concentration of each solution; thus, if the calculation theoretically indicated no glucose loss,
then it was not included in the data.
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Table 15 - Effect of Syringe-Filter Sterilization on 400 mg/dL Hyperglycemic Cell Media
Solutions
Effect of Syringe-Filter Sterilization on 400 mg/dL Hyperglycemic Cell Media
Solutions
PostAmount of
Initial Glucose
Sterilization
Test
Glucose
Glucose in
Concentration
Glucose
Solution #
Sample #
Lost (g)
Solution (g)
(mg/dL)
Concentration
(mg/dL)
1
387
0.0065
1
0.1613
416
2
412
N/A
3
402
0.0005
1
403
N/A
2
0.1608
411
2
392
0.004
3
406
N/A
1
403
N/A
3
0.1609
424
2
390
0.0049
3
396
0.0025
1
395
0.0031
4
0.1611
429
2
374
0.0015
3
405
N/A
Average

397.08

0.0033

Standard Deviation

10.33

0.002

Table 15 shows that all four solutions experienced a very small loss of glucose after
syringe-filter sterilization with an average glucose loss of 0.0033 g. Thus, the experiment
suggested that the root cause of the low glucose concentrations recorded at t = 0 was not the
sterilization process. However, a third set of experiments with BAECs and HUVECs was
conducted with an additional amount of glucose added to the initial calculated mass of glucose
for the 400 mg/dL hyperglycemic solution recipe. This compensation was conducted in the
attempt to limit the degree of glucose loss in the hyperglycemic solutions. The following section
describes these experiments.
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3.4.2 Third BAEC & HUVEC Experiment
3.4.2.1

Preparation and Application of Glycemic Cell Media Solutions

For the 400 mg/dL hyperglycemic solutions of the third BAEC and HUVEC experiments,
an additional 0.020 g of glucose was added to the calculated amount of Sigma G6152 D-(+)Glucose to compensate for any lost glucose during syringe-filter sterilization. Recall, Lonza
EBM was used for the BAEC experiment and Gibco Medium 199 was used for the HUVEC
experiment. Table 16 summarizes the recipes of the hyperglycemic solutions for each
experiment.
Table 16 - Recipes to Create 400 mg/dL Hyperglycemic Solutions for Final BAEC & HUVEC
Experiments
Recorded
Volume of Cell
Amt Glucose
Mixing
Glucose
Experiment
Media (mL)
Added (g)
Parameters
Concentration
(mg/dL)
12 hours
0.0813
461
20
BAECs 3
25˚C
12 hours
20
0.0807
519
HUVECs 3
25˚C
In addition, the amount of glycemic cell media solution added to each well was increased
from 3 mL to 6 mL per well (Figure 45). The results of these experiments are discussed in the
following section.
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Figure 45- Amount of glycemic cell media solution added to each well for the third BAEC &
HUVEC experiments

3.5

Results of Third BAEC & HUVEC Experiments

3.5.1 100 mg/dL Normal Glycemic Environment
3.5.1.2

Glucose Consumption

Figure 46 shows the average glucose concentrations of all wells exposed to the 100
mg/dL normal glycemic cell media solution at each time of evaluation. Additionally, Table 17
lists the average glucose concentrations for each experiment, as well as the calculated difference
in glucose concentration between t = 0 and t = 72 hours.
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Figure 46 – The BAECs and HUVECs exposed to the 100 mg/dL normal glycemic cell media
solutions in the third experiment exhibited similar decrease in glucose concentration.
Table 17 - Average Glucose Concentrations of the 100 mg/dL Normal Glycemic Cell Media
Solutions Exposed to BAECs & HUVECs of Final Experiments
Average Glucose Concentrations of 100 mg/dL Normal Glycemic Cell
Media Solutions Exposed to BAECs & HUVECs of Third
Experiments

Time (Hours)

Average Glucose Concentration of Three 100 mg/dL
Wells
BAEC 3

HUVEC 3

Average

St. Dev.

0

80.00

84.33

82.17

3.06

24

76.00

78.67

77.33

1.88

48

75.33

72.67

74

1.88

72

75.67

70.67

73.17

3.53

∆ (t0–t72)

4.33

13.67

9.00

6.599
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As expected, Figure 46 shows the same decrease in glucose concentration that the
previous experiments exhibited for the endothelial cells exposed to the 100 mg/dL normal
glycemic cell media solutions. In addition, Table 17 shows the little change in glucose
concentration from t = 0 hours to t = 72 hours – 9.00 mg/dL.

The series of two-tailed T-tests were conducted in order to analyze whether or not there
was a statistically significant difference between the average glucose concentration of the wells
at t = 0 and t = 72 hours (Table 18).

Table 18 - Two-Tailed T-Test Results for the Final BAEC & HUVEC Experiments Exposed to
100 mg/dL Normal Glycemic Cell Media Solutions
Two-Tailed T-Tests Results for the Third BAEC & HUVEC Experiments Exposed
to 100 mg/dL Normal Glycemic Cell Media Solutions
Ho: µ1=µ2; Ha: µ1≠µ2; α=0.05
Array 1 (hours)

Array 2 (hours)

p-Value

0

24

0.097796746

0

48

0.010774561

0

72

0.006721393

24

48

0.255720974

24

72

0.166718562

48

72

0.769038752

The statistical analysis shows a statistically significant difference between the average
glucose concentration at t = 0 hours and t = 72 hours. As before, this difference was compared to
the statistical difference seen between the average glucose concentration at t = 0 and t = 72 hours
for the endothelial cells exposed to the 400 mg/dL hyperglycemic cell media solutions.
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3.5.1.3

Cell Confluency

For the third BAEC & HUVEC experiments, cell morphology was observed at each time
of evaluation. Studies have shown that hyperglycemia can induce cellular apoptosis in HUVECs
and BAECs [145, 152]; thus, the BAECs and HUVECs were observed under a microscope to see
if cell confluency had decreased over the 72 hour experimentation time. Since the BAECs and
HUVECs exposed to the 100 mg/dL normal glycemic cell media solutions were generally in a
state of homeostasis, a significant decrease in cell confluency was not expected.

Figure 47 shows that the HUVEC (Figure 47a) and BAEC (Figure 47b) cell confluency
did not decrease from t = 0 hours to t = 72 hours (HUVEC confluency was also initially much
better than BAEC confluency).
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(a)
t=0

t = 72

t=0

t = 72

(b)
Figure 47 – (a) The cell confluency of the HUVECs exposed to the 100 mg/dL normal glycemic
cell media solution did not change from t = 0 to t = 72 hours. (b) Additionally, the cell
confluency of the BAECs exposed to the 100 mg/dL normal glycemic cell media solution did not
change from t = 0 to t = 72 hours either.
The evaluation of the endothelial cells under the microscope confirmed little change in
cell morphology in the 100 mg/dL normal glycemic cell media solutions over the 72 hour time
period.

3.5.2 400 mg/dL Hyperglycemic Environment
3.5.2.1

Glucose Consumption

Figure 48 shows the recorded glucose concentrations at each time of evaluation.
Additionally,
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Table 19 lists the average glucose concentrations of each experiment, as well as the calculated
difference in glucosee concentration between t = 0 and t = 72 hours.

Figure 48 - The BAECs and HUVECs exposed to the 400 mg/dL hyperglycemic cell media
solutions for the third experiment exhibited a decrease in glucose concentration over the 72 hour
test time; thus, exhibiting glucose consumption.

Table 19 - Average Glucose Concentrations of the 400 mg/dL Hyperglycemic Cell Media
Solutions Exposed to BAECs & HUVECs of Third Experiments
Average Glucose Concentrations of the 400 mg/dL Hyperglycemic
Cell Media Solutions Exposed to BAECs & HUVECs of Third
Experiments
Average Glucose Concentration of Three 400 mg/dL
Wells
Time (Hours)
BAEC 3
HUVEC 3
Average
St. Dev.
0

362.67

352.67

120

357.67

7.07

24

303.67

306.67

305.17

2.12

48

296.00

296.00

296.00

0.00

72

283.67

283.67

283.67

0.00

∆ (t0–t72)

79.00

69.00

74.00

7.07

The data of Figure 48 shows greater decrease in glucose concentration over the 72 hour
test period. Additionally, the values recorded in

Table 19 were calculated by taking the average of the recorded glucose concentrations for
all three wells containing the 400 mg/dL hyperglycemic cell media solution at each evaluation
period. This table shows a significantly greater average change in glucose concentration from t =
0 to t = 72 hours – 74.00 mg/dL.

Again, a series of two-tailed T-tests were conducted in order to analyze whether or not
there was any statistical significant difference between the average glucose concentration of the
wells at t = 0 and t = 72 hours (Table 20).

Table 20 - Two-Tailed T-Tests for Final BAEC & HUVEC Experiments Exposed to the 400
mg/dL Hyperglycemic Cell Media Solutions
Two-Tailed T-Tests for Final BAEC & HUVEC Experiments Exposed to the 400
mg/dL Hyperglycemic Cell Media Solutions
Ho: µ1=µ2; Ha: µ1≠µ2; α=0.05
Array 1 (hours)

Array 2 (hours)

p-Value

0

24

0.001406033

121

0

48

0.000591077

0

72

4.39249E-05

24

48

0.452472321

24

72

0.054662491

48

72

0.265310104

The resulting p-values showed that there was statistical significant difference between the
average glucose concentration of the well at t = 0 and t = 72 hours.

3.5.2.2

Cell Confluency

The BAECs and HUVECs exposed to the 400 mg/dL hyperglycemic cell media solution
were in a hoemstatic imbalanced environment with high glucose toxicity. Thus, the evaluation
of the cells under the microscope from t = 0 hours to t = 72 hours should have exhibited greater
decrease in cell confluncy.
Figure 49 shows that the HUVECs (Figure 49a) and the BAECs (Figure 49b) both did not
exhibit significant decrease in cell conflunecy from t = 0 hours to t = 72 hours.

(a)
t=0

t = 72
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(b)
t=0

t = 72

Figure 49 – The cell confluency of the HUVECs exposed to the 400 mg/dL hyperglycemic cell
media solution did not significantly decrease from t = 0 to t = 72 hours. (b) Additionally, the cell
confluency of the BAECs exposed to the 400 mg/dL hyperglycemic cell media solution did not
decrease from t = 0 to t = 72 hour.
The evaluation of the endothelial cells under the microscope confirmed insignificant
levels of cell death in the 400 mg/dL hyperglycemic cell media solutions over the 72 hour time
period.
Above all, there was still cause for concern due to the continuous low glucose
concentration of the 400 mg/dL hyperglycemic cell media solution at t = 0. During this third
experiment; however, it was realized that the decreased glucose concentration of the 400 mg/dL
solutions in the second BAEC experiment, first two HUVEC experiments, and the third BAEC
and HUVEC experiments was due to a missed step in the established procedure during the
implementation of the glycemic cell media solutions to the wells containing the endothelial cells.
This discovery and evaluation is discussed in Section 3.6.3 of the discussion section below.

3.6

Discussion and Conclusion
The purpose of the experiments in this chapter was to determine whether or not the

developed 400 mg/dL hyperglycemic cell media solutions and 100 mg/dL normal glycemic cell
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media solutions would evoke a cellular response similar to cells exposed to an actual
hyperglycemic environment. This was done in the attempt to confirm that a solution with an
elevated glucose concentration resembles a hyperglycemic environment.
The two glycemic cell media solutions were introduced to the endothelial cells in sterile
6-well plates. The hypothesis was tested by monitoring the glucose concentration, with the
Aviva Accu-Chek blood glucose meter, over a 72 hour time period at 24-hour time intervals in
order to observe any glucose consumption. Additionally, the last experiment observed cell
confluency of the cells under a microscope to observe any cell death.
The 400 mg/dL hyperglycemic cell media solutions were developed with the protocol
established in Chapter 2. Sigma G6152 D-(+)-Glucose was added to either Lonza EBM (for
experimentation with BAECs), or Gibco Medium 199 (for experimentation with HUVECs).
Since the Sigma G6152 D-(+)-Glucose was an unsterile substance, the composed 400 mg/dL
hyperglycemic cell media solutions had to be sterilized via syringe-filter sterilization before
being introduced to the endothelial cells. The sterilization was conducted in the laminar flow
hood with 10 mL syringes and 0.22 µm syringe filters. The 100 mg/dL normal glycemic cell
media solutions were already sterile; thus, did not require sterilization before application to the
endothelial cells. The experiments began right when the glycemic cell media solutions were
introduced to the endothelial cells and the initial evaluation at t = 0 was conducted.

3.6.1 100 mg/dL Normal Glycemic Environment
According to the p-value calculated in Table 11, the endothelial cells exposed to the 100
mg/dL normal glycemic cell media solutions exhibited a statistical significant difference in
average glucose concentration from t = 0 to t = 72 hours. Although these cells were in a
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balanced glycemic environment, there was still a good amount of glucose consumption. To see a
lower glucose values at t = 72 hours compared with t = 0 was actually not completely surprising
as the cells were alive; thus, they would be consuming glucose for up to at least 72 hours.
Additionally, this is why it is standard procedure in cell culture to change out the media every
three days.
Although statistical analysis did show a statistical significant difference in glucose
concentrations, the evaluation of the cells under the microscope showed hardly any decrease in
cell confluency – meaning the 100 mg/dL normal glycemic environment did not evoke any
unexpected cell death. While the initial cell morphology for the HUVECs was excellent (and
remained excellent throughout the experiment), the initial cell morphology of the BAECs was
poor, but was constant throughout the experiment.

3.6.2 400 mg/dL Hyperglycemic Environment
The accumulated results for the initial experiments with HUVECs and BAECs indicate a
greater amount of glucose consumption in the 400 mg/dL hyperglycemic environment.
Additionally, the average ∆ (t0–t72) of the glucose concentration in the cells was 38.75 mg/dL,
which is greater than the glucose consumption of the cells in the 100 mg/dL normal glycemic
cell media solutions that only had an average ∆ (t0–t72) of 11.58 mg/dL. However, although there
was a high number of consumption when comparing the two environments, relative to one
another, the consumption was not drastically greater in the 400 mg/dL wells than the 100 mg/dL
wells (12.14% vs. 12.64% for BAEC & HUVEC experiments 1 & 2). The average change in
glucose concentration would most likely have been even greater for the 400 mg/dL environment
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had the error not occurred with the three experiments that had a substantially lower glucose
concentration than planned at t = 0 hours.
However, statistical analysis confirmed no statistical significant difference in the average
glucose concentrations between any of the evaluation periods. Obviously, the analysis was
biased due to the unexpected low glucose concentrations recorded at t = 0 hours for the second
BAEC experiment and the first two HUVEC experiments. Additionally, the analyzed sample
size was small; therefore, the calculated p-values may not have given a fair evaluation of the
endothelial cells exposed to the 400 mg/dL hyperglycemic cell media solutions.
Since the first BAEC experiment ran as expected, the same two-tailed T-tests were
conducted on only the data accumulated from the first BAEC experiment. Table 21 shows the
calculated p-values.

Table 21 - Two-Tailed T-Test Results for First BAEC Experiment Exposed to 400 mg/dL
Hyperglycemic Cell Media Solutions
Two-Tailed T-Test Results for the First BAEC Experiment Exposed to the 400
mg/dL Hyperglycemic Cell Media Solutions
Ho: µ1=µ2; Ha: µ1=µ2; α=0.05
Array 1 (hours)
0
0
0
24
24
48

Array 2 (hours)
24
48
72
48
72
72
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p-Value
0.004460281
0.003424838
0.001345804
0.979821034
0.423717128
0.413348961

The results of these t-tests confirmed a statistical significant difference between the
average glucose concentrations at t = 0 and t = 72 hours. In addition, the calculated p-value was
less than the calculated p-value comparing the average glucose concentrations at t = 0 and 72
hours for the 100 mg/dL wells; therefore, supporting the test’s original hypothesis that the
endothelial cells exposed to the 400 mg/dL hyperglycemic cell media solutions would experience
greater glucose consumption than the endothelial cells exposed to the 100 mg/dL cell media.
Though this was the case for the first BAEC experiment, recall, the same outcome did not occur
for all experiments.

The final BAEC and HUVEC experiments accumulated increased results with an average
∆ (t0–t72) of 74.00 mg/dL. Thus, greater glucose consumption was observed in the third
experiment by the BAECs and HUVECs exposed to the 400 mg/dL hyperglycemic cell media
solutions compared to the cells exposed to the 100 mg/dL normal glycemic cell media solutions,
which had an average ∆ (t0–t72) of 9.00 mg/dL. Also, the ∆ (t0–t72) observed in the 400 mg/dL wells
greater than the ∆ (t0–t72) of the initial BAEC & HUVEC experiments. Additionally, the
calculated p-value was smaller than the p-value recorded comparing the average glucose
concentration of the wells exposed to the 100 mg/dL normal glycemic cell media solution
between t = 0 hours and t = 72 hours. The greater statistical difference confirms that there was
greater glucose consumption by the endothelial cells exposed to the hyperglycemic environment
in these particular experiments.

There was little evidence of any cell death of the BAECs and HUVECs exposed to the
400 mg/dL hyperglycemic cell media solutions. At first this was discouraging; however, the
unsubstantial amount of cell death in the 400 mg/dL environment is a preferable outcome as this
127

hyperglycemic environment can now be an adequate environment to evaluate endothelial cells in
a hyperglycemic BVM.

However, even though additional glucose was added to the original recipe for the 400
mg/dL hyperglycemic solution, to compensate for any lost glucose during the sterilization, the
results still showed slightly low glucose concentrations at t = 0 – roughly 357.67 mg/dL. Thus,
something other than the sterilization process was diluting the hyperglycemic solution. The
following section discusses the resolution.

3.6.3 Removal Complete Cell Media during Application of Glycemic Cell
Media Solutions
The initial part of the experiment required the BAECs and HUVECs to be cultured into
6-well plates and routinely fed with approximately 2-3 mL of complete cell media (base media
plus all the aliquots). This media was also a “low glucose” cell media like the Gibco Medium
199 and Lonza EBM; thus, it already contained 100 mg/dL of glucose. In addition, the
procedure for the first BAEC experiment was conducted by a trained lab technician; therefore,
there was no error in the procedure and the results of this experiment came out as expected.
Unfortunately, one significant step in the procedure was missed when observing and developing
the protocol. Before introducing the glycemic cell media to the endothelial cells, it was necessary
to remove the complete cell media feeding the cultured endothelial cells first. It seems like an
obvious step in the protocol; however, throughout the strict maintenance of a sterile environment
during these experiments, it can be an obvious but easy step to miss.
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Recall, approximately 3 mL of glycemic cell media solution was added to each well
during the second BAEC experiment and the first two HUVEC experiments. This volume of
was increased to 6 mL for the third BAEC and HUVEC experiments. Assuming that the wells
originally contained 2 mL of the homogenous cell media, the amount of glucose in the small
volume of added glycemic cell media solution (3 mL or 6 mL) was calculated using the amount
of glucose weighed and added to create the solutions, and then adjusted to compensate for the
additional 2 mL of complete “low glucose” cell media. Table 22 shows the results of these
calculations.

Table 22 - Calculated Glucose Concentrations Compensating for Additional 2 mL of Complete
Cell Media that was mistakenly not removed
Assumed
Volume of
Complete
“Low
Glucose” Cell
Media (mL)

Volume of
Applied
Glycemic
Cell Media
Solution
(mL)

Average
Glucose
Concentration
of Wells
(mg/dL)

Adjusted
Glucose
Concentration
of Wells
(mg/dL)

Experiment

Glucose
Added (g)

Cell Media
Volume
(mL)

BAEC 2

0.0613

20

2

3

287.67

223.90

HUVEC 1
HUVEC 2

0.1214

40

2

3

246.67

222.10

BAEC 3

0.0813

20

2

6

362.67

328.75
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HUVEC 3

0.0807

20

2

6

352.67

327.63

For example, the adjusted glucose concentration of the BAECs from the second experiment was
calculated as follows:

1. Find the amount of glucose in the volume of applied glycemic cell media solution.
0.0613 g / 20 mL = x g / 3 mL
x = 0.009195 g / 3 mL
2. Compensate the result by adding the addition 2 mL of “low glucose” media.
0.009195 g / 3 mL + 0.002 g / 2 mL = 0.011195 g / 5 mL
3. Convert g / mL to mg / dL.
0.011195 g / 5 mL × 1000 mg / 1 g × 100 mL / 1 dL = 223.90 mg/dL
The calculated adjustments are slightly smaller than the recorded average glucose
concentrations; however, this calculation was conducted assuming 2 mL of homogenous media
was already in the wells. Nonetheless, the adjustments confirmed that this incorrect step in the
protocol was the most likely root cause for the decreased glucose concentration of the 400 mg/dL
hyperglycemic cell media solutions at the t = 0 evaluation time. In the future, similar studies
should be contucted by removing all normoglycemic complete media before adding the
hyperglycemic media, so that the composition of media exposed to the cells is well controlled.
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3.6.4 Summary
A total of six studies were conducted for this chapter – three studies with BAECs and
three studies with HUVECs. There were four key factors that differed among the experiments:
1.

Adding Glycemic Cell Media Solutions
a. 10 mL of the glycemic cell media solution was added to each well for the first
BAEC experiment.
b. 3 mL of glycemic cell media solution was added to each well for the second
BAEC experiment and first two HUVEC experiments.
c. 6 mL of glycemic cell media solution was added each well for the third BAEC
and HUVEC experiments.

2.

The first and second HUVEC experiments used the same 400 mg/dL
hyperglycemic cell media solution.

3.

The third BAEC and HUVEC experiments had additional glucose added to
compensate for any lost glucose during the sterilization process.

4.

Cell morphology was evaluated and recorded for only the third BAEC and
HUVEC experiments.

In addition, Table 23 summarizes the conclusions derived from the results of the experiments of
this chapter.

Table 23 – Summary of Conclusions from Experimentation with BAECs & HUVECs in 100
mg/dL & 400 mg/dL Environments
Summary of Conclusions from Experimentation with BAECs & HUVECs in 100 mg/dL & 400 mg/dL
Environments
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Glycemic
Environment

Hypothesis
Glucose
Cell
Consumption Morphology

Results
Glucose
Cell
Consumption Confluency

100 mg/dL
Normal
Glycemic Cell
Media
Solutions

Minimal
decrease in
glucose
concentration
= minimal
glucose
consumption

Minimal
decrease in
cell
confluency =
minimal cell
death

Statistically
significant
difference in
average
glucose
concentration
between t = 0
& t = 72
hours

Little or no
decrease in
cell
confluency

400 mg/dL
Hyperglycemic
Cell Media
Solutions

Significant
decrease in
glucose
concentration
= significant
glucose
consumption

Significant
decrease in
cell
confluency =
significant
cell death

Statistically
significant
difference in
average
glucose
concentration
between t = 0
& t = 72
hours

Little
decrease in
cell
confluency

Conclusion
Glucose
Cell
Consumption
Confluency
Cells are
Cells are
active and
active and
consuming
healthy in 100
glucose;
mg/dL normal
however, not
glycemic
as much as
environment.
cells exposed
Cell death is
to
not evoked.
hyperglycemic
environment.
Cells are able
Cells are more
to survive 400
active and
mg/dL
consuming
hyperglycemic
higher
environment.
amounts of
Allows for
glucose
adequate
compared to
evaluation of
normal
cells within
glycemic
hyperglycemic
environment.
BVM.

Thus, pardoning the improper step conducted during the procedure of the experiments, in
conclusion, the results of the BAEC and HUVEC experiments did in fact support the hypothesis
that the developed 400 mg/dL hyperglycemic cell media evoked the expected glucose
consumption, although cell morphology was not drastically affected. Although the results did
not accumulate as planned, the constant inquiries contributed to an excellent learning experience.
Finally, the high glucose concentrated solutions developed in Chapter 2 evoked one of
the expected characteristics that endothelial cells would exhibit in an actual hyperglycemic
environment: they increased glucose consumption. Though this was not true for all the
conducted experiments, the results did show that hyperglycemic solutions can be introduced to
endothelial cells, the glucose concentration can be monitored over time (no matter what the
initial concentration is), and endothelial cells are able to survive high glycemic environments,
which would allow for adequate evaluation of BVMs introduced to various glycemic
environments. The conclusions from this chapter open the opportunity to further evaluate the
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effects induced by various glycemic environments by analyzing the phenotype and expression of
endothelial cells exposed to these environments.

Chapter 4: Discussion & Conclusion
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4.1

Overview of Thesis

4.1.1 Diabetes Mellitus
Diabetes Mellitus is a disease that affects the body’s ability to properly produce and use
insulin in order to metabolize blood glucose and maintain an adequate blood glucose level. At
first, the disease was a slow and painful death. While years of research were conducted on
attempting to cure the disease, the first breakthrough didn’t occur until 1879 when Joseph Von
Mering and Oscar Minkowski, of Germany, discovered that removing the pancreas of a dog
caused the dog to develop diabetes as the dog excessively urinated and the urine contained high
levels of glucose [1]. Thus, the anti-diabetic substance researchers were looking for was within
the pancreas. While many tried to extract a purified sample of the substance for human use, it
was an extremely challenging procedure – to the point where many scientists were giving up and
losing hope. However, in 1921, Dr. Fredrick Banting, Dr. James M Macleod, and James B.
Collip, from the University of Toronto, were able to obtain the first purified sample for human
testing – insulin [3]. Insulin drastically improved the condition of diagnosed patients, and the
discovery awarded Banting and Macleod the Nobel Prize in Medicine in 1923 [3]. Due to this
discovery, what used to be a horrifying experience for physicians and patients became an open
door for new research in quest of a cure for the disease.
There are two common types of diabetes mellitus – type 1 diabetes mellitus, and type II
diabetes mellitus. Type I diabetes is an autoimmune that involves the degeneration of pancreatic
β-cells – cells that produce and secrete insulin – thus, patients are unable to regulate blood
glucose levels and require constant blood glucose monitoring and injections of insulin. Type II
diabetes mellitus is different from Type I in in that that the pancreatic β-cells are impaired and
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cannot produce proper amount of insulin, and the body cells exhibit a resistance to the insulin.
Thus, patients are unable to regulate blood glucose levels with only insulin injections and require
an overall lifestyle adjustment with an improved diet and increased level of exercise, along with
medications.

4.1.2 Complications of Diabetes Mellitus
Diabetes mellitus involves homeostatic imbalance in the body’s blood sugar; therefore,
hyperglycemia is a chronic condition associated with diabetes – especially type II diabetics.
Chronic hyperglycemia can lead to significant complications, such as hypertension, ketoacidosis,
nephropathy, neuropathy, and cardiovascular disease – particularly, coronary artery disease
(CAD) [88]. Since patients with type I diabetes are able to manage their blood glucose levels
well with continuous insulin injections, most complications are frequently seen in patients with
type II diabetes. Out of all these major complications, this thesis focused on the condition of
coronary artery disease, as it is the significant contributing factor to the high mortality rate seen
with type II diabetics.
Coronary artery disease results in the narrowing of the coronary arteries due to
atherosclerosis – the build-up of plaques within the arteries. The hyperglycemic environment in
diabetics contributes to an increase of endothelial cell dysfunction in coronary blood vessels,
making diabetics more susceptible to atherosclerotic build-up. Revascularization treatments are
necessary for patients with CAD, and the most common treatment is coronary stent implantation
[69]. Numerous studies show that CAD patients with diabetes experience a greater need for
coronary stent replacement procedures and have a lower overall survival rate following the
coronary therapy procedure compared to non-diabetic patients [153]. CAD patients with
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diabetes especially experience a high rate of restenosis and a need for repeat revascularization
with coronary stent replacement. In-stent restenosis is the reformation of atherosclerotic
blockage due to the vascular injury caused by the implantation of the stent. Studies show that
hyperglycemia is correlated with high levels of expression of vascular adhesion molecules
throughout coronary blood vessels, leading to the high rate of in-stent restenosis [154]. Even
with the introduction of drug-eluting stents, the rate of restenosis is still high among the CAD
population with diabetes.
Due to this high failure rate of stents in diabetics, it would be beneficial to have a testing
system that could be used to optimize stent configurations and coatings for diabetic patients.
While in vivo animal models and clinical testing are vital for product evaluation, it would also be
valuable to test and evaluate stent designs prior to in vivo environments with an in vitro test that
resembles the physiologic environment of a native diabetic blood vessel – a diabetic blood vessel
mimic (BVM) [155].

4.1.3 Purpose & Direction of Study
The purpose of this thesis was to demonstrate the concept that a diabetic environment
could be replicated by inducing a high glucose concentrated environment in the attempt to
resemble a hyperglycemic environment. This thesis was driven by the notion that a high
concentration of glucose would properly replicate the chronic state of hyperglycemia seen in a
diabetic environment. Although the scope of this concept was beyond a single thesis, the goal of
the present work was to take initial steps towards creating a hyperglycemic in vitro environment.
In order to achieve this goal, the thesis was broken down into three major parts:
1.

Establish a protocol to create high glucose solutions in standard cell culture media
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2. Establish a protocol to accurately monitor the concentrations of the high glucose
solutions
3. Test this monitoring protocol in cell culture over time and determine how the high
glucose solutions affect endothelial cells
This was done to serve the single purpose of determining whether or not the
hyperglycemic solutions could be induced into an in vitro BVM.

4.1.4 Method of Creating & Monitoring Glycemic Cell Media Solutions
The first stage of the thesis was to establish a protocol of creating glycemic cell media
solutions at specific glucose concentrations. Preliminary tests were conducted and a feasible
method was established using Sigma G6152 D-(+)-Glucose and Gibco Medium 199.
The next stage was to test and establish a method to accurately measure the glucose
concentration of the glycemic solutions. After studying the literature, the most feasible methods
that were tested were the blood glucose meter (specifically the Aviva Accu-Chek blood glucose
meter) and the Glucoflex-R visual blood glucose test strips. The goal of these experiments was
to determine whether or not the Aviva Accu-Chek blood glucose meter and Glucoflex-R visual
blood glucose test strips could accurately and precisely record the glucose concentrations of
developed 200 mg/dL, 350 mg/dL and 500 mg/dL glycemic cell media solutions. The results
confirmed two things:
1.

The Aviva Accu-Chek blood glucose meter was the best method of monitoring
the developed glycemic solutions as it was the most accurate and precise method.
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2.

The base Gibco Medium 199 was a “low glucose” solution that already contained
100 mg/dL of D-glucose.

4.1.5 Monitoring Glucose Consumption of BAECs and HUVECs
Once the method of creating and monitoring glycemic cell media solutions was
established, the next stage was to assess whether the developed glycemic cell media solutions
affected bovine aortic endothelial cells (BAECs) and human umbilical vein endothelial cells
(HUVECs) in culture. Base cell medium was used as the control at 100 mg/dL, and was
compared to a developed 400 mg/dL hyperglycemic cell media solution. Glucose consumption
was evaluated by monitoring the glucose concentration of the glycemic cell media solutions, and
the cell death was evaluated, for only the third set of experiments, by monitoring the cell
confluency of each well under a microscope.
The endothelial cells exposed to the 100 mg/dL normal glycemic cell media solution
exhibited a statistically significant amount of glucose consumption. Additionally, there was little
or no cell death observed in the 100 mg/dL wells for the final experiments. The endothelial cells
exposed to the 400 mg/dL hyperglycemic cell media solution exhibited greater glucose
consumption only during the final experiments; however, these cells did not exhibit significant
cell death throughout the experiment. The results of the initial experiments did not exhibit the
expected glucose consumption of the endothelial cells within the 400 mg/dL environment, and
further investigation uncovered the cause of the obscure results. An important step in the
protocol of these experiments was to first remove the complete cell media before adding the
glycemic cell media. By not conducting this step, the glycemic solutions were diluted and
resulted in low glucose concentrations at t = 0.
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Therefore, the results of the initial test showed no difference in glucose consumption
between the cells exposed to the 100 mg/dL environment and the cells exposed to the 400 mg/dL
environment. However, the results of the final experiments did exhibit greater glucose by the
endothelial cells, especially in comparison to the initial experiments. Additionally, the
endothelial cells in the 400 mg/dL environment did not exhibit significant cell death from t = 0 to
t = 72 hours. These results show that the composed glycemic solutions can be introduced to
endothelial cells, the glucose concentration of the glycemic solutions can be monitored over time
(no matter what the initial concentration) with an Aviva Accu-Chek blood glucose meter, and the
endothelial cells are able to survive a high glucose concentrated solution up to 400 mg/dL. All
of these steps lead towards to development of a replicable hyperglycemic environment within a
BVM.
Table 24 summarizes the experiments, results, and conclusions derived from this entire
thesis.

Table 24 – Summary of Experimentation, Results, and Conclusions of Entire Thesis
Test
Development of Glycemic
Solution Recipes

Summary of Conclusions from Experimentation of Thesis
Hypothesis
Results
Conclusions
Adding x g of Sigma
Initial readings were high
1. Base cell media is a
G6152 D-(+)-Glucose to y
by 100 mg/dL. Aviva
“low glucose”
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mL of base cell media will
yield a solution with a
glucose concentration of z
mg/dL

Method of Monitoring
Glucose Concentration of
100 mg/dL, 250 mg/dL,
and 400 mg/dL

The Aviva Accu-Chek
blood glucose meter and
Glucoflex-R visual blood
glucose strips can
accurately and precisely
measure the glucose
concentration of various
glycemic solutions
developed using the
established protocol

Accu-Chek blood glucose
meter had precise
measurements of all
glucose concentration.
The Glucoflex-R visual
blood glucose strips
recorded imprecise results
with extremely high
variability.

2.

3.

1.

Evaluation of Endothelial
Cells in 100 mg/dL and
400 mg/dL Environments

BAECs and HUVECs
exposed to 400 mg/dL
hyperglycemic cell media
solution will exhibit
greater glucose
consumption and cell
death than ECs exposed to
100 mg/dL normal
glycemic cell media
solution

140

1. Initial experiments
showed statistically
significant decrease in
glucose concentration
in100 mg/dL solutions,
but insignificant
decrease in glucose
concentration in 400
mg/dL solutions.
Additionally, all 400
mg/dL environments
(except for BAEC1)
had low glucose
concentrations at t = 0.
2. Final experiments
showed significant
decrease in glucose
concentration in 100
mg/dL solutions, and
even greater decrease
in glucose
concentration in 400
mg/dL solutions.
3. Final experiments
showed no significant
decrease in cell
confluency for neither
the cells in the100
mg/dL nor the 400
mg/dL environments.

2.

3.

solution that contains
100 mg/dL of Dglucose
Established protocol
to develop various
glycemic solutions is
a valid method.
Aviva Accu-Chek
blood glucose meter
accurately and
precisely measured
glucose concentration
of developed
glycemic cell media
solutions
Unexpected decrease
in glucose
concentration for
initial experiments
was caused by not
removing “complete”
cell media already in
the wells. This
diluted the 400 mg/dL
solutions.
Cells in both the 100
mg/dL and 400
mg/dL solutions
exhibited glucose
consumption;
however, final
experiments showed
400 mg/dL
environment to
promote greater
consumption.
The 400 mg/dL
environment did not
evoke greater cell
death than the 100
mg/dL environment.
This is acceptable as
now 400 mg/dL
environment may be
used to evaluate
endothelial cells
within a diabetic
BVM.

4.2

Discussion of Thesis

4.2.1 Improvements to Test Protocols
The experiments conducted during this thesis made initial steps towards creating an
environment that can resemble a hyperglycemic environment to potentially develop a diabetic
blood vessel mimic for stent evaluation. With the completion of this thesis, a protocol is
established for the development of hyperglycemic cell media solutions for incorporation with
BVMs. In addition, the glucose concentration of these solutions can be accurately and precisely
measured with an Accu-Chek blood glucose meter.
As with any set of experiments, there were steps in the procedure that caused trouble and
likely caused obscurities in the data. For example, one significant observation was the
inaccuracy of the balance used to weigh the initial amount of Sigma G6512 D-(+)-glucose.
Although the balance read the desired mass, the reading frequently decreased as much as 0.02
mg in one minute. Although this seems to be an insignificant amount, remember that an
extremely small amount of glucose can alter the glucose concentration of a glycemic cell media
solution drastically. Thus, it wasn’t uncommon for multiple measurements to ensure that the
correct amount of glucose was used for a particular glycemic cell media solution.
The potential for error when measuring the mass of glucose was a continuous problem for
the accuracy of the experiments. A small volume of cell media was used for many of the
experiments (20-40 mL); thus, the amount of glucose added to each solution was extremely
small as well. Therefore, the established protocol, for the development of the glycemic cell
media solutions, calls for Sigma G6152 D-(+)-Glucose to be added to at least 100 mL of cell
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media. For example, in order to make 20 mL of 400 mg/dL hyperglycemic cell media solution,
approximately 0.060 g of glucose was added to 20 mL of cell media solution (this was done via
calculations and compensation of the 100 mg/dL of glucose already in the base cell media).. In
order to make 20 mL of 200 mg/dL hyperglycemic cell media solution, approximately 0.030 g of
glucose needs to be added to the 20 mL of cell media. Thus, only a difference of 0.030 g of
glucose differentiates 200 mg/dL from 400 mg/dL. However, if the volume of media was
increased to as much as 1000 mL, then a 400 mg/dL hyperglycemic solution would require
approximately 3.0 g of glucose, while a 250 mg/dL hyperglycemic solution would require
approximately 1.5 g of glucose – a difference of 1.5 g is a much more practical margin of error
than a difference of 0.03 g.
Another error that occurred was the use of the incorrect media during test with the
BAECs and HUVECs. For the initial measurements (tests conducted for Chapter 2), the Gibco
Medium 199 was the correct media to use. However, the normal complete BAEC media and the
normal complete HUVEC media should have been used for the experiments of Chapter 3. This
is BAEC & HUVEC base media with all the necessary aliquots. Using the Gibco Medium 199
for the HUVECs and the Lonza EBM did not hamper the experiments, but it should be noted that
any further experiments should be conducted using the cell type’s normal, complete media.
Lastly, using the Aviva Accu-Chek blood glucose meter was a practical and extremely
convenient method of measuring the glucose concentration of glycemic cell media solutions.
However, it was crucial to maintain the sterility of the test strips. The strips are sterile; thus,
must be handled in a sterile environment only to avoid any contamination – especially when used
with the endothelial cells. One consistent problem was remembering to not expose the strips
outside of the laminar hood, which was necessary since many glucose concentrations were
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recorded outside of the sterile environment. One solution for this is obtaining a second batch of
test strips that is used for the sterile experiments only. Therefore, one set of test strips may be
used for preliminary glucose measurements, while the other may be used for glucose
concentrations of solutions interacting with endothelial cells.

4.2.2 Future Work in Support of this Thesis
As pointed out by the literature researched for this thesis, there is a vast amount of
research being conducted on the physiological mechanisms occurring within diabetic
vasculature. These studies are focusing on primarily the expression and aggravation of
particular genes or molecules caused by endothelial cell exposure to a hyperglycemic
environment. As stated in a mentioned study, TUNEL staining can be conducted in order to
evaluate apoptosis of endothelial cells exposed to a hyperglycemic environment for an extended
period of time [145]. In addition to that, a study showed that exposure of HUVECs to high
levels of glucose (which, according to this study, mimicked hyperglycemia), induced the
expression of microRNA 221 (miR-221) – a short RNA structure that controls the expression of
other genes [156]. This in turn, triggers the inhibition of the proto-oncogene c-Kit (or tyrosineprotein kinase Kit) – a protein receptor that is expressed on the surface of hematopoietic stem
cells, which plays a crucial role in endothelial cell proliferation, differentiation, and migration
[157]. This study, along with others, support the development of high glucose concentrated
solutions in attempt to replicate a hyperglycemic environment, as well as experimentation with
BAECs and HUVECs as reliable methods of evaluating endothelial cells dysfunction in a
hyperglycemic environment.
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Additionally, researchers are evaluating the expression of intercellular adhesion molecule
(ICAM) – 1, as well as the expression of vascular cellular adhesion molecule (VCAM) – 1
within endothelial cells exposed to a hyperglycemic environment. ICAM1 and VCAM 1 are
both responsible for the adhesion of leukocytes to endothelial cells when they are activated [158,
159]. Studies have concluded that the hyperglycemic environment induced by diabetes promotes
the expression of ICAM-1 and VCAM-1 along endothelial cells [160, 161]. This high
expression of these adhesion molecules is most likely the cause of the high rate of in-stent
restenosis in diabetics with CAD. Therefore, the next significant step of this thesis will be to
evaluate whether the glycemic media solutions developed in this thesis affect cellular adhesion
and proliferation within a BVM, and whether the solutions induce a similar expression of
VCAM-1 and ICAM-1 on the endothelial cells within the BVM. The BVM can be analyzed by
the following:
•

Cellular morphology with a scanning electron microscope (SEM)

•

Endothelial cell confluency and density with bisbenzimide (BBI) nucleus staining

•

Blood vessel wall cellular thickness and cell confluency with hematoxylin and
eosin (H&E) staining

•

Cellular apoptosis with TUNEL staining

•

VCAM-1 & ICAM-1 expression with VCAM-1 antibody and ICAM-1 antibody
staining

While this entire thesis revolved around the affects hyperglycemia has on the cellular
level, it is worth noting that hyperglycemia is not the only significant contributor to the
detrimental vascular complications associated with diabetes. Recall, obesity is a pandemic
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caused by a combination of genetics and a modern environment where calorie-dense foods are
widely available and inexpensive [187]. Coinciding with the obesity epidemic, type II diabetes
mellitus is a related disorder with insulin resistance playing a crucial part in the pathogenesis of
the disorder [188]. The cellular mechanisms contributing to the progression are poorly
understood; however, previous studies by Randle et al. have hypothesized that the high
availability of lipids as a source of fuel generate metabolic signals that impair the use of glucose
through inhibition of key glycolytic enzymes [189]. Testing of this hypothesis has shown that
lipid infusion raised plasma muscle lipids [190], and impaired oral glucose tolerance [191] and
insulin-stimulated glucose disposal in healthy individuals [192, 193]. Thus, in healthy
individuals, exposure to high concentrations of plasma fatty acids caused insulin resistance
associated with an induced defect in either glucose transport or phosphorylation activity, not
impairment of glycolysis [188]. Along with parallel studies, the results suggest that
accumulation of lipids within muscle might be the cause of insulin resistance [188]. In addition,
it has also been hypothesized that insulin resistance develops with the accumulation of fatty-acid
metabolites (diacylglycerols) within insulin-responsive tissues [194]. The model of
diacylglycerol-induced insulin resistance accounts for the insulin resistance seen in obesity and
type II diabetes; moreover, reductions in in intracellular diacylglycerol content account for the
improvements in insulin sensitivity after weight loss [195]. This drastic effect that lipid
infiltration has on the development of insulin sensitivity encourages further research in its effect
in type II diabetes; thus, it would be additionally beneficial to test the development of a
hyperlipidemic cell media solutions and see the effect on endothelial cells in culture.
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If the endothelial cells within a hyperglycemic and hyperlipidemic environment exhibit
characteristics similar to endothelial cells within a native diabetic blood vessel, then the goal of
creating an in vitro diabetic blood vessel mimic for stent evaluation will be achieved.
This thesis is only a small part of the larger amount of research supporting both the
development of blood vessel mimics for in vitro medical device evaluation at Cal Poly, as well
as the understanding of mechanisms inducing many of the complications within diabetic patients
at hospitals and labs worldwide. The lifestyle – and life expectancy – of diabetic patients has
improved immensely since the significant discovery of insulin. New technologies and
medications are continuously being studied and evaluated to further improve current methods of
treatment. While this thesis was only able to study a minor part incorporating diseased blood
vessel mimics with medical technologies treating diagnosed patients, this thesis was a new
“gateway” to help improve not only the vascular devices used to treat CAD patients with
diabetes, but hopefully to improve devices treating other diseases as well.
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Appendix A: Results for Preliminary Testing to
Establish Method of Developing Glycemic Cell Media
Solutions
Preliminary testing was conducted in order to analyze the simple procedure of adding
specified amounts of Sigma G6152 D-(+)-Glucose to distilled water, and eventually base cell
media. These experiments also helped determine the feasibility of certain methods of monitoring
glucose concentrations, such as the blood glucose meter and visual blood glucose strips. The
following tables show the results of these experiments.

Table 25 - Development of 100 mg/dL Solution Trial #1
Development of Hyperglycemic Solution Trial #1

D-(+)- Glucose
(g)

Aviva AccuChek Blood
Glucose Meter
Measurement
(mg/dL)

20

0.2004

76

20

0.2002

129

3

20

0.2001

162

4

20

0.206

35

Tube #

Expected
Glucose
Concentration
(mg/dL)

1
2

Volume of
Distilled H2O
(mL)

Amount of
Sigma G6152

100 mg/dL
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Table 26 - Development of 100 mg/dL & 180 mg/dL Solutions Trial #2

Expected
Glucose
Concentration
(mg/dL)

100

180

Development of 100 mg/dL & 180 mg/dL Solutions Trial #2
Amount of
Sigma
Volume of
G6152
Time (min)
Distilled
D-(+)H2O (mL)
Glucose
(g)

10

10

0.011

0.0187

5

17

10

71

15

83

20

106

25

117

30

129

5

136

10

201

15

x

20

x

25

x

30

x

x Ran out of glucose test strips
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Aviva AccuChek Blood
Glucose Meter
Measurement
(mg/dL)

Table 27 - Development of 100 mg/dL Normal Glycemic & 400 mg/dL Hyperglycemic
Solutions Trial #3
Development of 100 mg/dL Normal Glycemic & 400 mg/dL Hyperglycemic Solutions Trial #3
Amount of
Sigma G6152
Expected Glucose
Blood Glucose Meter
D-(+)- Glucose
Time (min)
Concentration (mg/dL)
Measurement (mg/dL)
(g) added to 10
mL H2O

100

460

0.0134

0.00165

165

5

74

10

130

20

152

30

217

40

251

Average

164.8

5

445

10

467

20

480

30

515

40

485

40

496

40

501

45

479

Average

483.5

Table 28 - Development of 100 mg/dL Normal Glycemic & 350 mg/dL Hyperglycemic
Solutions Trial #4
Development of 100 mg/dL Normal Glycemic & 350 mg/dL Hyperglycemic Solutions Trial #4
Expected Glucose Amount Glucose
Blood Glucose Meter
Volume of Gibco
Measurement
Concentration
Added to Media
Time (min)
Medium 199 (mL)
(mg/dL)
(mg/dL)
(g)
30
156
60
189
0.0506
50
120
198
240
201
720
215
100
30
148
60
165
0.1061
100
120
184
240
209
720
206
30
318
60
397
0.1758
50
120
413
240
481
720
435
350
30
388
60
417
0.3507
100
120
451
240
466
720
458
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Appendix B: Results for Experimentation to
Determine Most Feasible Method of Measuring
Glucose Concentration of Developed Glycemic Cell
Media Solutions
A set of experiments was conducted to evaluate the precision and accuracy of the Aviva
Accu-Chek blood glucose meter and the Glucoflex-R visual blood glucose strips among
glycemic solutions of 200 mg/dL, 350 mg/dL, and 500 mg/dL glucose concentrations. The
following tables show the results of these experiments. Notice the calculated percent error as
well as the standard deviation between the Aviva Accu-Chek blood glucose meter and the
Glucoflex-R visual blood glucose test strips.
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Table 29 - Method of Monitoring 200 mg/dL Normal Glycemic Environment Test Results
Method of Monitoring 200 mg/dL Normal Glycemic Environment Test Results
Measured
Measured
Measured
Glucose
Glucose
Glucose
Calibration
Method of
Concentration Concentration Concentration
Time (hours)
Value (mg/dL)
Measurement
Solution 3
Solution 2
Solution 1
(mg/dL)
(mg/dL)
(mg/dL)
1
437
189
169
174
2
444
200
200
196
3
456
204
199
190
4
446
209
195
188
5
452
206
192
192
6
443
200
200
197
Aviva AccuChek Blood
12
439
215
207
208
Glucose Meter
24
447
209
215
212
36
455
213
213
207
48
441
202
195
189
446.56
204.7
198.5
195.3
Average
6.55
7.54
12.89
11.38
St. Dev.
-0.77
2.35
-0.75
-2.35
%Error
Measured
Measured
Measured
Glucose
Glucose
Glucose
Calibration
Method of
Concentration Concentration Concentration
Time (hours)
Value (mg/dL)
Measurement
Solution 3
Solution 2
Solution 1
(mg/dL)
(mg/dL)
(mg/dL)

Glucoflex-R
Visual Blood
Glucose Test
Strips

1

400

150

160

500

2

N/A

200

160

300

3

N/A

200

120

200

4

N/A

300

160

200

5

N/A

200

160

200

6

N/A

180

200

160

12

N/A

200

160

300

24

N/A

300

160

800

36

N/A

160

500

300

48

N/A

160

160

160

Average

N/A

205

194

312

St. Dev.

N/A

53.59

109.16

199.38

% Error

N/A

2.50

-3.00

56.00
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Table 30 - Method of Monitoring 350 mg/dL Hyperglycemic Environment Test Results
Method of Monitoring 350 mg/dL Hyperglycemic Environment Test Results
Measured
Measured
Measured
Glucose
Glucose
Glucose
Calibration
Method of
Concentration Concentration Concentration
Time (hours)
Value (mg/dL)
Measurement
Solution 3
Solution 2
Solution 1
(mg/dL)
(mg/dL)
(mg/dL)

Aviva AccuChek Blood
Glucose Meter

Glucoflex-R
Visual Blood
Glucose Test
Strips

1

446

271

137

133

2

467

276

226

257

3
4
5
6

433
441
457
425

292
310
352
355

299
337
359
350

302
342
349
359

12
24
36
48
Average (t=4)

449
458
461
453
449.00

373
363
357
387
356.71

354
341
366
371
354.00

360
356
365
372
357.57

St. Dev. (t=4)

13.06

23.91

11.54

9.91

% Error

-0.22

1.92

1.14

2.16

1

300

300

200

200

2

N/A

300

300

250

3

N/A

500

300

300

4

N/A

300

500

300

5

N/A

400

300

300

6

N/A

250

300

250

12

N/A

200

250

300

24

N/A

800

500

300

36

N/A

300

200

300

48

N/A

300

200

300

Average (t=4)

N/A

364.29

321.43

292.86

St. Dev. (t=4)

N/A

201.48

128.64

18.90

% Error

N/A

4.08

-8.16

-16.33
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Table 31 - Method of Monitoring 500 mg/dL Hyperglycemic Environment Test Results
Method of Monitoring 500 mg/dL Hyperglycemic Environment Test Results
Measured
Measured
Measured
Glucose
Glucose
Glucose
Calibration
Method of
Concentration Concentration Concentration
Time (hours)
Value (mg/dL)
Measurement
Solution 3
Solution 2
Solution 1
(mg/dL)
(mg/dL)
(mg/dL)

Aviva AccuChek Blood
Glucose Meter

Glucoflex-R
Visual Blood
Glucose Test
Strips

1
2

447
451

177
247

164
253

165
251

3
4
5
6
12
24

450
439
444
453
448
437

303
289
459
469
479
511

313
395
457
466
472
483

299
392
452
460
461
468

36
48
Average (t=5)
St. Dev. (t=5)
% Error

448
454
447.33
6.250
N/A

528
514
493.33
27.990
-1.333

473
485
472.67
10.482
-5.467

475
483
466.50
11.221
-6.700

1

400

400

400

400

2

500

500

300

500

3

N/A

500

500

500

4

N/A

800

500

300

5

N/A

500

500

500

6

N/A

800

300

300

12

N/A

200

400

300

24

N/A

500

400

400

36

N/A

500

300

500

48

N/A

500

400

400

Average (t=5)

N/A

500.00

383.33

400.00

St. Dev. (t=5)

N/A

189.737

75.277

89.443

% Error

N/A

0.000

-23.333

-20.000
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Appendix C: Results for Experimentation of BAECs &
HUVECs Exposed to 100 mg/dL Normal Glycemic
Cell Media Solutions & 400 mg/dL Hyperglycemic
Cell Media Solutions
The following tables show the results of the six experiments conducted with BAECs and
HUVECs. The purpose of these tests was to evaluate the glucose consumption of the cells in the
100 mg/dL and 400 mg/dL glycemic cell media solutions. Additionally, the change in glucose
concentrations was calculated in order to analyze the rate of glucose consumption between the
different times of evaluation (0, 24, 48, and 72 hours).
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Table 32 - BAEC Glucose Consumption Comparative Study Experiment #1
BAEC Glucose Consumption Comparative Study Experiment #1
Expected Glucose
Concentration
(mg/dL)

Time

0
24
48
72

Glucose Measurements via Accu-Check Glucose Meter (mg/dL)
Well #1

Well #2

Well #3

100
400
100
400

99
416
100
335

98
398
103
365

99
414
98
341

100
400
100

94
355
96

91
355
95

94
330
95

400

347

340

323

Table 33 - BAEC Glucose Consumption Comparative Study Experiment #1 - Well ∆ mg/dL per
Time Chart
BAEC Glucose Consumption Comparative Study Experiment #1 Well ∆ mg/dL per Time Chart
100 mg/dL
Well
#

∆ mg/dL
(t0 - t72)

1

3

2

3

3

4

Avg ∆
mg/dL
(t0 - t72)

∆ mg/dL
(t0 - t24)

Avg ∆
mg/dL
(t0 - t24)

-1
3.333

-5

∆ mg/dL
(t24 - t48)

Avg ∆
mg/dL
(t24 - t48)

6
-1.667

1

12

∆ mg/dL
(t48 - t72)

Avg ∆
mg/dL
(t48 - t72)

-2
7.333

4

-4

-2.333

-1

400 mg/dL
Well
#

∆ mg/dL
(t0 - t72)

1

69

2

58

3

91

Avg ∆
mg/dL
(t0 - t72)

∆ mg/dL
(t0 - t24)

Avg ∆
mg/dL
(t0 - t24)

81
72.667

33

∆ mg/dL
(t24 - t48)

Avg ∆
mg/dL
(t24 - t48)

-20
62.333

73

10
11

172

∆ mg/dL
(t48 - t72)

Avg ∆
mg/dL
(t48 - t72)

8
0.333

15
7

10.000

Table 34 - HUVEC Glucose Consumption Comparative Study Experiment #1
HUVEC Glucose Consumption Comparative Study Experiment #1
Glucose Measurements via Accu-Check Glucose Meter (mg/dL)

Expected Glucose
Concentration
(mg/dL)

Time

0
24
48
72

Well #1

Well #2

Well #3

100
400
100
400
100

103
258
90
229
89

106
222
96
226
88

100
260
96
218
90

400
100

223
90

219
91

224
90

400

234

224

223

Table 35 - HUVEC Glucose Consumption Comparative Experiment Trial #1 - Well ∆ mg/dL per
Time Chart
HUVEC Glucose Consumption Comparative Experiment Trial #1 Well ∆ mg/dL per Time Chart
100 mg/dL
Well #

∆ mg/dL
(t0 - t72)

1

13

2

15

3

10

Avg ∆
mg/dL
(t0 - t72)

∆ mg/dL
(t0 - t24)

Avg ∆
mg/dL
(t0 - t24)

13
12.667

10

∆ mg/dL
(t24 - t48)

Avg ∆
mg/dL
(t24 - t48)

1
9.000

4

8

∆ mg/dL
(t48 - t72)

Avg ∆
mg/dL
(t48 - t72)

-1
5.000

6

-3

-1.333

0

400 mg/dL
Well #

∆ mg/dL
(t0 - t72)

1

24

2

-2

3

37

Avg ∆
mg/dL
(t0 - t72)

∆ mg/dL
(t0 - t24)

Avg ∆
mg/dL
(t0 - t24)

29
19.667

-4

∆ mg/dL
(t24 - t48)

Avg ∆
mg/dL
(t24 - t48)

6
22.333

42

7
-6

173

∆ mg/dL
(t48 - t72)

Avg ∆
mg/dL
(t48 - t72)

-11
2.333

-5
1

-5.000

Table 36 - BAEC Glucose Consumption Comparative Study Experiment #2
BAEC Glucose Consumption Comparative Study Experiment #2
Time

Expected Glucose
Concentration
(mg/dL)

0
24
48
72

Glucose Measurements via Accu-Check Glucose Meter (mg/dL)
Well #1

Well #2

Well #3

100
400

90
289

85
277

89
297

100
400
100
400
100

89
288
83
253
75

88
263
82
253
70

90
281
82
266
70

400

252

241

252

Table 37 - BAEC Glucose Consumption Comparative Study Experiment #2 - Well ∆ mg/dL per
Time Chart
BAEC Glucose Consumption Comparative Study Experiment #2 Well ∆ mg/dL per Time Chart
100 mg/dL
Well #

∆ mg/dL
(t0 - t72)

1

15

2

15

3

19

Avg ∆
mg/dL
(t0 - t72)

∆ mg/dL
(t0 - t24)

Avg ∆
mg/dL
(t0 - t24)

1
16.333

-3

∆ mg/dL
(t24 - t48)

Avg ∆
mg/dL
(t24 - t48)

6
-1.000

-1

6

∆ mg/dL
(t48 - t72)

Avg ∆
mg/dL
(t48 - t72)

8
6.667

8

12

10.667

12

400 mg/dL
Well #

∆ mg/dL
(t0 - t72)

1

37

2

36

3

45

Avg ∆
mg/dL
(t0 - t72)

∆ mg/dL
(t0 - t24)

Avg ∆
mg/dL
(t0 - t24)

1
39.333

14

∆ mg/dL
(t24 - t48)

Avg ∆
mg/dL
(t24 - t48)

∆ mg/dL
(t48 - t72)

20.000

12

35
10.333

16

10
15

174

Avg ∆
mg/dL
(t48 - t72)

1
14

9.000

Table 38 - HUVEC Glucose Consumption Comparative Study Experiment #2
HUVEC Glucose Consumption Comparative Study Experiment #2
Expected Glucose
Glucose Measurements via Accu-Check Glucose Meter (mg/dL)
Concentration
Well #1
Well #2
Well #3
(mg/dL)

Time
0
24
48
72

100
400
100
400
100
400

94
263
85
277
86
274

91
288
79
246
79
267

90
296
81
288
78
266

100

79

80

74

400

261

259

257

Table 39 - HUVEC Glucose Consumption Comparative Study Experiment #2 - Well ∆ mg/dL
per Time Chart
HUVEC Glucose Consumption Comparative Study Experiment #2 Well ∆ mg/dL per Time Chart
100 mg/dL
Well #

∆ mg/dL
(t0 - t72)

1

15

2

11

3

16

Avg ∆
mg/dL
(t0 - t72)

∆ mg/dL
(t0 - t24)

Avg ∆
mg/dL
(t0 - t24)

9
14.000

12

∆ mg/dL
(t24 - t48)

Avg ∆
mg/dL
(t24 - t48)

-1
10.000

9

0

∆ mg/dL
(t48 - t72)

Avg ∆
mg/dL
(t48 - t72)

7
0.667

3

-1

3.333

4

400 mg/dL
Well #

∆ mg/dL
(t0 - t72)

1

2

2

29

3

39

Avg ∆
mg/dL
(t0 - t72)

∆ mg/dL
(t0 - t24)

Avg ∆
mg/dL
(t0 - t24)

-14
23.333

42

∆ mg/dL
(t24 - t48)

Avg ∆
mg/dL
(t24 - t48)

3
12.000

8

-21
22

175

∆ mg/dL
(t48 - t72)

Avg ∆
mg/dL
(t48 - t72)

13
1.333

8
9

10.000

Table 40 - BAEC Glucose Consumption Comparative Study Experiment #3
BAEC Glucose Consumption Comparative Study Experiment #3
Expected Glucose
Concentration
(mg/dL)

Time

0
24
48
72

Glucose Measurements via Accu-Check Glucose Meter (mg/dL)
Well #1

Well #2

Well #3

100
400
100
400
100

74
367
77
311
76

82
364
79
324
70

84
357
72
276
80

400
100

306
75

313
71

269
81

400

292

293

266

Table 41 - BAEC Glucose Consumption Comparative Study Experiment #3 - Well ∆ mg/dL per
Time Chart
BAEC Glucose Consumption Comparative Study Experiment #3 Well ∆ mg/dL per Time Chart
100 mg/dL
Well #

∆ mg/dL
(t0 - t72)

1

-1

2

11

3

3

Avg ∆
mg/dL
(t0 - t72)

∆ mg/dL
(t0 - t24)

Avg ∆
mg/dL
(t0 - t24)

-3
4.333

3

∆ mg/dL
(t24 - t48)

Avg ∆
mg/dL
(t24 - t48)

1
4.000

12

9

∆ mg/dL
(t48 - t72)

Avg ∆
mg/dL
(t48 - t72)

1
0.667

-8

-1

-0.333

-1

400 mg/dL
Well #

∆ mg/dL
(t0 - t72)

1

75

2

71

3

91

Avg ∆
mg/dL
(t0 - t72)
79.000

Avg ∆
mg/dL
(t0 - t24)

∆ mg/dL
(t24 - t48)

56

5

40

48.000

11

∆ mg/dL
(t0 - t24)

81

7

176

Avg ∆
mg/dL
(t24 - t48)

∆ mg/dL
(t48 - t72)

Avg ∆
mg/dL
(t48 - t72)

14
7.667

20
3

12.333

Table 42 - HUVEC Glucose Consumption Comparative Study Experiment #3
HUVEC Glucose Consumption Comparative Study Experiment #3
Time

Expected Glucose
Concentration
(mg/dL)

0
24
48
72

Glucose Measurements via Accu-Check Glucose Meter (mg/dL)
Well #1

Well #2

Well #3

100
400

85
386

86
353

82
319

100
400
100
400
100

75
316
68
313
69

86
318
72
306
68

75
286
78
269
75

400

288

298

265

Table 43 - HUVEC Glucose Consumption Comparative Study Experiment #3 - Well ∆ mg/dL
per Time Chart
HUVEC Glucose Consumption Comparative Study Experiment #3 Well ∆ mg/dL per Time Chart
100 mg/dL
Well #

∆ mg/dL
(t0 - t72)

1

16

2

18

3

7

Avg ∆
mg/dL
(t0 - t72)

∆ mg/dL
(t0 - t24)

Avg ∆
mg/dL
(t0 - t24)

10
13.667

0

∆ mg/dL
(t24 - t48)

Avg ∆
mg/dL
(t24 - t48)

7
5.667

7

14

∆ mg/dL
(t48 - t72)

Avg ∆ mg/dL
(t48 - t72)

-1
6.000

-3

4

2.000

3

400 mg/dL
Well #

∆ mg/dL
(t0 - t72)

1

98

2

55

3

54

Avg ∆
mg/dL
(t0 - t72)

∆ mg/dL
(t0 - t24)

Avg ∆
mg/dL
(t0 - t24)

70
69.000

35

∆ mg/dL
(t24 - t48)

Avg ∆
mg/dL
(t24 - t48)

3
46.000

33

12
17

177

∆ mg/dL
(t48 - t72)

Avg ∆ mg/dL
(t48 - t72)

25
10.667

8
4

12.333

Appendix D: Protocol for the Development of Sterile
400 mg/dL Hyperglycemic Cell Media Solution
•

Materials
o 100 mL complete cell media
o 0.30 g Sigma G6152 D-(+)-Glucose
o Aviva Accu-Chek Blood Glucose Meter & Test Strips
Note: Use two different sets of blood glucose test strips – one for use in a nonsterile environment and one for use within a sterile environment.
o 50 mL graduate cylinder
o 250 mL beaker
o Magnetic stir bar & stir plate
o Balance
o Four 50 mL conicals
o Two 10mL syringes
o Four 0.22µm syringe filters

•

Procedure
o Development of 400 mg/dL Hyperglycemic Cell Media Solution
1.

Weigh 0.3g of Sigma G6152 D-(+)-Glucose

2.

Using a 50 mL graduated cylinder, measure 100 mL of cell media into a
250 mL beaker.

3.

Add all 0.3g of Sigma G6152 D-(+)-Glucose to the 100 mL of cell media.

4.

Place magnetic stir bar into beaker and stir solution on stir plate for at
least six hours at 25ºC to allow uniform mixing.

5.

Using Aviva Accu-Chek blood glucose meter, record the glucose
concentration of the glycemic cell media solution.

6.

Transfer solution from 250 mL beaker to two 50 mL conicals.

o Sterilization of 400 mg/dL Hyperglycemic Cell Media Solution
1. Ensure hands are washed with gloves on. Spray gloves with 70% IPA.
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2. Spray inside of laminar flow hood with 70% IPA.
3. Keep sterile packaged syringes and syringe filters inside packaging and place
inside hood.
4. Sterilize two brand new 50 mL conicals and place inside hood.
5. Sterilize 50 mL conical with 400 mg/dL hyperglycemic cell media solution
(cap closed) with 70% IPA.
6. Open syringes and syringe filters inside hood. Do not allow the tips to touch
the outside of the packing. Discard of packaging.
7. Uptake 10 mL of 400 mg/dL hyperglycemic cell media solution into 10mL
syringe.
8. Place 22µm syringe filter on end of syringe.
9. Slowly transfer 10 mL of solution through filter into a brand new conical.
This solution is now sterile.
10. Repeat steps 8-10 for all 100 mL of unsterile 400 mg/dL hyperglycemic
solution. Use second conical when necessary.
11. Once all media has been sterilized into sterile conicals, tightly cap the conicals
inside laminar flow hood and store sterilized 400 mg/dL solution at 5-10 ºC.
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Appendix E: Protocol Using Aviva Accu-Chek Blood
Glucose Meter
*All images provided from Aviva Accu-Chek Owner’s Booklet
1. Overview of the blood glucose meter

Display

Test Strip Slot

Power Button
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Code Key Slot

Battery Door

Code Key
(example of code on front)

Golden end inserted
into meter

Test Strip Container
(example of code on bottle)
Capillary mouth
(touch solution here)
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2. Coding the Meter

Ensure that the meter is off

Turn meter over

Remove old code key (if there is one in the meter) and discard it

Insert new code key for test strip container (ensure that the code is
facing away from you). Push in the code key until it stops. Leave
code key in meter until a new container of test strips (with a
different code key) is being used.
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3. Running a Glucose Concentration Test

Insert a test strip into the test strip slot of the blood glucose meter.
The meter will automatically turn on.

Ensure that the code on the display shows the same code that is
on the container. If missed, remove the test strip and reinsert it
to observe the code on the display screen.

When blood/solution drop image flashes on display, dip test strip
into solution. Ensure solution goes into capillary mouth.
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The result will appear on the display.

184

